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ABSTRACT 
 
Epidemiological information on sexually transmitted infections (STIs) is 
necessary to assess the magnitude of the burden of infections, to identify 
vulnerable population groups, to mobilise resources for intervention activities 
and to monitor the impact of these activities. In addition, specific STI 
surveillance systems, such as studies on the relative prevalence of 
aetiological agents of STI syndromes and their antimicrobial susceptibility 
patterns, are aimed at improving patient care.  
 
The studies included in this thesis were designed and implemented to 
improve our understanding of the epidemiology of STIs and HIV infection in 
southern Africa. In all the study populations, we observed that high level STI 
epidemics preceded the explosive spread of HIV infection among high-risk 
individuals. The studies reported here also demonstrate the importance of 
triangulating data collected from different recommended STI surveillance 
components, using a tiered surveillance approach.  
 
The studies reported here also explored the bidirectional interactions of HIV 
and STIs. We observed that different STIs have shown different magnitudes 
of interaction with HIV infection. We found particularly strong interactions 
between genital herpes and HIV. At the individual level, HIV-seropositive 
patients with genital herpes were more frequently found to have atypical 
clinical presentations, delays in spontaneous healing, longer duration of HSV 
shedding and increased association with HIV shedding from ulcer and genital 
exudates. Mixed infections involving chancroid and genital herpes were found 
to be common, particularly in HIV-seropositive patients. The effectiveness of 
syndromic treatment targeting only bacterial causes of genital ulceration was 
significantly reduced due to persistent ulcerations as a result of co-infection 
with genital herpes. The successful treatment of herpes in men and women 
was found to be associated with a decline or cessation in HIV shedding into 
ulcer exudates or genital fluid. The studies have also shown that HIV plasma 
viral load is the main determinant for HIV shedding in both men and women 
presenting with STIs. 
 
As was the case with HSV infection, there was a strong association between 
HIV and HPV infection in both men and women. A higher prevalence of HPV 
infection was found among HIV-seropositive patients in our study population 
and this may reflect the higher frequency of recurrences and/or longer 
duration of infection (i.e. persistency).  
 
The studies also found that the biological false positive reactions in syphilis 
serology (i.e. RPR) are not a common occurrence in our HIV-seropositive 
study population. On the other hand, syphilis serology could be falsely 
negative in patients with PCR-confirmed primary syphilis who are co-infected 
with HIV and other aetiological agents causing GUD.  
 
In conclusion, the findings of our studies have supported the bidirectional 
nature of interactions between conventional STIs and HIV infection in 
southern Africa.
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CHAPTER 1 
 
Historical perspective and recent developments in the field of 
conventional sexually transmitted infection - human 
immunodeficiency virus interactions 
 
 
1.1 Early history of sexually transmitted infections 
The history of sexually transmitted diseases (STDs) has been extensively documented in 
early writings and has been summarized in an excellent chapter in a standard STD manual by 
Waugh in 19901. Early accounts of STDs include descriptions in papyri from ancient Egypt, 
dating about 1550 BC of “strictures of the flesh” of men and women2 and genital inflammation 
in women3. Urethral and vaginal discharges likely to be gonorrhoea were described in biblical 
times4 and possibly in the 4th and 5th centuries BC by Hippocrates who used the term 
“strangury” for what was likely to have been gonorrhoea in men5. The clinical manifestations 
of male gonorrhoea were also described in ancient Chinese and Roman literature6. 
 
The history of syphilis, especially related to clinical manifestations and epidemiological impact, 
is remarkable and in many respects (but not in terms of severity of the disease and magnitude 
of the problem) similar to HIV/AIDS. Both conditions have an insidious course, affect many 
parts of the body and early in their respective histories carried a poor prognosis with little to 
offer with respect to effective treatment. Historically, the devastating effect of syphilis in 
Western Europe was documented during the latter years of the fifteenth century. An epidemic 
of the disease emerged rapidly, appeared to be spread by sexual contact and was 
characterized by skin ulcers and eruptions, often causing systemic illness and death7,8.  The 
origin and clinical manifestations of syphilis have been debated over many years. Based on 
the many similar manifestations of yaws, pinta, endemic syphilis and sporadic syphilis   
and their widespread occurrence in equatorial Africa, Hudson suggested in 1946  that these 
entities are varieties of the same disease caused by Treponema pallidum and that they are 
evolutionary linked and evolved in sub-Saharan Africa9. Evidence provided by paleopathology, 
based on bone changes likely due to tertiary syphilis, strongly suggests pre-Columbian 
syphilis in the Americas while such lesions were not found in ancient Egyptian mummies nor 
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in human remains in Europe prior to 149310. Only in the late seventeenth century did Phillipe 
Ricord (1799 – 1889) establish the clinical presentation and describe the stages of syphilis11 
and later, Fritz Schaudinn (1871 – 1906) and Erich Hoffmann (1986 – 1959) identified the 
causative organism of the disease12. 
 
The history of other ‘minor’ STDs, including the genital ulcer diseases (GUDs) such as 
chancroid, lymphogranuloma venereum and granuloma inguinale and causes of genital 
discharge has also been documented by Waugh1. 
 
1.2 Recent explosion of knowledge on HIV and STDs 
Since the beginning of the 20th century, scientific knowledge on STDs has advanced rapidly 
and many breakthroughs in diagnosis and management of these infections have been 
documented. The history of STD epidemiology with evolving scientific knowledge relating to 
sexually transmitted infections (STIs) in the latter half of the 20th century is highlighted by 
major advances in STI research. These involve not only innovative approaches to our 
understanding of the microbiology and pathogenesis of STIs and HIV, but at the practical 
level led to the development of microbiological and molecular methods that proved to be 
extremely useful tools for the diagnosis of STIs and investigative epidemiological studies 
(Figure 1.1)13. 
 
Despite the achievements listed in Figure 1.1, STIs remain a major public health problem in 
both industrialised and developing countries14. The World Health Organization (WHO) 
estimated that, globally, 340 million new cases of curable STIs (syphilis, gonorrhoea, 
chlamydial infections and trichomoniasis) were acquired in 1999 by men and women aged 15 
– 49 years15. Rapidly changing demographic, economic, and cultural factors in many 
countries led to an escalation in risky sexual behaviour among vulnerable population groups, 
which, in turn, facilitated the spread of STIs. 
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1.2.1 Progress in epidemiological research 
 
Figure 1.1 History of STD epidemiology and the evolving level of disease-related 
knowledge (After Aral and Holmes,1999) 
 
 
1.2.2 The advent of AIDS and discovery of the HIV agent 
In the early 1980s, a new infectious disease was recognized mostly among men who have 
sex with men (MSM), who presented with immunosuppression and associated Kaposi’s 
sarcoma and Pneumocytis carinii pneumonia. The causative agent, the human 
immunodeficiency virus (HIV), was isolated and linked to the disease which was subsequently 
called acquired immunodeficiency syndrome (AIDS)16-18. Later, HIV was detected in genital 
fluids and it became obvious that the sexual route was the major mode of transmission of HIV 
globally19-25. Since then, HIV infection has spread rapidly throughout the world with 
devastating effects, particularly in sub-Saharan Africa. An increasing number of babies were 
born with HIV infection due to the high rate of infection among women in the reproductive 
age-group. In 2003, WHO/UNAIDS estimated that 40 million adults and children had been 
infected with HIV globally and that 23.3 million were living in sub-Saharan Africa26. Although it 
accounts for less than 2% of the world’s population, southern Africa is currently inhabited by 
up to 30% of people living with HIV/AIDS worldwide. 
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1.3 STI-HIV interactions 
1.3.1 Risk of HIV acquisition 
The bi-directional nature of interactions between conventional STIs and HIV has been 
documented in many studies27,28. It has been recognized that the presence of STIs can 
increase the risk of acquisition of HIV infection and also promote its transmission29-31; likewise 
the natural history and treatment outcome of STIs might be altered by HIV infection and 
related immunodeficiency. The magnitude of the impact of this interaction on the HIV 
epidemic is more prominent in developing countries where the devastating epidemics of HIV 
infection and STIs exist together and produce a vicious cycle of impoverishment that is less 
evident in more developed countries (Figure 1.2).  
 
Determinants of the HIV/AIDS Epidemic in 
Developing Countries
HIV/AIDS
Impoverishment
Social Factors*
(Majority of Population)
High Risk Sexual 
Behaviour
High Prevalence of
Conventional STIs
* Including :
Poor Education
Rapid Urbanisation
Migratory Labour
Social Instability
 Determinants of the HIV/AIDS Epidemic in 
Industrialised Countries
HIV/AIDS
* Including :
Inner City Deprivation
Intravenous Drug Abuse
MSM
Social Factors*
(Minority of Population)
High Risk Sexual 
Behaviour
Low Prevalence of
Conventional STIs
IV Drug Abuse
 
 
 
 
 
 
Figure 1.2 Determinants of the HIV/AIDS epidemic 
 
Epidemiological evidence indicates that a significantly higher HIV prevalence occurs among 
patients with a history of conventional STI episodes when compared with the general 
population27. It is difficult to interpret these epidemiological findings due to the cross-sectional 
nature of theses early studies, especially as they relate to the excess risk of acquiring HIV as 
a result of co-infection with an STI. The common high-risk sexual behaviors that predispose 
individuals to acquisition of both HIV and conventional STIs confound this association. The 
complexity of factors inherent in the design of these studies, therefore compromises 
quantification of the attributable risk of active STIs in the acquisition of HIV infection. This 
situation is more marked in many developing countries where over 90% of conventional STI 
and HIV transmission occurs through heterosexual transmission. 
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1.3.2 Risk of HIV transmission related to gender and STI type 
During the 1990s, several studies indicated that HIV incidence among patients with repeated 
STI episodes was significantly higher compared to those without STI. This association was 
more prominent among those patients presenting with genital ulcer disease (GUD)32-34. 
Statistically significant increases in the risk of HIV seroconversion were found among patients 
with GUD with an odds ratio (OR) of 3.7 for women and 4.7 for men35,36. In the presence of 
STIs, the risk of HIV infection increases 10 – 50-fold for male to female transmission and a 50 
– 300-fold increase for female to male transmission per single sexual act37. Although the 
strength of association was smaller, similar findings were documented for patients presenting 
with non-ulcerative (discharge-associated) STIs38. In recent years, attempts have been made 
to obtain unbiased information regarding the determinants of HIV transmission by conducting 
randomised control trials (RCTs)39. However, ethical issues related to study design pose 
problems for, and result in significant delays in the implementation of such studies.  
 
1.3.3 Proposed mechanisms of STI-HIV interactions related to HIV 
transmission/acquisition  
The biological plausibility which explains the mechanisms enhancing the efficiency of HIV 
acquisition in the presence of active sexually transmitted infections, has been well 
documented40-43. Such enhancement is thought to be due to several mechanisms including 
the disruption of normal epithelial barriers with either macro- or micro-ulceration and the 
recruitment of HIV-susceptible cells such as T- lymphocytes or macrophages to the infected 
area as part of the host’s immune response. Studies indicate that HIV target cells such as 
lymphocytes and macrophages are normally present in male and female genital tract tissues 
and secretions. Genital inflammation associated with STIs increases the number of target 
cells in the genital tract and is likely to augment the susceptibility of HIV-seronegative 
partners by enhancing HIV entry into susceptible host cells44,47. Furthermore, epithelial 
barriers of the genital tract play an important role in host defence against infection. Disruption 
in the lining of the genital tract, either due to micro- or macro-lacerations is therefore likely to 
lead to an increase in the susceptibility of individuals to HIV. The scenario outlined above thus 
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constitutes a compelling argument that the presence of GUD in both men and women could 
potentially increase the acquisition of HIV infection.  
 
Recent studies have also shown that the presence of an active STI in HIV-seropositive 
individuals increases the migration of CD4+ cells containing HIV to the genital tract and 
increases the shedding of HIV in genital secretions48. Thus, the presence of STIs could 
increase the infectiousness of HIV-seropositive partners by increasing the cell-associated 
viral load in genital secretions. The presence of viable HIV in genital ulcer exudates has also 
been demonstrated in earlier studies49,50. These findings suggest that the transmission 
efficiency of HIV is increased by co-infection with a symptomatic or asymptomatic 
conventional STI.  
 
1.3.4 Effect of STIs on the HIV transmission, based on Anderson and May’s model 
As discussed in Anderson and May’s basic reproductive rate of infection model (Figure 1.3)51 
an increase in efficiency of HIV transmission will, theoretically, accelerate the spread of HIV 
infection. Furthermore, the increase will reduce the effectiveness of behavioural interventions 
which have been a major focus in strategies to decrease the rate of sexual partner change 
(D). An overall increase in efficiency of HIV transmission due to conventional STIs therefore 
becomes an important problem in developing countries where a significant proportion of the 
population has been infected with HIV.  
 
R 0  =  β c D
R 0 =  B as ic  R ep ro d u ctiv e  N u m b er
A v erag e n u m b er o f seco n d ary  cases  o f 
in fec tio n  g en era ted  b y  o n e  p rim ary  case  in  a  
su scep tib le  p o p u la tio n
β =  A v erag e T ran sm iss io n  C o effic ien t
D  =  A v erag e  D u ra tio n  o f In fectio u sn ess
c  =  A v erag e  R ate  o f S exu al P artn er C h an g e
 
Figure 1.3 Anderson and May’s model of the spread of  
HIV infection 
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1.3.5 Role of STIs on progression of HIV infection to AIDS 
STI episodes are also believed to be associated with the accelerated progression of 
asymptomatic HIV infection to AIDS. However, confounding variables such as duration of HIV 
infection at the time of diagnosis, baseline immunological status and other co-factors related 
to immunosuppression need to be taken into account when designing studies to show this 
association. The progression from latent HIV infection to AIDS is generally preceded by 
accelerated viral replication. In most infected individuals, a reduction in CD4+ cell level is 
paralleled by an increase in viral load, leading to progression to AIDS, characterized by the 
onset of opportunistic infections. Various infectious agents have been thought to be 
associated with up-regulating the HIV replication52. It has been hypothesized that frequently 
recurring STI episodes in HIV-seropositive individuals either due to re-infection or reactivation 
of latent infection, as may occur with genital herpes, might lead to rapid progression to HIV-
related immunodeficiency53. In vitro studies have indicated that viral STIs might enhance HIV 
infection by various mechanisms, eg. stimulating expression of cell surface receptors that 
facilitate HIV attachment, coding for gene products that are necessary for HIV growth, or by 
temporarily or permanently altering HIV expression through phenotypic mixing or genetic 
recombination54,55. Several in vitro studies have also suggested that herpesviruses may 
transactivate HIV. The clinical significance of these findings, including in vivo up-regulation of 
HIV in people co-infected with both viruses, has however not been fully substantiated.  
 
Studies have also indicated reduced efficiency of standard therapies for other common STIs 
and their complications in HIV-infected patients. Such STIs include chancroid (particularly 
with single dose therapy), genital herpes ( the association of HIV infection with emergence of 
drug resistant strains) and genital warts56-61. 
 
As mentioned earlier, the effect of the co-existing STI epidemic on HIV transmission at a 
community level might include other complex sociocultural determinants. It is therefore 
necessary to confirm or quantify these co-factor effects of STI on HIV transmission by 
conducting community-based randomised control trials. 
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Recently, several community-based RCTs have been conducted to determine the effect of 
management of STI on the incidence of HIV infection. In order to determine the population 
attributable fraction (PAF) of improved STI management on HIV transmission, two community 
randomised control trials (RCT) were conducted in the early 1990s. Firstly, during 1992-94, a 
RCT was performed in the Mwanza district of Tanzania to assess whether improved 
treatment services for symptomatic STIs could reduce HIV transmission at the population 
level62-64. The results of the Mwanza RCT showed that improved STI case-management led to 
a 38% reduction in HIV incidence during the two-year follow-up period. In contrast, no 
significant difference between the intervention and control communities in the incidence of 
HIV infection was observed in the Rakai study conducted in Uganda65,66 where mass 
treatment for STIs was the intervention. Critical analysis of the possible reasons for the 
unexpected different outcomes of these two large community-based RCTs produced 
hypotheses regarding the STI co-factor effect on HIV transmission. The fundamental 
differences between the two intervention trials that may explain the differences in outcome 
have been debated in the literature. Differences in study design, type of intervention and the 
characteristics of the study populations emerged as the most important factors. It became 
clear that differences in the maturity of the HIV epidemic and the aetiological patterns of STIs 
in the study populations of the two studies had a major impact on the effectiveness of specific 
intervention activities67-69. In summary, the pattern and magnitude of interactions between 
STIs and HIV infection appears to vary with different phases of the HIV epidemic and the local 
patterns and epidemiology of conventional STIs . 
 
Most epidemiological studies conducted to explore the determinants of HIV transmission and 
STI/HIV interactions were conducted during the early phase of the HIV epidemic. The findings 
of these earlier epidemiological studies should be interpreted with caution due to the complex 
nature of the natural history of some STIs even in HIV-seronegative individuals and the lack 
of reliable gold standard laboratory tests in detecting all stages of infection. With major 
advances in the knowledge on the natural history of HIV infection together with the availability 
of newer, more sensitive and specific diagnostic methods, researchers have recently revisited 
these importance issues. 
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1.4 Concluding remarks 
During the 1990s, great strides were made towards our understanding of the interactions 
between conventional STI and HIV infection. Although the spread of HIV infection reached 
pandemic proportions in the 1990s, there is considerable variation in the maturity of the 
epidemic and the distribution of dominant viral clades in different regions of the world. The 
diverse nature of the epidemic made generalization of research findings on the HIV-STI 
interactions problematic. For example, research studies conducted during the late 1990s have 
shown that the extent of HIV shedding from genital lesions might vary with the aetiology of 
STIs while co-factors such as immunodeficiency and prevailing HIV sub-types in an area may 
also play a role. It is therefore important that when research studies are being planned for a 
specific region, a unique study design be developed for that population group/region. 
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CHAPTER 2 
Methods used for STI–HIV interaction studies 
In order to study the interactions between STIs and HIV infection, several investigational 
approaches involving appropriately chosen populations at high risk of infection have been 
followed. In all these studies, core methods have been used for the demonstration of specific 
aetiological agents of STI syndromes and these are described in this chapter. 
 
2.1. Introduction 
Epidemiological information on STIs is necessary to assess the magnitude of the burden of 
infections, to identify vulnerable population groups, to mobilise resources for intervention 
activities and to monitor the impact of these activities. In addition, specific STI surveillance 
systems, such as studies on the relative prevalence of aetiological agents of STI syndromes 
and their antimicrobial susceptibility patterns, are aimed at improving patient care1. For the 
implementation of such specialised surveillance, comprehensive laboratory support is 
mandatory.  
 
2.2. Types of tests and their underlying principles 
Laboratory tests that are used to determine specific aetiological agent(s) in research studies 
can be grouped into six categories and are based on the following principles: (i) direct 
visualization of the causative organism(s) under an ordinary or specialised microscope, (ii) 
culture of the organism in specific, usually selective, culture media, (iii) detection of antigen by 
immunological means, (iv) employment of non-amplifying techniques with nucleic acid 
(DNA/RNA) probes (NAT) for pathogen identification, (v) demonstration of target DNA or RNA 
of organisms by nucleic acid amplification techniques (NAAT) and (vi) using serological 
methods for measuring antibody responses to the organism(s)2,3.  
 
In this chapter, standard specimen collection and laboratory methods used in subsequent 
studies are described. The comparison of performance of different laboratory methods 
applied in these studies are summarised in Table 2.1.  
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Table 2.1 Comparisons of performance of different laboratory methods applied in the 
research studies 
 
Laboratory tests Sensitivity Specificity Comments
Syphilis
Darkfield microscopy 74% - 86%   97% - 100%
Multiplex PCR (M-PCR) 91% 99%
Serology tests for syphilis
RPR   72% - 100% 93% - 98%
TPHA 69% - 90%   98% - 100%
Chancroid
Culture 56% - 90% 100%
PCR 77% - 98%  98% - 100%
Donovanosis
Microscopy 60 -80% 100%
Herpes simplex virus
Culture Gold standard 100%
Multiplex PCR (M-PCR) more sensitve than culture  98% - 100%
Gonorrhoea
Microscopy 90% - 95%   98% - 100%
Culture   81% - 100% 100%
LCR   95% - 100%  98% - 100%
Chlamydia
Culture Gold standard 100%
LCR 90% - 97%  99% - 100%
Trichomonas
Microscopy 38% - 82% 100%
Culture 98% 100%
Bacterial vaginosis
3 of 4 Amsel criteria 81% 94%
Gram stain 89% 93%
Human papilloma virus
Hybrid Capture 74% - 93% 64% - 68%
PCR    80% - 100%1 40% - 61% 1 for detection of biopsy-confirmed high-grade dysplasia
Sensitivity and specificity are for detection of T. vaginalis by combnied
wet prep and culture results
Sensitivity and specificity are for diagnosis of BV by presence of 
3 of 4 criteria and/or positive Gram stain.
Sensitivity and specificity are for detection of primary syphilis. 
The sensitivity of both nontreponemal and treponemal antibody 
detection increases for detection of secondary syphilis. The sensitivity 
of nontreponemal antibody detection decreases for detection of latent 
and tertiary syphilis. The tests for T. pallidum  are only relevant when 
lesions are present in primary and secondary syphilis.
The sensitivity of culture varies depending on the type of medium used 
and can only be estimated since there is no gold standard on which to base the 
diagnosis of chancroid. Resolved sensitivity of PCR vs H. ducreyi culture.
Sensitivity and specificity are for dectection of N. gonorrhoea in urethral, 
endocervical and urine samples by culture except for microscopy, which is for 
detection in urethral samples from symptomatic men.
Sensitivity and specificity are for detection of C. trachomatis 
by culture or by DNA amplification test.
 
 (Adapted from WHO’s publication: Laboratory tests for the detection of reproductive tract infections, 1999)4
 
Details of methods employed for specific purposes will be provided in subsequent chapters. In 
general, the most specific and sensitive diagnostic methods available during the study period 
were used at the National Reference Centre for STD (NRC-STD) in Johannesburg and/or 
other local and international collaborating centres. Standard quality assurance practices 
prescribed by the South African Institute for Medical Research (SAIMR), now the National 
Health Laboratory Services (NHLS), at the time were in place throughout5. 
 
2.3. Demonstration of STI aetiologies according to syndromes 
2.3.1 Aetiology of genital ulcer diseases 
A complete microbiological investigation was conducted for genital ulcer disease (GUD) 
presenting in patients enrolled in aetiological studies. Standard methods were used to detect 
the agents of GUD, namely Treponema pallidum, Haemophilus ducreyi, herpes simplex virus 
(HSV), Klebsiella granulomatis (formerly Calymmatobacterium granulomatis), and the L-
serovars of Chlamydia trachomatis  (lymphogranuloma venereum biovar). Appropriate 
inclusion and exclusion criteria for patients were established and strictly followed during the 
studies (See Table 2.1 – Patient eligibility for enrolment in GUD studies). 
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All specimens were collected from a single target ulcer or the largest ulcer if more than one 
ulcer was present. When multiple swabs were collected, in order to avoid bias, random 
allocation of swabs for different laboratory investigations was performed.  In addition, serum 
samples were collected for serological testing for syphilis, and type-specific assays for HSV 
and chlamydial infections. Where appropriate, urine and endo-urethral swabs were taken for 
the detection of concomitant urethral infections caused by Neisseria gonorrhoeae and 
Chlamydia trachomatis. 
 
Table 2.2 Patient eligibility for enrolment in GUD studies 
The following criteria were used for determining patients’ eligibility for 
enrolment into GUD studies 
 
• Presenting with visible genital ulceration(s) of at least 2 mm in size with or without 
inguinal and/or femoral lymphadenopathy (bubo) 
• No history of treatment with antibiotics or anti-viral therapy during the past 7 days 
• Agreement to complete questionnaires and collection of clinical specimens 
• Voluntary participation based on informed consent  
 
 
 
 
 
 
 
2.3.1.1 Diagnosis of syphilis (primary and latent infection) 
2.3.1.1.1 Darkfield microscopy 
After thorough cleansing with sterile saline, material from the ulcer base was collected with a 
platinum scraper or the lesion was firmly squeezed between the fingers and thumb and 
serous fluid collected on a microscope slide. The lesion material on the slide was then mixed 
with saline, and immediately examined by darkfield (DF) microscopy for motile spirochaetes 
resembling T. pallidum (TP) as described elsewhere6-8.   
 
2.3.1.1.2 Multiplex polymerase chain reaction (M-PCR) 
The lack of a laboratory method for the in vitro culture of T. pallidum has necessitated the use 
of alternative diagnostic methods. Later, M-PCR assays were used as the gold standard for 
detecting T. pallidum from genital ulcer exudates. M-PCR was also used to detect other 
aetiological agents of GUD including H. ducreyi and HSV simultaneously in the same 
specimen. Material from the base of the target lesions was collected on a cotton-tipped swab 
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(Medical Wire and Equipment, Corsham, UK). Each swab was then expressed into 0.2 ml 
sterile distilled water and stored frozen at –70•C until analysed. Later M-PCR assay (Roche 
Molecular Systems) was used to detect target DNA from T. pallidum, H. ducreyi, and HSV 
from the swabs. An aliquot of the processed specimen was also used in a C. trachomatis 
PCR test (Amplicor, Roche Molecular Systems). M-PCR assays were performed at the 
Centers for Disease Control and Prevention, Atlanta, GA, USA using methods described 
previously9.  
 
2.3.1.1.3 Serology tests for syphilis (RPR, FTA-ABS & TPHA) 
Clearly marked vacuum collection tubes without anticoagulant were used to collect serum 
specimens from patients. After collection, specimens were allowed to clot at room 
temperature. Each specimen was then centrifuged at 1200 x g for at least 5 minutes to 
sediment cellular elements and the serum subsequently stored at 4 °C or frozen at ─70° C.  
 
Serum samples were tested using both non-treponemal (quantitative RPR card test, 
IMMUNOTREP® Omega Diagnostics, Alloa, Scotland, UK) and treponemal tests (FTA-ABS, 
Marburg, Germany and/or TPHA, Randox Laboratories, Antrim, UK) to determine the 
serological status of patients for syphilis. All serological tests were performed according to 
standard operating procedures (SOPs) of the South African Institute for Medical Research 
(SAIMR)5.  
 
2.3.1.2 Diagnosis of chancroid 
Haemophilus ducreyi was identified from ulcer exudate either by culture using a modified 
Columbia agar system5,10,11 or by M-PCR9.  
 
2.3.1.2.1 Culture 
The selective culture medium used to isolate the H. ducreyi comprised Columbia agar base 
(Sigma), activated charcoal, 1% haemoglobin, 1% (vol/vol) IsoVitaleX (BBL Microbiological 
Systems, Cockeysville, Md.), 5% foetal calf serum (Adcock Ingram Diagnostics, 
Johannesburg, SA), and 3 μg/ml vancomycin. After thorough cleansing, material from the 
 - 18 - 
base of each target ulcer was collected on calcium alginate swabs (Calgiswab, Medical Wire 
and Equipment, Corsham, UK) and inoculated directly onto the selective solid medium. The 
inoculated culture plates were immediately placed in a candle-extinction jar (5-10% CO2) and 
kept at room temperature during transport to reach the laboratory within 12 hours after 
collection. On arrival, the inoculated agar plates were placed in an anaerobic jar without catalyst 
(BBL Microbiological Systems, Cockeysville Md.) to create a humidified atmosphere containing 
and incubated at 33-350 C for 48-72 hours. Colonies were identified by typical morphology (see 
below) and the following confirmatory tests: 
- Cohesive whitish-grey colonies 
- Push test: intact colonies move across agar surface  
- Gram stain: Gram -ve short rods in parallel arrangement or "school of fish" 
appearance 
- Production of acid in glucose but not in lactose or sucrose 
- Oxidase positive (tetramethyl-p-phylenediamine reagent)  
- Produces porphyrin from δ-aminolaevulinic acid (porphyrin test positive) 
- Catalase negative (5% H2O2 v/v),  
- beta-lactamase positive  
- alkaline phosphatase positive 
Colonies from purified cultures were stored in three polypropylene vials per isolate. A heavy 
inoculum was placed in DMSO + 20% foetal calf serum (Adcock Ingram Diagnostics, 
Johannesburg, SA) or 20% skimmed milk + 10% glycerol (Diagnostic Media Products, 
Johannesburg, SA) and stored at -700C. 
 
2.3.1.2.2 Multiplex polymerase chain reaction (M-PCR) 
M-PCR was used as gold standard for detecting H. ducreyi according to the procedure 
described in Section 2.3.1.1.29.  
 
2.3.1.3 Diagnosis of lymphogranuloma venereum (LGV) 
Historically, the diagnosis of LGV has been based on a positive Frei skin test, a positive 
serological test for LGV, isolation of C. trachomatis (L1, L2, L3) from infected 
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tissues/secretions, histological identification and/or PCR12. However, the poor sensitivity of 
the Frei skin test (test usually become positive after appearance of buboes or 2-8 wks after 
infection) and likewise poor specificity (Frei antigen common to all Chlamydia spp. and life-
time positivity despite successful treatment) has limited its utility for routine diagnosis13,14  and 
is no longer used. 
 
In the present studies, attempts were made to diagnose LGV by applying a combined 
approach which included C. trachomatis (CT) culture, Chlamydial LCR™ (Abbott 
Laboratories, North Chicago, Ill.) and quantitative measurement of type-specific chlamydial 
antibodies using the micro-immunofluorescence (MIF) technique. Genotyping of C. 
trachomatis strains was not performed. 
 
2.3.1.3.1  Chlamydial culture  
After thorough cleansing, material from the base of each target ulcer was collected on dacron 
swabs (Hardwood Products Company, Guilford, Maine). Immediately following collection, 
swabs were agitated vigorously in chlamydial transport medium and discarded after expressing 
the liquid from the swab to avoid leaving toxic swab material in the transport medium. Sucrose 
phosphate buffer (2SP) (Highveld Biologicals, Johannesburg, SA) was used as transport 
medium for clinical specimens. Specimens were kept on ice and transported to the laboratory 
within 24 hours for immediate processing or stored at –700C until batch inoculation. The cell 
culture method using McCoy cells (mouse fibroblasts) (Highveld Biologicals, Johannesburg, 
SA) was employed to isolate the C. trachomatis from clinical specimens17. Cells were grown 
in Eagle’s minimal essential medium (MEM), supplemented with 10% foetal calf serum, 2 mM 
glutamine, 30μM glucose, 0.75% sodium bicarbonate, 20 μM herpes buffer and 10 μg/ml of 
gentamicin (all constituents from Highveld Biologicals, Johannesburg, SA)15,16. 
 
Approximately 0.5-1.0 ml of the clinical specimen in transport medium inoculated into each of 
two vials of confluent cell monolayers on glass coverslips following standard procedures as 
described elsewhere3,5. After 72 hours’ incubation at 35°C in an atmosphere of 5-10% CO2 in 
air, the monolayers were transferred onto glass slides and were then fixed in methanol and 
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stained either with fluorescein-labelled monoclonal antibody (MicroTrak, Syva, Palo Alto, CA). 
The stained slides were examined under a fluorescence microscope at 40x magnification. In a 
positive specimen, homogenous, granular cytoplasmic inclusions are found in infected cells 
exhibiting characteristic apple-green fluorescence.  
 
2.3.1.3.2 Chlamydial serology (microimmunofluorescence test) 
Although the microimmunofluorescence (MIF) test has limited value in the diagnosis of active 
chlamydial infection, it is a useful test for epidemiological studies18-20. 
 
Elementary bodies of chlamydial organisms grown in the yolk sacs of embryonated eggs are 
used as antigen. Standard microscope slides with eight clusters containing antigens of 
immunotypes grouped according to clinical disease entities were used. Pooled antigens 
groups included were (i) ABC (trachoma serovars), (ii) DEFGHIK (oculo-genital serovars), (iii) 
L1, L2, L3 (LGV serovars), (iv) Chlamydia psittaci, (v) Chlamydia pneumoniae and (vi) a 
normal yolk sack suspension served as a negative control. The testing was done according to 
standard procedures described elsewhere3,5. Antigen clusters were examined by fluorescent 
microscopy using a X40 objective. Fluorescence was graded according to colour brightness and 
evenly distributed elementary bodies. 
 
2.3.1.4 Diagnosis of donovanosis (GI) 
The characteristics of Donovan bodies in macrophages and epithelial cells of the stratum 
malpighii were described by Donovan in 1905. Since then, tissue smears stained by the 
Leishman or Giemsa methods are used as standard diagnostic method21,22. There is no 
established culture system for the routine identification of the aetiologic agent, 
Calymmatobacterium klebsiella granulomatis. Several investigators have claimed the 
successful isolation of the causative organism since 191323-26. However, more recently 
Kharsany et al25 in Durban, South Africa and Carter et al26 from Australia reported the 
propagation of C. granulomatis in monocyte and McCoy cell cultures respectively, but these 
techniques have yet to be used routinely for diagnostic purposes. A molecular amplification 
method has been developed to characterize DNA sequences of the organism from genital 
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donovanosis lesions using PCR27. Serological tests applying complement-fixation and indirect 
immunofluorescent technique have been developed and have been used in epidemiological 
studies28,29. In the studies, reported here, only clinically suspicious lesions were investigated 
for the presence of Donovan bodies using the Giemsa staining method. After thorough 
cleansing, material from the edges of the target ulcer was collected with a platinum scraper, 
spread on a microscope slide, fixed with methyl alcohol, stained (with Giemsa’s stain), and 
examined for the presence of Donovan bodies. Donovan bodies are pleomorphic, bean-
shaped microorganisms with small intrabacterial inclusions showing a bipolar distribution, and 
giving the microorganism a closed safety-pin appearance. 
 
2.3.1.5 Diagnosis of herpes simplex virus (HSV) infection 
Four categories of test have been used for the diagnosis of genital herpes: rapid detection 
techniques, tissue culture-based methods, serological methods and molecular amplification 
methods30,31. In these studies, herpes simplex virus culture using human embryonic lung 
fibroblasts (HLF), type-specific PCR and/or M-PCR techniques were used to demonstrate 
viable virus or virus-specific DNA sequences in lesions, while type-specific serology was 
employed in some studies.  
 
2.3.1.5.1     Culture of herpes simplex virus  
After thorough cleansing, material from the base of each target ulcer was collected on a 
dacron swab. Immediately following collection, the swab was agitated in viral transport 
medium (MEM plus 10% foetal calf serum with antibiotics; Highveld Biologicals, 
Johannesburg, SA) expressed and then discarded. Specimens were kept on ice for up to 8 
hours, transported to the laboratory where they were either cultured immediately or stored at 
–700C until inoculation into cell cultures. 
 
Human embryonic lung fibroblast (HLF) monolayers were cultured in Eagles E-MEM with L-
glutamine plus 10% FCS and antibiotics (all constituents from Highveld Biologicals, 
Johannesburg, SA). The standard procedures, described elsewhere5, were followed for 
preparation, storage and trypsinization of cells. Each tissue culture tube (with one containing 
 - 22 - 
a coverslip) was seeded with 2ml of 2x107 cells/ml in growth media plus 10% FCS and 
antibiotics and incubated at 35ºC in a CO2 incubator. The medium was changed after 72 
hours with growth medium containing 2% FCS prior to inoculation.  
 
Each of two roller tubes was inoculated with 0.2ml of sample in MEM plus 2% FCS and 
incubated at 35°C in an atmosphere of 5-10% CO2 in air in a roller drum apparatus. The 
tubes were examined microscopically every day for the presence of cytopathic effect (CPE).  
Positive tubes with coverslips were fixed in Bouins’ fixative (SAIMR-STD Quality Assurance 
Manual, 1996). The slides were then stained with haematoxylin for one hour and 
counterstained with eosin for 2 minutes after which they were mounted with DPX and read at 
400x magnification. The presence of herpes simplex virus was indicated by a characteristic 
bulging or “ballooning” of the infected fibroblasts and the presence of a typical cytopathic 
effect with intracellular eosinophilic inclusions, producing a “stippling effect” with a halo 
formation. The isolates were typed as either HSV-1 or HSV-2 using fluorescein labelled 
monoclonal antibodies3,32. 
 
2.3.1.5.2 Multiplex PCR 
M-PCR was used as gold standard for detecting type-specific HSV and the procedure has 
been described in Section 2.3.1.2 and elsewhere9. 
 
2.3.1.5.3 HSV PCR 
In addition to M-PCR, type-specific HSV PCR testing was performed in some studies, using 
an in-house PCR method. After thorough cleansing, material from the base of each target 
ulcer was collected on a calcium aginate-coated dacron swab. Swabs were stored at -700C 
and processed in batches using the method described in the annexure 2.1. 
 
2.3.1.5.4 Herpes serology  
Although various type-specific serological tests for HSV infection are available, they are not 
useful for diagnosing mucosal lesions caused by HSV. In some studies, complementary type-
specific serology was used to detect the individuals’ previous exposure to herpes simplex 
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viruses. Standard serological methods such as ELISA and/or Western Blot were applied to 
detect the type-specific antibodies to HSV-1 and HSV-2. In each case blood samples were 
collected and allowed to clot at room temperature prior to centrifugation. Serum was then 
transferred aseptically to a tightly closing sterile container for storage. Samples were frozen at 
-70°C and processed in batches following thawing.  HSV type-specific antibody testing was 
performed at the CDC, Atlanta, USA, as previously described using Western Blot analysis of 
recombinant-derived, baculovirus-expressed HSV glycoprotein G1 and G2 from HSV-1 and 
HSV-2, respectively33,34. In some studies the Focus HSV-2 ELISA IgG test (Focus 
Diagnostics, Cypress, CA) was used for the detection of antibodies to HSV-2. The test 
procedure was followed according to the manufacturer’s instructions35,36.
 
2.3.2 Aetiology of acute urethritis in men 
Patients complaining of painful or burning micturition with or without visible signs of urethral 
discharge, were enrolled into the studies. Asymptomatic men were also enrolled in 
community-based prevalence assessment studies. Other eligibility criteria for enrolment were 
the same as in the GUD studies (See Table 2.2). 
 
2.3.2.1 Diagnosis of gonococcal urethritis 
The laboratory diagnosis of gonococcal infection37 includes identification of N. gonorrhoeae 
by; 
• microscopic examination of stained smear 
• culture   
• non-culture diagnostic methods  
• non-amplified techniques such as EIA, DNA probe test  
• amplified nucleic-acid detection techniques such as LCR, PCR, transcription-
mediated amplification (TMA). 
In these studies, microscopy of stained smears (Gram stain), culture and LCR tests were 
employed to diagnose acute gonococcal urethritis in men.  
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2.3.2.1.1 Microscopy of genital exudates for gonococci 
The genital exudate from the urethral meatus was collected using a cotton swab at least two 
hours following the last micturition. Immediately following collection, the swab was rolled onto 
two clean microscope slides immediately following collection and allowed to air dry. Smears 
were fixed with the film uppermost by passing the slide rapidly three times through a flame, 
avoiding overheating which may distort morphology of the cellular material. The slides were 
stained using the standard Gram’s staining method5. The stained smears were examined 
microscopically for evidence of urethritis (5 or more polymorphs per high power field). The 
presence of Gram-negative intracellular diplococci supported a presumptive diagnosis of 
gonococcal urethritis. The absence of diplococci with 5 or more polymorphs per high power 
field was indicative of non-gonococcal urethritis (NGU). 
 
2.3.2.1.2 Culture for N. gonorrhoeae 
An endourethral swab, also taken at least two hours after micturition, was inserted at least 2 
cm into the urethra and gently rotated. Swabs were then inoculated immediately at the clinic 
onto New York City (NYC) medium and placed into a candle extinction jar. Inoculated plates 
were placed at 35•C in a humidified atmosphere in a candle-extinction jar containing an 
atmosphere of 5-10% CO2 in air and incubated for 24 - 48hrs. Typical translucent colonies of 
N. gonorrhoeae were identified by Gram staining, a positive oxidase test and conventional 
carbohydrate utilization tests or employing commercially available rapid fermentation tests. All 
confirmed gonococcal isolates were stored in at least three polypropylene vials per isolate. A 
heavy inoculum was placed in trypticase soy broth + 20% glycerol and stored in vials at  
−70•C3,5. 
 
2.3.2.1.3 Ligase chain reaction for gonococcal infection (LCR-GC) 
First catch urine specimens were collected in sterile containers and stored at 4•C for immediate 
processing or at -70•C for batch processing. The Ligase Chain Reaction (LCx™, Abbott 
Laboratories, North Chicago, Ill.) was used for the qualitative detection of a specific target 
nucleic acid sequence in the opa gene of N. gonorrhoeae. The standard amplification and 
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detection procedure was carried out according to the manufacturer's instructions provided with 
the kit and described elsewhere38. 
 
2.3.2.2 Diagnosis of chlamydial urethritis 
First catch urine specimens and/or endourethral swabs from patients presenting with urethritis 
were tested for the presence of C. trachomatis (CT) using either McCoy cell or LCR 
techniques culture as described in sections 2.3.1.3.1 and 2.3.2.1.3 respectively. A specific 
target nucleic acid sequence detected by the LCR test is the chlamydial plasmid. 
 
2.3.2.3 Diagnosis of ureaplasma infection 
Four species of the order Mycoplasmatales are found in the human genital tract: Mycoplasma 
hominis, Mycoplasma fermentans, Mycoplasma genitalium and Ureaplasma urealyticum. An 
association between acute urethritis in men and infection with Ureaplasma urealyticum was 
first documented in 1974 by Shepard39. More convincing evidence of an aetiological role for 
Ureaplasma urealyticum in NGU was obtained following human intraurethral inoculation of 
ureaplasma and the development of signs and symptoms of urethritis40,41. Recovery of 
ureaplasmas from the urethra from a person with NGU does not always indicate that they are 
the cause of the urethritis. U. urealyticum has been isolated from many men who have had no 
clinical evidence of urethritis42. It has been suggested that Ureaplasma urealyticum causes 10 
to 40% cases of NGU.  In theses studies, genital mycoplasmas were detected by using 
culture methods. Endourethral swabs were collected as described in section 2.3.2.1.2 and  
U. urealyticum and M. hominis were isolated using standard culture methods described 
below. No attempt was made to identify other mycoplasma species during the study period.  
 
2.3.2.3.1 Culture of U. urealyticum  
Immediately following collection, swabs were agitated in Shepards' U9 broth, expressed 
against the sides of container, and discarded. Inoculated U9 broth was kept on ice and 
transported to the laboratory within 24 hours. The broths were placed with loosened lids in an 
anaerobic atmosphere (anaerobic jar) and incubated at 35•C for 24 - 72hrs. Cultures were 
examined for a colour change every 12 hours.  A change of colour from yellow to light 
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orange/pink was interpreted provisionally as positive.  All positive U9 broths were subcultured 
on A2 medium for growth of colonies of U. urealyticum. The inoculated A2 medium was 
incubated at 35•C for 24-48hrs anaerobically. The agar plates were examined under light 
microscope (X10 objective) for colonies which appeared as coccoid particles. M. hominis 
colonies were also detected based on their "fried-egg" appearance. 
 
2.3.2.4 Diagnosis of other causes of urethritis 
Studies have shown that 30 to 50 percent of heterosexual men with NGU were negative for 
both C. trachomatis and U. urealyticum. Other possible causes of urethritis include M. 
genitalium, Trichomonas vaginalis, yeasts, HSV, adenovirus, Haemophilus species and other 
bacteria43. Owing to logistical constraints, attempts were only made to identify T. vaginalis in 
selected studies. In most studies, NGU was categorised as either C. trachomatis and U. 
urealyticum-positive (CT/UU +ve) group, C. trachomatis or U. urealyticum-positive group (CT 
+ve/ UU−ve or CT−ve/UU+ve), and a C. trachomatis and U. urealyticum-negative (CT/UU –
ve) group. 
 
2.3.2.4.1 Diagnosis of T. vaginalis 
Trichomonas vaginalis can be identified using direct microscopy of urine or stained urethral 
smears using Gram, Giemsa, periodic acid-Schiff, acridine orange, fluorescein, neutral red or 
immuoperoxidase staining techniques44,45. Culture methods using liquid and semisolid media 
have remained the “gold standard” tests for the detection of T. vaginalis46-48. However, better 
detection rates were reported using PCR when compared to culture. Further evaluations are 
required to determine both the optimal specimen for PCR testing and the clinical significance 
of a positive result49-52. 
 
In these studies only culture methods were used to identify T. vaginalis in the urethra of men 
presenting with urethritis. Endourethral swabs were collected as described in section 2.3.2.1.2 
and inoculated directly by agitating the swab in Diamonds' medium. The inoculated bottles of 
Diamonds' medium were placed at 35•C in an anaerobic atmosphere with loosened lids initially 
for 24-72 hours. A drop of the incubated Diamonds' medium was examined daily for 7 days on a 
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clean glass slide covered with a coverslip and scanned microscopically under X400 
magnification for motile trichomonads.  
 
2.3.3 Aetiology of reproductive tract infections (RTIs) in women 
Non-menstruating women complaining of vaginal discharge with or without lower abdominal 
pain were enrolled in the studies described in this thesis. Asymptomatic women were also 
enrolled in community-based prevalence assessment studies.  
 
Appropriate laboratory methods were employed to detect the aetiological agents of both 
vaginal and cervical infections, namely, T. vaginalis, Candida spp, Mycoplasma spp, bacterial 
vaginosis, N. gonorrhoeae, C. trachomatis, Human Papilloma Virus (HPV) and Herpes 
Simplex Virus (HSV).  
 
2.3.3.1 Diagnosis of bacterial vaginosis (BV) 
In 1983 Amsel et al 53 established criteria for the diagnosis of bacterial vaginosis based on the 
presence of at least three of the following four clinical signs; 
1. Characteristic homogenous white adherent discharge 
2. Vaginal fluid pH >4.5 
3. Release of a fishy amine odour from vaginal fluid when mixed with 10% KOH 
4. Presence of clue cells (representing at least 20 percent of vaginal epithelial cells). 
 
However, subsequent studies have indicated that the presence of clue cells represents the 
best single criterion for the diagnosis of BV54. 
 
Specific guidelines for the reading of vaginal Gram-stained smears were described by 
Dunkelberg55 and Spiegel et al56. Later, in 1991, Nugent developed a standardized scoring 
system for evaluation of Gram-stained vaginal smears57. This system was based on three 
bacterial morphotypes: large Gram-positive rods (lactobacilli), small Gram-negative or 
variable rods (Gardnerella and anaerobic rods), and Mobiluncus57. Due to the high number of 
women without BV (up to 58%) harbouring G. vaginalis, culture for G. vaginalis has little value 
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for the diagnosis of BV58. However, a specific oligonucleotide probe test adjusted to detect 
only high concentrations (>107/mL of vaginal fluid) of G. vaginalis has shown improved 
specificity in detecting the infection59. In the studies reported here the Amsel criteria were 
applied to diagnose BV. However, the presence of typical clue cells together with absence of 
lactobacilli is used in some studies where only Gram-stained smears were available to 
establish the diagnosis. 
 
2.3.3.1.1. Microscopy of vaginal wet mount (Amsel criteria) 
The vaginal fluid accumulating in the posterior fornix was collected using sterile cotton-tipped 
swabs (Medical Wire and Equipment, Corsham, UK). The sample was directly placed onto pH 
paper immediately following collection. The swab was then agitated in 1ml of saline and a 
drop of fluid placed on a clean glass slide, a drop of 10% KOH solution was added, and the 
generation of a distinctive "fishy" odour, due to the releases of amines, was considered 
indicative of BV. Two drops of fluid were also placed to a clean glass slide and covered with a 
coverslip. The slide was examined for "clue cells" which are epithelial cells covered with many 
vaginal bacteria giving the margins of the cells a granular appearance under light microscopy 
using a X40 objective. 
 
2.3.3.1.2 Gram stain for BV diagnosis 
Immediately following collection, the swab was rolled onto a clean glass slide and stained with 
Gram’s stain. The smear was examined under X400 magnification for "clue cells", epithelial 
cells containing large numbers of Gram-negative or Gram-variable coccobacilli. These bacteria 
obscure the defined edges of the epithelial cells. This finding together with the absence of 
lactobacilli was considered indicative of BV. 
 
2.3.3.2 Diagnosis of vaginal trichomoniasis 
In all studies, undertaken on women both wet mount microscopy and culture methods were 
employed to identify T. vaginalis in vaginal secretions.  
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2.3.3.2.1 Wet mount microscopy for T. vaginalis 
A procedure similar to that used for detecting clue cells (Section 2.3.3.1.1) was used to detect 
motile flagellate trichomonads.  Microscopically, these protozoa have an ovoid globular shape 
and a characteristic jerky or twitching motility. 
 
2.3.3.2.2 Culture of T. vaginalis 
Vaginal fluid from the posterior fornix was collected using a sterile cotton-tipped swab 
(Medical Wire and Equipment, Corsham, UK) and cultured for T. vaginalis as described in 
Section 2.3.2.4.1. 
 
2.3.3.3 Diagnosis of vaginal candidiasis  
Over 80 percent of cases of vulvovaginal candidiasis (VVC) have been associated with the 
species Candida albicans while the remainder are caused by non-albicans species such as 
Candida glabrata60. Yeast cells and pseudohyphae may be readily detected in vaginal 
secretions using microscopic examination of wet mounts or KOH preparations. Up to 50 
percent of patients with culture-positive symptomatic VVC however have been found to have 
negative microscopy61. On the other hand, owing to the carriage of commensal yeasts in the 
vagina, a positive culture does not necessarily indicate a pathogenic role of the yeasts62. It is 
therefore necessary to consider clinical findings, in conjunction with microscopic examination 
and vaginal culture for the diagnosis of VVC.  
 
In our studies, women presenting with vaginal discharge who were positive for yeasts and 
pseudohyphae on wet mount microscopy and/or on culture, were considered having VVC. 
 
2.3.3.3.1 Wet mount microscopy for Candida organisms 
A procedure similar to that used for detecting clue cells as described in Section 2.3.3.1.1 was 
employed and examined under microscopy for the presence of yeasts/pseudohyphae. 
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2.3.3.3.2 Culture for Candida spp. 
Vaginal fluid from the posterior fornix was collected using a sterile cotton-tipped swab 
(Medical Wire and Equipment, Corsham, UK). Immediately after collection, the vaginal swab 
was inoculated onto a dextrose/chloromycetin agar plate and kept at room temperature. 
Subsequently the inoculated plates were incubated at 33-35OC aerobically for 24-48 hours. The 
presence of typical colonies on the agar plate and presence of yeast cells on Gram-staining 
confirmed the presence of yeasts. Differentiation of Candida species using the germ tube 
method was performed in these studies.  
 
2.3.3.4 Diagnosis of vaginal mycoplasmal infections 
Although both ureaplasmas and M. hominis may colonize the female genital tract without 
producing disease, several studies have found that M. hominis can be recovered more 
frequently from vaginal and cervical specimens collected from patients presenting with PID63. 
In the present studies, attempts were made to isolate only U. urealyticum and M. hominis 
from vaginal secretions. 
 
2.3.3.4.1 Culture of U. urealyticum 
Vaginal fluid from the posterior fornix of women was collected using sterile cotton-tipped 
swabs. Similar procedures to those described in Section 2.3.2.3.1 were used. 
 
2.3.3.4.2 Culture of M. hominis 
Specimens for culture of M. hominis were collected as for U. urealyticum. Immediately following 
collection, swabs were agitated in PPLO broth (Diagnostic Media Products, Johannesburg, SA), 
expressed in the liquid medium and discarded. The specimens were stored on ice and 
transported to the laboratory within 24 hours. The inoculated PPLO broths were placed with 
loosened lids in an anaerobic atmosphere (anaerobic jar) and incubated at 35OC for 24-72hrs. 
The presence of a colour change of the broth from red to dark red was reported as positive. All 
‘positive’ PPLO broths were subculture onto PPLO agar and incubated at 35OC for 3 – 5 days. 
The agar plates were examined under a light microscope (X10 objective) for colonies with a 
typical "fried-egg" appearance. 
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2.3.3.5 Diagnosis of gonococcal cervicitis 
Endocervical swabs for culture of N. gonorrhoeae were collected by rotating the swab in the 
endocervical canal after the cervix was wiped clean of accumulated discharge with a sterile 
ball of cotton wool or gauze. Urine specimens were collected for gonococcal LCR assays. 
Similar laboratory procedures for culture and LCR for N.gonorrhoeae were followed as 
described in Sections 2.3.2.1.2 and 2.3.2.1.3. Microscopic examination of stained cervical 
smears has a lower predictive value compare to that of the urethral smear in men with 
urethritis and therefore direct microscopic examination of Gram-stained cervical smears was 
not performed. 
 
2.3.3.6 Diagnosis of chlamydial cervicitis 
 Endocervical swabs for culture of C. trachomatis and urine specimen for LCR were collected 
as described in Section 2.3.3.5. The endocervical swab was tested for the presence of C. 
trachomatis (CT) using the standard culture method as described in Section 2.3.1.3.1. LCR 
was used to detect C. trachomatis in urine specimens as described in Section 2.3.2.1.3.  
 
2.3.3.7 Diagnosis of cervical HSV infection  
Cervical HSV infection may be asymptomatic or may present as a mucopurulent cervicitis. 
Studies suggest that evidence of HSV cervicitis may be found during colposcopy and on 
Papanicolaou smear microscopy in up to 70 percent of cervical HSV infection30. In our studies 
both culture and type-specific PCR were used to diagnose cervical HSV infection. 
 
After thorough cleansing of accumulated discharge on the cervix, the specimen was collected 
from the ectocervical area on a sterile dacron swab. HSV infection was detected using culture 
and PCR methods as described in Sections 2.3.1.5.1 and 2.3.1.5.3 respectively. 
 
2.3.3.8 Diagnosis of human papilloma virus (HPV) infection 
Human papilloma viruses cannot be propagated in tissue culture although McLean et al has 
reported a successful animal model to mimic natural HPV infection using a transplantation 
technique in mice with a karatinocyte cell line expressing HPV16 E7 or E764. For diagnostics 
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and epidemiological research purposes, the molecular hybridization and amplification 
techniques have been used to identify HPV in various specimens65,66. Serological tests have 
been developed mainly for use in seroepidemiological studies of HPV. In our studies, the 
presence of cervical HPV lesions was detected using PCR and Hybrid Capture Assay 
(Digene Diagnostics, Silver Spring, MD). 
 
2.3.3.8.1 Hybrid capture assay 
Specimens were collected from the endocervical canal and transformation zone using the 
swab provided in the Hybrid Capture Assay (HCA-Digene Diagnostics, Silver Spring, MD). 
Immediately after collection, swabs were placed in the transport medium provided by the 
manufacturer and then stored at -70OC until processed. The presence of low- and high-risk 
HPV types was tested according to the manufacturer’s instructions67. HPV types were detected 
in specimens by using probe A (HPV types 6, 11, 42, 43, and 44) and probe B (HPV types 16, 
18, 31, 33, 35, 45, 51, 52, and 56).  
 
2.3.3.8.2 HPV PCR (consensus primer; MY9/11) 
In addition to the Hybrid Capture System, HPV PCR assays using the consensus primer 
(MY9/11) were conducted at the Centers for Disease Control and Prevention (CDC), Atlanta, 
GA. The detailed procedure for HPV PCR has previously been described elsewhere68. 
 
2.3.4. Diagnosis of HIV infection  
HIV infection can be detected by culture of the virus or direct identification of viral-specific 
antigens or nucleic acid sequences such as P24 antigen, viral DNA or RNA. The 
demonstration of HIV-specific antibodies is the most widely used diagnostic method owing to 
its simplicity and low-cost. It cannot, however, detect recently infected individuals because of 
the presence of the seronegative “window period“ which may last approximately 6 – 12 
weeks.  
 
In the studies reported here, the HIV status of patients was determined by standard antibody 
tests. An unlinked, anonymous testing protocol was employed for routine surveillance studies. 
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Patients who requested voluntary counselling and testing were provided with pre-test and 
post-test counselling. HIV antibodies were detected using a standard automated ELISA 
method  (AxSYM HIV1/2g0, Abbott Diagnostics, North Chicago,ILL) and/or a rapid test 
employing a latex agglutination method (Capillus HIV-1/HIV-2, Cambridge Biotech, USA) or 
chromatographic strip test (Determine HIV, Abbott Laboratries, North Chicago, ILL). In 
selected studies, all HIV antibody positive participants were further evaluated by performance 
of a quantitative HIV plasma viral load assay and CD4+ lymphocyte count. Viral isolation, p24 
antigen and HIV proviral DNA tests were not performed during these studies. 
 
2.3.4.1 HIV antibody 
Blood samples were collected and sera separated as described in Section 2.3.1.1.3. The 
South African Department of Health and SAIMR HIV antibody testing protocol was employed 
for all patients who requested voluntary HIV counselling and testing. It comprised screening 
using a rapid test (i.e., Capillus® HIV-1/HIV-2, Cambridge Biotech, USA) and positive 
samples were confirmed by an ELISA test (AxSYM HIV1/2g0, Abbott Diagnostics). All 
indeterminate or low-titre positive specimens were further tested using the Western Blot 
method (HIV2.2 Blot, Genelab Diagnostics). In studies where unlinked anonymous HIV 
testing was performed on all participants, only a single rapid test (Capillus® 1&2) was used. 
The performance of the rapid test used in all studies was evaluated under local conditions69. 
 
2.3.4.2 HIV plasma viral load measurements 
Vacuum blood collection tubes with EDTA were used to collect plasma specimens from 
patients. After collection, blood specimens were kept at room temperature and subsequently 
centrifuged at 1200 x g for at least 5 minutes to sediment cellular elements. The plasma was 
separated and stored at -70°C. Viral load measurements were performed using the Amplicor 
Monitor Assay (Roche Molecular Systems, Branchburg, NJ) at the National Institute for 
Virology (NIV), Johannesburg, South Africa. The manufacturer’s instructions were followed70. 
A quantitation standard was used to measure RNA with a detection limit of 400 RNA 
copies/mL. The method detects a range of up to 750,000 RNA copies/mL.  
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2.3.4.3 CD4+ lymphocyte counts  
As the CD4+ lymphocyte is the primary target of HIV, CD4+ cell counts have been routinely 
used to determine the level of immunosupression in HIV-1 infected individuals. The depletion 
of CD4+ lymphocytes is strongly associated with the occurrence of specific opportunistic 
infections71. 
 
The enumeration of T-cell subsets involves three distinct measurements: the white blood 
count (WBC), the lymphocyte differential count (percent lymphocytes), and the percentage of 
T lymphocytes that were CD4+, CD8+ and CD3+ positive. In these studies, the WBC and 
percent lymphocyte were routinely measured on whole blood samples using an automated 
haematology instrument (EPICS XL-MCL Flow Cytometer and Coulter T-Q prep, Coulter 
Corporation, Hlaleah, FL). The CD4+, CD8+, CD3+ percentages were determined on whole 
blood by flow cytometric immunophenotyping. 
 
Vacuum blood collection tubes containing EDTA were used to collect whole blood specimens 
from patients. After collection, specimens were kept at room temperature and sent to the 
laboratory within 24 hours for further processing, as described elsewhere72. The following 
reference ranges for adults were used in the interpretation of results; 
White cell count:  4-11 x 109/l 
Total lymphocyte count:  1-4 x 109/l 
CD4+ cells:  500-2010 x 106/ml 
CD8+ cells:   250-990 x 106/ml 
CD3+ cells:   699-3001 x 106/ml 
CD4:CD8 Ratio:   2:1 
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CHAPTER 3 
 
Changes in clinical presentations and aetiology of sexually 
transmitted infections among South African mineworkers, 
coinciding with the advent of the HIV/AIDS epidemic 
 
3.1 Introduction 
3.1.1 Global perspective 
Since the early 1980s, the global epidemiology of sexually transmitted infections (STIs) 
including HIV and its determinants have been extensively studied by researchers from the 
sociological, anthropological and medical disciplines1-5. Like many other infectious diseases, 
the epidemics of conventional STIs and HIV/AIDS have been largely driven by social, cultural, 
economic, behavioural and biological factors. Both epidemics have triggered an intense and 
ongoing debate over the issues related to wider socioeconomic, racial and gender inequities 
which have plagued many societies for past decades.  
 
In general, the most common mode of transmission of STIs and HIV is through the practice of 
unsafe sexual activities.  To have effective insights into STIs and HIV epidemics in a defined 
geographical area, an in-depth understanding of the existing sexual networking patterns in the 
area is required. This knowledge has assisted many public health authorities to implement 
effective prevention and control strategies for STIs and HIV/AIDS.  
 
Globally, the existence of diverse social determinants and sexual networking patterns 
between population groups within countries and regions leads to continuous challenges to our 
understanding of STI and HIV epidemiology. UNAIDS/WHO has established working 
definitions of HIV/AIDS epidemics, whereby countries have been classified into three 
categories  based on the magnitude of the problem and the dominant transmission pattern 
prevailing in a particular country 6-7 (Figure 3.1).  
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  Source: UNAIDS 
 
 
 
 
 
 
 
 Figure 3.1 Global distribution of HIV infection 
(Numerical proxy for type of HIV epidemics – Generalized epidemic: HIV prevalence 
>1% in general population & >5% in a high-risk population group; Concentrated 
epidemic: HIV prevalence <1% in general population but >5% in a high-risk population 
group; Low-level epidemic: HIV prevalence <5% in high-risk groups)  
 
3.1.2 STIs and HIV/AIDS in southern Africa 
In sub-Saharan Africa (SSA), almost all countries have generalized HIV epidemics where the 
majority of transmissions occur through unsafe sexual practices with a phase of accelerated 
spread playing havoc among the sexually active general population (e.g. pregnant women). 
During the early 1990s, a high burden of STIs and HIV infections had already been reported 
in many countries in SSA, especially in central Africa.  
 
Rapid and sustained spread of HIV followed and the disease became rampant in many 
southern African countries during the mid-1990s. This caused major concern, and by 2002, 
South Africa had become the country with the largest number of HIV-infected people on the 
continent, despite the fact that the epidemic started much later than in central and west 
African countries8. Similar trends were observed in countries bordering South Africa such as 
Botswana, Lesotho, Swaziland, Zimbabwe and Zambia as well as in Malawi 8 (Figure 3.2). 
This southern African epidemic has been characterized by several unique features which 
could have contributed to its rapid progression in the region9. During the 1980s, many 
countries in southern Africa, particularly South Africa, enjoyed more stable economies when 
compared to other countries in SSA10. The labour-intensive mining and farming industries 
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played a crucial role in maintaining the country’s economy. The creation of a migrant labour 
system to serve the mines in the early 1900s led to an influx of large numbers of sexually 
active men who subsequently engaged in internal and cross-border migratory labour activities 
within the region.  
 
  
Figure 3.2 HIV prevalence among women attending antenatal care clinics in southern 
Africa, data reported by clinic site or city, 2001-2002 
(Source: World Health Organization 2003) 
 
3.1.3 Genital, including HIV, infections in South African miners 
On average, more than 400,000 workers were employed in the mining industry throughout 
South Africa in 1992, the majority being migrant miners from the former homelands of South 
Africa (KwaZulu, Transkei, Ciskei, Bophutatswana, Qwa Qwa) as well as neighbouring 
countries such as Mozambique, Lesotho, Swaziland, Botswana and Malawi11. Many of the 
migrant mineworkers lived in single-sex hostels, having left their sexual partners at their 
permanent residential place. Anecdotal evidence indicated high levels of STI endemicity in 
both mining areas as well as rural regions where these miners originated12. Extensive mobility 
of sexually active individuals within regions posed major difficulties in implementing effective 
STI/HIV control programmes during the early 1990s. The increasing incidence of major 
conventional STIs cumulated into a hyper-endemic situation in the mines and it was reported 
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that large numbers of patients attended medical treatment stations with genital ulcer disease 
(GUD), inguinal lymphadenopathy and urethritis during that period. It is apparent that the STI 
situation in the early 1990s should have served as an early warning of the forthcoming 
accelerated spread of HIV infection after its introduction into southern Africa during the early 
1980s. Unfortunately, major social and political developments such as the end of the 
apartheid era in South Africa coincided with the early exponential phase of HIV dissemination 
in the region. Unlike in other countries, (e.g. Uganda and Thailand), the lack of decisive 
preventive action against HIV/AIDS and STIs by policy makers and civil societies in the early 
1990s allowed both epidemics to rage virtually unabated in southern Africa13. 
 
3.1.4 Research activities involving sexually transmitted infections in miners, 1981 –
2001 
 
The establishment of the Emergent Pathogen Research Unit (EPRU) of the South African 
Medical Research Council and the South African Institute for Medical Research (SAIMR), 
1981-1993, resulted ongoing STI-related research being conducted among miners in the 
Carletonville region. These activities were expanded with the establishment, in 1994, of the 
National Reference Centre for STD (NRC-STD).  
 
Since 1994, the NRC-STD has provided clinical, epidemiological and microbiological 
assistance to many private and public service providers in southern Africa. In this chapter, the 
findings of epidemiological and microbiological studies conducted at selected STI clinics 
situated at the Carletonville gold mines up to 2001 are presented. 
 
3.2 Mine environment and STI-related services during the study 
period 1992-2000 
 
3.2.1 Geographical location of studies 
With the exception of one investigation into the effect of HIV co-infection on the laboratory 
diagnosis of STIs, notably serological testing for syphilis (see section 4.1), all studies included 
in this chapter were conducted in a dedicated STI clinic located within the Carletonville gold 
mining area.  
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The town Carletonville is situated southwest of Johannesburg approximately 50 km from 
central Johannesburg. The area measures about 800 sq km and three private mining 
companies (Goldfields of SA, Harmony and Anglo-Gold) have been operating in the area 
since the early 1980s. The economy of the district is largely dependent on migrant labour and 
white collar workers employed by these mining companies. The area is strategically located 
on the long distance Johannesburg-Cape Town truck route, stretching from Johannesburg via 
Potchefstroom, Klerksdorp, Bloemfontein or Kimberley, to Cape Town (Figure 3.3).  
 
 
 
 
Figure 3.3 Gauteng province and Carletonville study site in relation to other 
South African provinces and Carletonville District   
(source: http://www.routes.co.za/gp/carletonville/) 
 
3.2.2 The Carletonville mineworker population 
Most residents of the district have either direct or indirect economic and social links with 
mining companies. In 1995, it was estimated that the district had a population of over 200,000 
of which more than 40% were migrant men working in the mines. On average, the mining 
companies employed over 80,000 miners in the Carletonville area from different regions of 
southern Africa. There were some fluctuations in the size of the workforce in response to 
local/international economic situations. However, most employees work for the same 
company for a significant number of years. 
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3.2.3 STI services in mines 
All mine employees are provided with comprehensive health care by the mining companies as 
part of their employment conditions. Unfortunately, most sexual partners of miners (both 
locally and at distant location) are required to seek health care at public or private clinics. All 
symptomatic STI patients from the Goldfields of SA mines were referred to a dedicated STI 
clinic situated at the referral hospital or a mine medical station. The NRC-STD research team 
provided comprehensive STI services for these patients on a regular bi-weekly basis. 
Although systematic health care seeking behaviour studies had not been conducted, key 
informants (clinic/medical staff, community leaders and miner representatives) reported that 
over 90% of symptomatic STI patients in mines in the region sought medical care at the STI 
clinic. This system of service provision remained in place during the period 1992 to 2000. 
Since 2001, however, the mine medical services and NRC-STD introduced a system of 
decentralized STI services which operated at primary health care clinics. During 1999 – 2000, 
surveillance activities introduced by NRC-STD were expanded to determine the burden of 
selected STIs including asymptomatic infections among miners, as well as local communities 
surrounding the mines, by conducting serial community-based, cross-sectional, prevalence 
studies. 
 
3.2.4 Major STI-related events at the study sites (1992 – 2000)  
Although major socio-political transformation occurred in South Africa during the mid-1990s, 
there were no major changes in the mining operations in the Carletonville area. Although 
there were changes in mine ownership, the composition and broad layout of the workforce 
was largely maintained throughout the study period. With the establishment of NRC-STD in 
1994, the clinical and microbiologically-oriented STI services were augmented by public 
health-related intervention activities. On-site voluntary counselling and testing (VCT) was 
introduced for the diagnosis of HIV infection in STI patients by NRC-STD staff, although 
unlinked anonymous testing for surveillance purposes was still maintained. Syndromic STI 
management protocols were established and used for patient care. More health education 
including passive partner notification and management using contact slips were implemented. 
In 1999, both clinical and public health intervention activities were extended to communities 
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surrounding the mines. Targeted intervention programmes for women at high risk who had 
sexual contact with the miners in exchange for kind or cash were also implemented14. As 
mentioned earlier, STI services were decentralized to primary health care clinics in 2001. This 
major rationalization of health services was preceded by an appropriate training programme 
which included syndromic management of STIs.  
 
Measures to improve health care delivery during the period 1992 – 2000 will have to be taken 
into account when interpreting the changing patterns of STIs observed during this period. 
Some of the changes are presented in Figure 3.4 and include such major events as 
introduction of syndromic management in the public and mining sectors in 1995 and the 
periodic presumptive treatment (PPT) programme of women at high risk instituted at that time 
(Figure 3.4). 
 
 
 
 
Figure   
 
Early Events 
 
- Improvement in treatment of STIs through 
providing dedicated STI services, clinical & 
microbiological research, trainings, referrals 
 
- Limited community-based and behavioural 
intervention activities 
Established  RCSTI* 
 
- Syndromic STI management including 4 Cs** 
- Improved STI & HIV surveillance including 
introduction of new tiered surveillance system 
- Facilitate multiagency collaboration# 
- Advocacy 
- Training & integrated interventions 
 
 
 
Figure 3.4 Important interventional activities in Carletonville mine community 
(1988 – 2000) 
Community-based intervention 
- Periodic presumptive therapy 
in high-risk women in 
Carletonville 
- Community-based intervention 
(Mothusimpilo) project 
Established  N D* 
1988 1990 1992 1994 1996 1998 2000  
Community-based intervention 
- Periodic presumptive therapy 
in high-risk women in 
Carletonville 
- Community-based intervention 
(Mothusimpilo) project 
 
* National Reference Centre for STD;  
** Condom promotion, Counselling (risk-reduction), Contact tracing, Compliance to treatment. 
# Initiate & participate collaborative projects between international NGOs such as Family Health International, 
Population Council, DFID (UK), the National and Provincial departments of Health, Mining Company such as 
Goldfields of SA & Harmony Mining Companies. 
 
Figure 3.4 Measures to improve STI prevention and control in Carletonville 
mining areas during the period 1988 – 2000 
 
 
 
3.2.5 Introduction of a routine STI surveillance system  
A standard data collection system was established in 1990. Basic personal characteristics 
such as a unique identifier (i.e. mine employment number), name, date of birth, marital status 
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and place of origin (permanent residence) were entered onto a simple specially designed 
form, together with a summary of clinical and routine laboratory findings. All patients 
presenting with new STI episodes were screened serologically for syphilis, using a 
quantitative RPR test. VCT for HIV was provided for all new STI patients and the refusal rate 
was negligible. All HIV-seropositive patients were referred to professional counsellors for 
further assistance. Only symptomatic HIV-seropositive patients were assessed for 
reassignment for less labour intensive duties or counseling for medical retirement according 
to prevailing occupational health regulations at the mine which dictated that such action would 
be warranted only when miners become sufficiently symptomatic to affect their work 
performance. No discriminatory measures were taken as a result of a patient’s HIV status (for 
further discussion, see Section 3.3.4).  
 
Patient information was captured in a database at the SAIMR, linked to a unique mine 
number specifically excluding patients’ names. Syndromic management of STIs was fully 
implemented in 1995 and the data collection form and database were updated to 
accommodate these changes. The modified surveillance form was used until end of the study 
period (See Annexure 3.1 - Routine Surveillance Form). 
 
3.3 STI research projects involving HIV-infected patients 
Although several STI-related research projects were coordinated by NRC-STD and its 
predecessor, the EPRU, in the 1980s and 1990s, only those with a relevant HIV component 
and, specifically, more recent HIV-directed studies involving the author of this thesis, will 
feature in this chapter. 
 
3.3.1 Cross-sectional aetiology studies 
Periodic cross-sectional studies to determine the aetiology of selected STI syndromes were 
conducted at the dedicated mine clinic at Carletonville. With rapid advances in STI diagnostic 
methodology, more sensitive, specific and non-invasive laboratory methods became available 
and were used where applicable and when considered cost-effective or affordable. In these 
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studies, established laboratory methods were however still included in parallel with new 
techniques, ensuring comparability of prevalence data.  
 
The cross-sectional studies were augmented by special ad hoc studies such as clinical trials 
and surveillance of antimicrobial resistance. In general, the basic design and laboratory 
methods were consistently maintained to provide continuity and afford additional scientific 
validity to the surveillance programme. Relevant historical data were also used to assess 
temporal changes in aetiological patterns (Table 3.1). 
 
Table 3.1 Summary description of studies included in Chapter 3 
Study Type Study Population Sampling Method 
Sample 
Size Laboratory Method 
Year 
of 
Study 
Record Reviews 
Miners presenting with 
new STI episodes at the 
Carletonville Mine STI 
Clinic 
All patients 
treated at the 
clinic 
 
Clinical diagnosis 
using pre-defined 
criteria and 
serological tests 
1992 
to 
2000 
Cross-sectional 
(Aetiology study) Miners with GUD Consecutive 239 
Microscopy,Culture, 
Serology 1986 
Cross-sectional 
(Aetiology study) Miners with GUD Consecutive 213 
Microscopy,Culture, 
Serology 1990 
Cross-sectional 
(Aetiology study) Miners with GUD Consecutive 232 
Microscopy,Culture, 
Serology, M-PCR 1994 
Cross-sectional 
(Aetiology study) Miners with GUD Consecutive 186 
Microscopy,Culture 
Serology, M-PCR 1998 
Prospective 
study (HIV 
Shedding) 
HIV-seropositive miners 
with GUD Consecutive 78 
Microscopy,Culture, 
Serology, M-PCR, 
HIV viral load, CD4+ 
count 
1998 
to 
1999 
Cross-sectional 
Multi-centre 
aetiology studies 
Patients presenting with 
GUDs patients at STI 
clinic in Maseru, Cape 
Town, Durban, 
Carletonville 
Consecutive  868 Microscopy,Culture, Serology, M-PCR 
1993 
to 
1998 
Case-reports STI patients co-infected with HIV Observations - 
Microscopy,Culture, 
Serology, M-PCR 
1994 
to 
2000 
 
3.3.1.1 Study population 
All studies were conducted at the STI clinics serving miners from Goldfield of S.A goldmines 
at Carletonville, near Johannesburg. A retrospective clinic record review was conducted to 
explore the temporal changes in aetiology of STI syndromes among male migrant miners 
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from southern Africa. The records of all STI patients presenting with new episodes of STI at 
the study clinic from 1992 to 2000 were reviewed and analysed by the investigator. 
The results of the aetiological studies are reviewed and compared with the studies 
prospectively conducted between 1994 and 1998 by the investigator. All patients presenting 
with GUD during each cross-sectional or prospective study during the study period who 
fulfilled the pre-defined criteria were consecutively enrolled after informed consent was 
obtained. A sub-group of HIV-seropositive patients with GUD were included in the HIV-
shedding study. 
 
3.3.1.2 Sampling method 
All patients presenting with genital ulcer disease were offered syphilis serology and voluntary 
HIV counselling and testing after obtaining written informed consent. The demographic, 
behavioural and clinical presentations were recorded by interviewers using standard 
questionnaires (Annexure 3.2). Blood was taken from all consenting patients and tested for 
syphilis, chlamydial, type-specific herpes (in some studies) and HIV serological tests. Firstly, 
all ulcer(s) were cleaned with 10ml of normal saline and the washings pooled and collected in 
a sterile screw-cap container and stored in –70º C until processed to measure HIV viral 
copies as described in Section 2.3.4. Ulcer scrapings are then taken from the edges of the 
largest ulcer and tested for T. pallidum and Donovan bodies by darkfield microscopy and 
Giemsa staining respectively. Swabs are taken from the base of active lesion and cultured for 
H. ducreyi and the molecular detection of H. ducreyi, T. pallidum and Herpes simplex virus by 
multiplex PCR (M-PCR) techniques as described in Section 2.3.1.  A sub-group of patients 
who agreed to return after 7 days and who were found to be HIV positive, had CD4+ counts 
performed, plasma HIV viral load and shedding of HIV in ulcer washings determined. Lastly, 
all patients were treated using the appropriate management algorithm for genital ulcer 
syndrome of the NRC-STD (Annexure 3.3). The same procedures were repeated at the return 
visit on day seven if complete re-epithelialisation has not been achieved.  All HIV-seropositive 
patients were provided with post-test counselling by trained counsellers and appropriate 
treatment or prophylaxis measures for opportunistic infections was given if indicated. 
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3.3.1.3 Inclusion and exclusion criteria 
All patients presenting with a new episode of STI were included in the record reviews. 
Patients who returned to the clinic for follow-up visits for any new STI episode were excluded 
from the analysis.  
 
The standard inclusion criteria for the cross-sectional aetiological studies and the prospective 
HIV-shedding study included:  
- patients presenting with genital ulcerations (> 2 mm in size) during the study 
period  
- no previous history of treatment for current episodes 
- availability for follow-up visits for two weeks 
- ability to provide informed consent 
- agreement for voluntary HIV counselling and testing 
 
3.3.1.4 Questionnaire 
Only limited demographic, clinical and serological information were collected for routine STI 
patients using a standard questionnaire (Annexure 3.1). However, more in-depth interviews 
were conducted in their own language by the study team member using pre-coded 
questionnaires. The patients’ demographic characteristics, sexual behaviour, presenting 
symptoms and clinical history of current STI episode were collected during the interview. The 
detailed clinical description of presenting STI episode was recorded by the investigators using 
standard clinical criteria. The results of laboratory tests performed on each patient were 
recorded when available.  
 
3.3.1.5 Laboratory methods 
The detailed methods of each laboratory investigation have been described in Section 2.3. All 
patients were screened for quantitative syphilis serology (by RPR) at the time of presentation 
with each new episode of STIs.  Almost all patients agreed to participate in the voluntary 
counselling and testing for HIV and the standard test algorithm recommended by the SAIMR 
serology laboratory was used for those patients. Those patients who refused to provide blood 
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were excluded from the aetiological studies although a participation rate of over 99% for 
voluntary counselling and testing was recorded during the study. 
 
Other appropriate microbiological investigations such as microscopic examinations, cultures 
and nucleic acid amplification tests (NAATs) were only conducted on specimens (e.g. genital 
ulcer exudates, urethral swabs and urine) collected from the patients enrolled in the 
aetiological studies. In addition, additional serological tests such as type-specific herpes 
serology, chlamydial micro-immunofluorescence (micro-IF) assays, and FTA-ABS were also 
conducted in these cases. Laboratory investigations such as CD4+ counts and HIV plasma 
viral load (PVL) measurements were conducted only on patients enrolled in the HIV-shedding 
study.  
 
The detection of aetiological agents and HIV viral load in the plasma and genital ulcer 
exudates were measured at both enrolment and subsequent follow-up visits when necessary. 
The detailed methods used in collection of genital ulcer exudates for the measurement of HIV 
shedding in ulcer exudates is described in Sections 5.1 and 5.2. 
 
3.3.1.6 Treatment protocol 
All patients were immediately treated according to the STI management algorithm for the 
respective STI syndromes at the initial visit (Annexure 3.3). Although “tests of cure” for all 
possible agetiological agents were not conducted routinely, microbiological, virological and 
serological investigations were conducted in those participating in follow-up studies or those 
identified as treatment failures at the follow-up visit. Patients presenting with mixed STI 
syndromes were treated by using the most logical combination of recommended therapy for 
the presenting syndromes. Anti-herpes therapy was only provided if there was laboratory 
evidence of HSV infection or patients presented with a typical clinical presentation of genital 
herpes during participation in the HIV shedding study, or patients who exhibited clinical 
failures but had demonstrable bacteriological cure for H. ducreyi, T. pallidum, C. trachomatis 
and donovanosis at the follow-up visit. Valacyclovir 500 mg BD for 5 days was used as 
standard therapy for suspected or confirmed cases of genital herpes. 
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3.3.2 Specific STI studies relating to effects of HIV co-infection 
During the period 1992 – 2000 several studies were conducted by the NRC-STD where the 
effects of HIV infection on other infections of the genital tract among mineworkers were 
assessed. 
 
3.3.2.1 HIV co-infection and clinical presentation of STIs 
Patients presenting with defined STI syndromes were enrolled consecutively in the studies. In 
each case, their HIV status was recorded when, on history-taking, miners who have had a 
previous STI confirmed at a clinic visit were tested for their serological status through NRC-
STD’s VCT service. Those who had not been tested previously, were offered VCT at the time 
of their visit, as were those of unknown serostatus.  
 
Standard questionnaires designed for specific STI syndromes were completed by the 
investigator. An aetiology-based clinical diagnosis was also made using pre-defined criteria 
for evaluation purposes. All patients were treated according to syndromic STI management 
protocols and subjected to syphilis screening by RPR testing (Annexure 3.3) The 
immunological status of patients whose positive HIV serological status had previously been 
established was assessed by the use of CD4+ counts and HIV plasma viral load (PVL) 
determinations.  
 
During the study period, the standard of care for HIV-seropositive individuals did not include 
provision of anti-retroviral drugs. HIV-seropositive mineworkers were provided with 
prophylaxis for selective opportunistic infections including tuberculosis and Pneumocystis 
jerovicii (formerly P. carinii) pneumonia (PCP) at the referral hospital. Standard laboratory 
investigations appropriate for STI syndromes as they presented in patients were performed as 
described in Section 2.3. The nature and severity of clinical presentations were analysed 
retrospectively according to objective criteria in relation to their HIV status. 
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3.3.2.2 Effect of HIV co-infection on the laboratory diagnosis of STIs 
The performance of routine laboratory tests in studies on the aetiology of STI syndromes in 
patients from Johannesburg, Carletonville, Durban, Cape Town and Lesotho, particularly 
syphilis serology in patients presenting with primary syphilis, was evaluated and the effect of 
co-infection with HIV investigated. Similar enrolment steps as outlined in sections 3.3.1.1 – 
3.3.1.3 were followed. Patients who were found to have M-PCR-confirmed primary syphilis at 
the various study sites were included in the analysis. The same protocol and laboratory 
methods as described for GUD (see sections 2.3.1.1 and 3.3.1.5) were followed throughout. 
 
3.3.2.3 Effect of HIV co-infection on response to treatment of STIs 
This section of the thesis concentrates on patients presenting with GUD. Their HIV status was 
determined as described in Section 2.3.4. Laboratory investigations to determine the 
aetiology of STI syndromes, HIV/syphilis serological status and immune function were 
conducted as described in Section 2.3. All patients were treated using standard treatment 
protocols for their respective STI syndromes. Follow-up visits were scheduled on Day 7, Day 
14 and Day 21 to monitor clinical progress and establish microbiological cure.  
  
3.3.2.4 Lesional shedding of HIV from genital ulcers 
Shedding of HIV from genital ulcers, the effect of treatment on viral shedding and the method 
including a novel specimen collection technique used to determine quantitatively the number 
of HIV RNA copies in fixed amounts of genital ulcer exduate were performed in male patients 
at the Carletonville mine clinic and subsequently in female sex workers at the Esselen Street 
Clinic in Johannesburg. These studies are described in detail in Chapter 5 (male patients) and 
Chapter 7 (female patients). 
 
3.3.3 Data entry, management and analysis 
All demographic, clinical and microbiological data were captured in pre-coded databases 
using EpiInfo Version 6.04 (CDC, Atlanta, GA) and Microsoft Access (Microsoft, SA) 
programmes. The accuracy of data entry was checked by double entries of randomly selected 
records into each database. Databases with discrepant information were re-checked, and 
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double entry of entire databases was performed when necessary. The data were exported 
into SPSS® Version 8.0 (SPSS Inc., Chicago, IL.) and analysed by the investigator. 
 
3.3.4 Ethical considerations 
All study protocols were submitted to the Committee for Research on Human Subjects, of the 
University of the Witwatersrand for ethical approval. A simple patient information sheet 
describing study objectives, procedures, risks and benefits was prepared and used to explain 
to patients in their mother tongue the nature of the study and the ethical issues involved by 
study coordinators at the enrolment visit. Written informed consent was obtained from all 
participating subjects. All symptomatic patients were treated immediately using standard 
syndromic management protocols. Follow-up visits were scheduled where patients were 
informed about their laboratory results. Additional treatment or referral was provided if 
necessary. All HIV seropositive patients were provided with post-test counselling and referred 
to local HIV clinics for follow-up. In unlinked anonymous studies, confidentiality was 
maintained by de-linking all identifiable personal information before testing for HIV. 
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Annexure 3.1  Surveillance form and data elements used for routine STI  
patients at Carletonville mine STI clinic 
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Annexure 3.2   Questionnaires used for GUD aetiology and HIV shedding studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  Name
     Surname  :                                                       Firstname  
2.  Age  (Years)
3. Origin (1=KZN, 2=Lesotho, 3=Ecape, 4=MZB, 5=Botswana, 6=Botswana)
4.  Marital Status (1=Single, 2=Married, 3=Others)
5. Where did you get this disease? (1=Mine, 2=Home, 3=Others)
  
6. From whom did you get it? (1=Regular partner,2=Casual partner/Prostitute)
7. Number of sexual partners ; in last month
in life-time
8. Have you ever used a condom ; in last month
in your life
9. Estimated incubation period (Days - Last sexual exposure to appearance of symptom)
     When did you have sex last time?
     When did you first notice this sore?
      Duration  of  symptoms? (Days)
10. How did the sore start ? (Blister/Rash/Pustule/Abscess etc.)
11. Did you have any treatment for this complaint in last four weeks?
12. History of recurrences of similar sores?
      How many times in this years? (Also check patient's card)
13. Did you have sex after you notice the sores?
       
      (if  yes) ou use condom?
      
14. History of any  illness in last 30 days (Review Card as well)
 
ed
Do y
Age
Marital
Partner1
Partner 2
Initial
1          2        3
1        2Source  of  infection
1        2
1        2
Condom 1
Condom 2
Incubation
Duration
 1      2       3 4      5       6Origin
Place of  infect.
Visit
Datesex  :
1          2         3
Datesore
1        2hsores
sorefreq 1        2
1        2
1        2
hsex
hcondom
19.  Is  HIV  status  known? 1        2Previous  HIV
Other relevant notes
20. Date diagnosed? Date HIV
D     D       M       M       Y     Y
HIV related and other diseases?
Dis1 :
Dis2 :
Dis3 :
Dis4 :
1        2Dis Other Comments ? 1        2Com
How long you have been working in the mine?
Year Months
D     D       M       M       Y     Y
Date
Mine Num
1        2RX
D     D       M       M       Y     Y
Others) 
? 
id
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 7. Photo  Num.                      
 1      2        3 4       5      6
1.   GENITAL ULCER
    11.1   Number
    11.2   Tender
    11.3   Deep
    11.4  Irregular/Ragged Margin
    11.5  Purulent Base 
 
    11.6  Size of Target Ulcer (mm)
    11.7  Erythematous Edges  
    11.8  Bleed on touch
 
4.  URETHRAL  DISCHARGE 1          2
2.  GLANDS
12.1   Site
12.2   Matted
12.3   Ruptured
12.4   Size (mm)     
1        2
Uni    B i
1        2
1        2
5.    OTHER  STD
15.1  HERPES  SIMPLEX 
15.2  G. WARTS
15.3  EPIDIDYMOORCHITIS 
15.4  SCABIES
15.5  Molluscum
 2
3  
4
5
1    
1        2
3.  CLINICAL DX        
       (1=Chancroid, 2=Syphilis , 3=G. Herpes, 4=LGV, 5=G.I, 6=Other)
6. Photo  taken                      1 2
1        2
1      2
1      2
1      2
1      2
1      2
1      2
Other Relevant notes
  BOM/Dysuria 1          2
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Annexure 3.3    Syndromic management of GUD (1994 – 2000) 
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3.4 Main findings of studies in miners 
3.4.1 STI and HIV trends in Goldfields miners at Carletonville (1992 – 2000) 
During the study period, the average daily workforce at the Goldfields of SA mines where the 
study was conducted (i.e. East Driefontein, West Driefontein, Deelkraal and Doornfontein) 
ranged from 38468 in 1992 to 18300 in 2000. A sharp decline in the number of miners 
employed occurred in 1997. This was due to the restructuring of the Goldfields Mining 
company while the Deelkraal mine was sold to another mining company. The average daily 
workforce in the two major mines, East Driefontein and West Driefontein, was, however, 
relatively stable with a moderate decline documented between 1997 and 2000. Overall trends 
in the size of different mine populations are shown in Figure 3.5. 
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Figure 3.5 Average daily workforce at the Goldfields of SA mines in Carletonville 
(1992 – 2000)  
 
During the study period, 36,686 new STI episodes were treated at the clinic and the mean 
annual STI incidence rate was 137.4 per 1000 miners (range – 99.6 to 162 per 1000).  The 
highest annual incidence occurred in 1994 when 5521 new STI episodes were treated. The 
incidence gradually declined to its lowest, 1822 episodes in 2000 (Figure 3.6). A significant 
increase in the annual STI incidence rate was found in 1994 when compared to that of 1993 
(114 vs. 162 per 1000, χ2 = 338.94, p<0.0001). The STI incidence remained at a high level 
throughout 1994–1999 although a slight decline was seen in 1997. The annual STI incidence 
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rate has significantly declined from 157/1000 in 1999 to 100/1000 in 2000 (χ2 = 266.3, p 
<0.0001). 
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Figure 3.6 Annual incidence of STI episodes seen at the Carletonville mine STI 
clinic (1992 – 2000) 
 
Over 90% of STI episodes occurred among miners from South Africa, particularly from 
KwaZulu-Natal and the Eastern Cape province, as well as from other neighbouring countries 
such as Lesotho, Mozambique, Swaziland and Botswana (Table 3.2). The ethnic distribution 
of miners was not available and therefore the ethnic-specific incidence of STI was not 
calculated. Table 3.2, however, records the regions/countries from where miners were 
recruited. 
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Table 3.2 Residential origin (area of permanent residence) for miners presenting with 
STIs, Carletonville (1992 – 2000) 
 
ORIGIN OF MINERS NUMBER %
KWAZULU NATAL 9055 24.7%
LESOTHO 8186 22.3%
EASTERN CAPE 7191 19.6%
MOZABIQUE 4569 12.5%
SWAZILAND 2230 6.1%
BOTSWANA 2130 5.8%
NORTHERN PROV.* 843 2.3%
GAUTENG 313 0.9%
NORTHWEST 222 0.6%
NORTHERN CAPE 212 0.6%
FREE STATE 106 0.3%
MPUMALANGA 75 0.2%
WESTERN CAPE 48 0.1%
MALAWI 5 0.0%
OTHERS 788 2.1%
MISSING 713 1.9%
Total 36686 100.0%  
* Now called Limpopo Province 
 
 
Overall, the mean age of STI patients was 30.9 years (range 18 to 65 years), the majority 
(64.5%) being in the 25 – 39 year age group. The proportion of miners in older age groups 
(i.e. 25 – 39 and above 39 years) increased in recent years. Of 5194 episodes treated in 
1995, 861 (16.6%) occurred in the 18 – 24 year age group compared to 11.2% in 1999 and 
7.6% in 2000 (χ2 = 43.04, p<0.0001) (Figure 3.7). The majority of miners (65.3%) were 
married but 32.8% denied ever being married. 
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Figure 3.7 Age distribution of miners with STIs (1992 – 2000)  
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All miners with STIs were offered voluntary counselling and testing for HIV antibody and the 
majority (over 99%) accepted. A total of 35,789 HIV tests were performed during 1992 – 2000 
and the overall HIV prevalence was 35.3% (95% CI – 34.8% - 35.8%). During 1992 – 1994, 
the HIV prevalence was high but stable within the range of 18% to 20.8%. It, however, 
increased significantly in 1995 (20.7% in 1994 vs. 42.4% in 1995, χ2 = 579.6, p<0.0001), and 
this increasing trend continued until 1998. The HIV prevalence peaked at 51.6% in 1998 (95% 
CI – 49.9% - 53.3%) followed by a gradual decline to 47.3% (95% CI – 36.7% - 41.3%) in 
2000 (Figure 3.8). 
 
A variation in HIV prevalence was detected among groups from different regions presenting at 
the STI clinic. Over the years, the HIV prevalence of STI patients originating in Mozambique 
and Eastern Cape was consistently lower than that among patients from Swaziland, KwaZulu-
Natal and Botswana. Except for those from Mozambique, the HIV prevalence rate peaked in 
1998 in miners from all regions. The HIV prevalence was consistently higher among STI 
patients from Swaziland with a peak prevalence of 63.5% (95% CI – 57.1% - 69.4%) in 1998. 
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Figure 3.8 Number of miners tested for HIV at STI clinic and HIV prevalence,
  Carletonville (1992 – 2000)  
 
The lowest HIV prevalence was found in STI patients from Eastern Cape which peaked in 
1998 with 43.8% (95% CI – 40.5% - 47.2%). As of 2000, the lowest HIV prevalence of 31% 
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(95% CI – 26.8% - 35.5%) was found in miners from Eastern Cape attending the STI clinic. 
The highest HIV prevalence of 50% (95% CI – 39.9% - 60.1%) was found in those from 
Swaziland (Figure 3.9). 
 
In summary, there was a rapid surge in the prevalence of STIs among miners up to 1994, 
followed by a step-wise increase during the period 1994 – 1998, and a gradual fall in 
prevalence during the succeeding three years. This rapid increase in HIV prevalence among 
miners with STIs peaked in 1998 at a rate marginally exceeding 50%. HIV prevalence rates 
among STI patients varied substantially in miners with different residential origins. 
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Figure 3.9 HIV prevalence among migrant miners by region of origin attending 
an STI clinic at Carletonville (1992 – 2000) 
 
3.4.2 Changing Patterns of STI Syndromes (1992 – 2000) 
STI syndromes such as genital ulcer diseases (GUD), urethritis, genital warts and epididymo-
orchitis were the most frequent presentations recorded during the period 1992 – 2000, 
representing 91% of total episodes. The relative prevalence of the major STI syndromes is 
shown in Figure 3.10.  
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The relative prevalence of GUD, including clinically diagnosed herpes and lymphogranuloma 
venereum (LGV), was significantly higher than urethritis during the period 1992 – 1998. The 
increasing trend in relative prevalence of GUD was found during the period 1992 – 1994 
rising from 50.6% (95% CI – 49% - 52.1%) in 1992 to 57.1% (95% CI – 55.8% - 58.4%) in 
1994 (χ2 = 38.6, p<0.0001). Thereafter, a decline in the proportion of cases presenting as 
GUD occurred. A sharp decline was found in 1998 with only 48% of 3482 STI episodes were 
GUDs compared to 54.4% in 1997 (χ2 = 32.7, p<0.0001).  
 
Meanwhile, there was a steady increase in the relative and absolute prevalence of urethritis. 
The definition of urethritis includes those complaining of burning on micturition and dysuria. 
Urethritis was the most common presentation among STI patients in 1999 and 2000, 
representing 44.3% and 43.5% of cases respectively. Similar increases were also found when 
comparing the relative prevalence of genital warts and epididymo-orchitis. The relative 
prevalence of genital warts and epididymo-orchitis increased from 0.8% in 1992 to 4% (χ2 = 
70.6, p<0.0001) and 0.8% to 1.7% (χ2 = 9.2, p=0.002) respectively, in 2000. 
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Figure 3.10 Proportion of specific STI syndromes diagnosed in Carletonville mine 
clinics (1992 – 2000) 
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 As shown in Figure 3.11, the proportion of GUD cases clinically diagnosed as herpes 
significantly increased from 9.1% (of 1951 GUD episodes) in 1992 to 36% (of 767 GUD 
episodes) in 2000 (χ2 = 285.5, p<0.0001). The relative prevalence of cases clinically 
diagnosed as LGV ranged between 8.8% in 1993 and 15.3% in 2000. A sharp decline in non-
herpetic, non-LGV GUD episodes occurred between 1992 and 2000 (80.5% in 1992 vs. 
48.8% in 2000, χ2 = 272.9, p<0.0001). The majority of these ulcerations were clinically 
diagnosed as chancroid (RC Ballard and Ye Htun, personal observations). 
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Figure 3.11 Relative prevalence of clinical presentations of GUDs, Carletonville 
(1992 – 2000) 
 
The incidence of GUD, which was not clinically compatible with genital herpes or LGV, 
increased sharply in 1992 – 1993, peaked at 70.8/1000 population in 1994 and then declined 
steadily to 20.4/1000 in 2000 (Figure 3.12). The incidence of clinically diagnosed herpes 
increased significantly from 4.6/1000 population in 1992 to 27.6/1000 in 1998 (χ2 = 62.8, 
p<0.0001). In contrast, the incidence of urethritis continued to increase during the period 1992 
– 1999 and then stabilized in 2000.  
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In summary, GUD was the most common STI presentation among miners during the period 
1992 – 1998. The decline in incidence of GUD was mainly attributable to a reduction in the 
number of GUD which were clinically incompatible with genital herpes or LGV. Although, 
there was a sharp decline in GUD cases, in more recent years this syndrome contributed to 
42% of STI episodes seen at the clinic. With a substantial reduction in clinically diagnosed 
non-herpetic/non-LGV GUD, other causes of GUD, particularly genital herpes together with 
urethritis, have contributed significantly to the STI burden on the mines. 
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Figure 3.12 Disease-specific incidence of STI among miners, Carletonville  
(1992 – 2000) 
 
As mentioned in Chapter 3.3.1, the HIV prevalence among STI patients significantly 
increased from 18% in 1992 to reach a prevalence of 51.6% in 1998. (χ2 = 918.0, p<0.0001) 
Similar trends were found among patients presenting with other STI syndromes.  The HIV 
prevalence was significantly higher among patients with genital warts (59.8%, 95% CI 56% - 
63.4%), followed by GUD (40.1%, 95% CI 39.4% – 40.8%) and epididymo-orchitis (36.3%, 
95% CI 41.2% - 31.8%). The HIV prevalence among urethritis patients was the lowest 
(29.6%, 95% CI 31.8% – 41.2%), and was significantly lower than that of among 
epididymoorchitis patients (29.6% vs. 36.3%, χ2 = 8.89, p 0.003) (Figure 3.13). 
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Figure 3.13 HIV prevalence and its 95% confidence interval among miners 
presenting with STI syndromes, Carletonville (1992 – 2000) 
 
The trend in HIV prevalence among miners presenting with different STI syndromes is shown 
in Figure 3.14. A consistent increase in HIV prevalence among all patients with the different 
STI syndromes during the period 1992 – 1998 was recorded. The prevalence peaked in 1998 
and a steady decline followed during the period 1998 – 2000. When GUD was compared 
based on clinical diagnosis, patients with non-herpetic genital ulcerations had a higher HIV 
prevalence rate than those with clinical herpes. However, the overall difference in HIV 
prevalence rates between the two groups was not statistically significant (41.4% vs. 40.5, χ2 = 
0.98, p 0.32). The association between HIV and different GUD pathogens was further 
explored using microbiological surveillance. 
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Figure 3.14 Trend in HIV prevalence among miners presenting with different  
STI  syndromes, Carletonville (1992 – 2000) 
 
During 1995 – 2000, 17,659 patients with new STI episodes were screened serologically for 
syphilis, using quantitative RPR tests and 1688 (9.6%, 95% CI – 9.1% - 10%) were found to 
be positive. The annual syphilis seropositivity rate ranged from 11.7% (95% CI – 10.3% - 
13.1%) in 1995 to 5.2% (95% CI - 4.1% - 6.1%) in 2000. The decline was most evident in 
1999 and was consistent for patients presenting with all major STI syndromes (Figure 3.15). 
There was a slight increase in the syphilis seropositivity rate among genital ulcer patients in 
2000, although this increase was not statistically significant (χ2 = 1.47, p 0.22). 
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Figure 3.15 Trend of syphilis seroprevalence among STI patients, Carletonville 
 (1995 – 2000) 
 
3.4.3 Changing aetiology of STI syndromes 
Cross-sectional studies to detect the aetiologies of STI syndromes were conducted at four-
yearly intervals using the most sensitive and specific laboratory tests available at the time. 
During the study period (1992 – 2000), two cross-sectional studies were conducted using 
standard study protocols as described in Chapter 3.2. The newly developed multiplex PCR 
(M-PCR) method was used to detect T. pallidum, H. ducreyi and HSV in ulcer exudates. To 
maintain comparability with previous studies conducted in 1986 and 1990, the traditional 
methods of culture for H. ducreyi and HSV were also employed in the 1994 and 1998 studies. 
The results of previous studies conducted in 1986 and 1990 were included for comparison.   
The comparative aetiology of GUD using non-NAAT technology is shown in Table 3.3. No 
significant change in the proportion of patients with a single aetiological agent was detected 
during the study period 1986 – 1998.   
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Table  3.3 Aetiology of genital ulcer diseases, Carletonville (1986 – 1998) 
1986 1990 1994 1998
  N = 239  N = 213  N = 232  N = 186
Single Aetiology 167 69.8% 129 60.6% 142 61.2% 120 64.5%
 Chancroid 127 53.1% 107 50.2% 93 40.1% 71 38.2%
 LGV 8 3.3% 2 0.9% 6 2.6% 9 4.5%
 G. Herpes 3 1.3% 3 1.4% 23 9.9% 31 16.7%
 RPR +ve 29 12.1% 17 8.0% 20 8.6% 9 4.8%
Mixed Infection 41 17.2% 27 12.7% 28 12.1% 15 8.1%
 Chancroid + RPR 28 11.7% 18 8.5% 19 8.2% 10 5.4%
 Chancroid + LGV 6 2.5% 3 1.4% 1 0.4% 1 0.5%
 Chancroid + LGV + RPR 0 1 0.5% 0 0
 LGV + RPR 2 0.8% 0 1 0.4% 2 1.1%
 Herpes + LGV + RPR 0 1 0.5% 0 0
 Herpes + LGV 0 0 0 0
 Herpes + RPR 2 0.8% 0 2 0.9% 1 0.5%
 Herpes + Chancroid + RPR 1 0 1 0.4% 0
 Herpes +  Chancroid 2 0.8% 4 1.9% 4 1.7% 1 0.5%
   
Indeterminate 31 13.0% 57 26.7% 62 26.7% 51 27.4%
*   H.ducreyi culture positive 
** C.trachomatis culture positive from ulcer exudates 
*** HSV culture positive 
 
However, the proportion of patients with positive H. ducreyi (HD) culture alone declined 
significantly from 53.1% in 1986 to 38.2% in 1998 (χ2 = 9.42, p 0.002). The overall relative 
prevalence rate of HD (single and mixed) had also declined from 68.6% in 1986 to 44.6% in 
1998 (χ2 = 24.7, p<0.001) (Figure 3.16).   
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 Figure 3.16 Trend of culture-confirmed chancroid among GUD patients,  
  Carletonville (1986 – 1998) 
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Similarly, rates of syphilis seropositivity among GUD patients also declined steadily from 
25.9% in 1986 to 11.8% in 1998 (χ2 = 13.1, p<0.001) (Figure 3.17). 
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 Figure 3.17 Trend of syphilis seropositivity rate (RPR-positive) among  
 GUD patients, Carletonville (1986 – 1998) 
 
In contrast, the relative prevalence of HSV increased significantly from 3.3% in 1986 to 17.7% 
in 1998 (χ2 = 24.9, p<0.001) (Figure 3.18). 
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Figure  3.18 Trend of relative prevalence of culture-confirmed HSV in GUD                                                          
patients (1986 – 1998) 
 
 
 - 73 - 
There was an increasing trend in the prevalence of HIV among patients presenting with GUD 
during the study period (Figure 3.19).  The HIV prevalence rapidly increased from 1.5% in 
1986 to 22.1% in 1990 and 56.0% in 1994 stabilizing at 58.8% in 1998.  
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Figure 3.19 HIV prevalence among GUD patients, Carletonville (1986 – 1998) 
 
During the period 1986 – 1994, the relative prevalence of genital herpes has rapidly increased 
among GUD patients with HIV co-infection: 0% in 1986, 4.7% in 1990 and 20.8% in 1994 (χ2= 
56.6, p<0.001) (Figure 3.20).  However, a stable trend of the relative prevalence of HSV was 
found among GUD patients without HIV co-infection: 3.3% in 1986, 3.9% in 1990 and 2.8% in 
1994, respectively (χ2 = 0.09, p=0.96).  
 
By 1998, the proportion of those with genital herpes among GUD patients co-infected with 
HIV stabilized at 19.6% while a significant increase was found among those without HIV co-
infection (2.8% in 1994 to 14.7% in 1998, χ2 = 8.1 6, p 0.004).  Although the relative 
prevalence of genital herpes was still higher among GUD patients with HIV infection in 1998, 
the difference was smaller and not significant (42.1% in 1994 vs 29.6% in 1998, p=0.09) as a 
result of a similar increase in the relative prevalence of genital herpes among HIV-
seronegative patients with GUD. The attributable risk of HIV in the increase of HSV as cause 
of GUD was 17% in 1990, 86.5% in 1994 and 25% in 1998. 
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Figure  3.20 Association between HIV and HSV infection* among GUD patients  
(1986 – 1998) (* Based on HSV culture) 
 
Only in the studies conducted in 1994 and 1998 was multiplex PCR (M-PCR) used for HSV, 
HD and TP and the results are shown in Table 3.4.  
 
Table 3.4 Results based on M-PCR for TP, HD and HSV (1994 & 1998). 
 
1994 1998
232 186
Single Aetiology 190 81.9% 116 62.4%
H.ducreyi 146 62.9% 67 36.0%
HSV 28 12.1% 39 21.0%
T.pallidum 16 6.9% 10 5.4%
Mixed Infection 17 7.3% 31 16.7%
H.ducreyi + T.pallidum 5 2.2% 3 1.6%
H.ducreyi + HSV 9 3.9% 18 9.7
H.ducreyi + T.pallidum + HSV 1 0.4% 6 3.2%
T.pallidum +  HSV 2 0.9% 4 2.2%
Indeterminate 25 10.8% 39 16.8%
M-PCR
%
 
 
As the sensitivity of M-PCR for HD and HSV is greater than that of culture, the relative 
prevalence of HSV and HD among GUD patients is higher than if cultures were performed 
(Table 3.5). In addition, M-PCR was able to detect the presence of TP in genital ulcer 
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exudates; therefore, for the determination of the relative prevalence of primary syphilis, M-
PCR provided improved sensitivity and specificity when compared to the results based on 
darkfield microscopy (DF) and/or serology.  
 
Table 3.5 Sensitivity and specificity of HSV & HD cultures compared to M-PCR 
 
Performance of H.ducreyi culture compared to MPCR (1994) Performance of H.ducreyi culture compared to MPCR (1998)
  MPCR - HD   PCR
Pos Neg Total Pos Neg Total
Pos 119 7 118 Pos 81 2 83
Neg 42 64 106 Neg 13 90 103
Total 161 71 232 Total 94 92 186
95% CI 95% CI
SS 73.9% 66.3 80.4 SS 86.2% 77.2 92.1
SP 90.1% 80.2 95.6 SP 97.8% 91.6 99.6
PPV 94.4% 88.5 97.5 PPV 97.6% 90.8 99.6
NPV 60.4% 50.4 69.6 NPV 87.4% 79 92.8
Performance of HSV culture compared to MPCR (1994) Performance of HSV culture compared to MPCR (1998)
MPCR - HSV   MPCR - HSV
Pos Neg Total Pos Neg Total
Pos 28 2 30 Pos 30 3 33
Neg 12 190 202 Neg 37 116 153
Total 40 192 232 Total 67 119 186
95% CI 95% CI
SS 70.0% 53.3 82.9 SS 44.8% 32.8 57.4
SP 99.0% 95.9 99.8 SP 97.5% 92.3 99.3
PPV 93.3% 76.5 98.8 PPV 90.9% 74.5 97.6
NPV 94.1% 89.6 96.8 NPV 75.8% 68.1 82.2
SS = Sensitivity, SP = Specificity; PPV = Predictive Value Positive, NPV = Predictive Value Negative
HD
Culture
HSV
Culture
HD
Culture
HSV
Culture
 
 
The relative prevalence of HSV detected among GUD patients with HIV co-infection was 
26.2% in 1994 and 42.1% in 1998 (χ2 = 6.68, p 0.009).  Similarly, there was a significant 
increase in the relative prevalence of HSV among GUD patients without HIV co-infection; 
5.9% in 1994 to 28% in 1998 (χ2 = 11.4, p<0.001) (Figure 3.21). Similar trends, but with lower 
relative prevalence rates, were observed based on HSV culture findings. 
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Figure 3.21 Relative prevalence of HSV among GUD patients by HIV status (1986 – 
1998) 
 
A significant decline in the relative prevalence of HD among patients with GUD was recorded 
between 1994 and 1998 [69.4% in 1994 to 50.5% in 1998 (χ2 =15.4, p<0.001)]. Unlike HSV, 
the decline was observed in HIV-seropositive and HIV-seronegative patients (64.3% to 46.7% 
in HIV-seropositive patients; χ2 = 7.25, p 0.007, and 75.5% to 57.3% in HIV-seronegative 
patients; χ2 = 6.64, p 0.009). 
 
The relative prevalence of TP (primary syphilis) increased from 10.3% in 1994 to 12.4% in 
1998 although the increase was not statistically significant (χ2 = 0.42, p 0.5). No significant 
difference in the relative prevalence of TP between HIV-seropositive and HIV-seronegative 
patients was observed in the 1994 and 1998 studies (8.7% vs 12.3% in 1994, p 0.4; 11.2% vs 
14.7% in 1998, p 0.5). 
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3.5  Discussion 
3.5.1  STI and HIV trends among Carletonville miners: a southern African perspective 
 
Although AIDS was first recognized among homosexual men in the United States in 198115-17, 
HIV infection is thought to have spread, largely unnoticed, throughout most of the world by the 
mid-1980s. Starting in the late 1980s, HIV infection spread extensively across sub-Saharan 
Africa. The epidemic extended from West Africa across the continent and reached the Indian 
Ocean in the early 1980s. In the meantime, countries north of the Sahara and in southern 
Africa remained apparently untouched. It was only by 1987 that the epidemic began to move 
south, culminating in explosive waves of spread involving all the countries in southern Africa 
by the mid-1990s18.  
 
In Uganda in 1990, the HIV prevalence among pregnant women in urban areas was 30% and 
45.3% among STI patients during the same period19. Meanwhile, the HIV prevalence among 
pregnant women in South Africa was found to be 0.7% in 1990 and increased to 2.2% in 
199220. In 1990, the HIV prevalence among STI patients in South Africa was less than 6% 
based on sentinel surveillance21. A similar trend was observed in neighbouring countries 
during the same period, for example rates of less than 6% in pregnant women and less than 
10% in STI patients were recorded in Lesotho22-23. 
 
In most countries in southern Africa, the mining industry contributes significantly to the 
economy.  For example, in South Africa, the mining industry contributes 6.6% of the gross 
domestic product and more than 9% of gross investment24. About 691 mines and quarries 
employ 410,000 people, many from neighbouring countries, representing about 3% of the 
economically active population in South Africa. A significant proportion of adult males in their 
productive years are employed in various mines as migrant labourers.  In South Africa, the 
mining companies hired a large number of migrant male workers from neighbouring countries. 
Among these countries, Botswana, Lesotho, Swaziland, Mozambique and Namibia shared 
unique socioeconomic determinants for rapid spread of HIV/AIDS during the early 1990s. 
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Most migrant workers continue to live in single-sex hostels on the mines while their spouses 
or regular sexual partners reside at their permanent homes. A thriving informal sex trade was 
maintained at localities surrounding the mines as well as in many urban areas frequented by 
migrant workers during their periods of leave. The sexual networks among migrant miners, 
their spouses or regular sexual partners, and casual sexual partners in so-called ‘hot-spots’ 
have contributed towards a sustained high prevalence of STIs during the 1980s and early 
1990s. These sexual networks have also fuelled the rapid spread of STIs not only in the 
mining areas, but also at the miners’ places of origin.  Among the risk determinants, the 
following are the most important factors creating a favourable environment for engaging high-
risk sexual practices undertaken by miners: long-term separation from their regular sexual 
partners and family units; easy access to affordable commercial sex establishments; rapid 
sexual partner change; excessive alcohol consumption and the influence of high-risk peers. 
Studies have also suggested that parallel sexual networks at the towns or villages where 
migrant miners are recruited, involving their spouses or regular sexual partners and local 
sexually active male residents play a role in STI spread25. 
 
Despite the rapid introduction of HIV into the population, most notably among high-risk local 
groups as had been reported in the early 1990s, the general complacency of communities 
and their respective health authorities in many countries in the region delayed a scaled-up 
implementation of intervention activities. Although comprehensive statistics on STI incidence 
were not readily available in these countries, anecdotal evidence clearly showed that STIs 
were one of the top ten disease groups causing morbidity in early-1990s. Most countries had 
either underestimated or ignored early warning indicators derived from STI incidence data 
and information of existing complex sexual networks associated with cross-border migratory 
labour systems. As a consequence, most countries failed to take advantage of the window of 
opportunity to contain the HIV epidemic before it could reach its exponential growth phase.  
 
The events leading to the rapid spread of HIV, as documented in our studies among miners, 
clearly support the existence of epidemiological synergies operating between STIs and HIV in 
southern Africa. Thus the high STI incidence among miners, coupled with existing complex 
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social and sexual networks in the region might have led to the rapid and explosive spread of 
HIV in the mid-1990s. By 2003, HIV prevalence in these countries reached extremely high 
levels - often exceeding 30% among pregnant women. Such levels have been recorded in 
South Africa, Botswana, Lesotho, Namibia and Swaziland26.  
 
Similar trends were observed in our study population. Although systematic HIV surveillance 
among miners was not implemented at the beginning of the HIV epidemic, cross-sectional 
studies conducted in the early 1990s indicated that the prevalence of HIV among miners with 
STIs was very low (<1%)27. Meanwhile, the STI incidence among miners was extremely high 
in the late 1980s, a situation which likely served as fertile soil for the subsequent rapid spread 
of HIV infection in this population.  
 
Unfortunately, strategies for the control of the STI epidemic in the mining industry during the 
1980s - mid-1990s, focused mainly on providing appropriate treatment for symptomatic STIs. 
This traditional approach in STI control seems to have had a limited impact on the STI 
epidemic in sexually active male migrant workers in the mines. As a result, the STI incidence 
among migrant miners in Carletonville remained high during the mid-1990s, despite 
significant improvements in the management of STIs on the mines. Likewise, the HIV 
prevalence among STI patients also reached its highest level in the mid-1990s. The overall 
situation in the mines triggered the rapid spread of HIV from relatively small high-risk “core” 
groups into the wider general population in the late-1990s. It was only in the mid-1990s that 
several targeted intervention and community-based STI/HIV prevention activities were 
implemented in the Carletonville region. These measures, together with epidemiological and 
social research projects on migration and HIV/AIDS conducted in mining areas contributed 
significantly in improving HIV/AIDS prevention and control activities in mining communities. 
Similarly, recommendations and policy changes were made by international bodies, 
governments and private mining companies to control further spread of HIV28. 
 
Our study findings have highlighted that STI control activities targeting a high-risk migrant 
population group must be accompanied by appropriate outreach intervention components 
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including prevention and treatment of STIs among the miners’ regular and casual sexual 
partners in the community. Overall, STI control activities targeting only the mine workforce did 
not prove to be cost-effective and did not achieve long-term sustainable control of STIs. It is 
believed that a significant decline in STI incidence could, however, be achieved by 
intervention activities aimed at comprehensive coverage, conducted with a high degree of 
intensity and aimed at sustainability in all vulnerable population groups. 
 
The present studies have demonstrated the ability of STI surveillance to provide indications of 
the level of vulnerability to the HIV epidemic. This approach has been discussed widely at the 
international level. UNAIDS and WHO recommended in their guidelines for second generation 
HIV surveillance that STI surveillance in individuals with high levels of risky sexual behaviour 
be used as a physical marker of unprotected sex with multiple partners29. The incidence of 
acute STIs is closely monitored in many developed countries and has provoked rapid 
response when resurgence of acute STIs has occurred, eg, prompt action was taken when 
infectious syphilis was recognised as an emerging problem in Europe30-31. With a better 
understanding of the interactions between the epidemiology of HIV and STI, many countries 
have used STI prevalence as a barometer of HIV vulnerability and recognised STIs as 
contributing factors to the spread of HIV. In a recent WHO meeting in Treviso, Italy, 
participants reaffirmed that selected STI incidence data as provided by comprehensive STI 
surveillance systems, could be utilized as early warning risk indicators for HIV in vulnerable 
population groups32. The epidemiological interactions between STIs and HIV are, however, 
strongly dependent on different phases of the HIV and STI epidemics. Therefore, caution 
should be exercised in utilising STI surveillance data as proxy early warning indicators of HIV 
vulnerability in various population groups, especially in situations when the HIV epidemic has 
reached a stage of relative maturity and STIs such as genital herpes may be missed33. 
 
In summary, our studies contribute towards better understanding of important epidemiological 
determinants which have fuelled the rapid spread of HIV in southern Africa. In addition, the 
findings highlight the utility and usefulness of STI surveillance data in predicting the 
magnitude of vulnerability to HIV transmission among high-risk population groups. The 
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importance of linking these two surveillance systems should be promoted and applied in 
tracking the HIV epidemic globally. It is also crucial for individual countries to implement an 
adequate STI surveillance system as recommended by WHO34.  
 
3.5.2  Changing aetiological patterns of STIs  
Studies have shown that the clinical diagnostic accuracy of STI in developing countries with 
high level of mixed infections is extremely poor27. The clinical diagnostic accuracy is likely to 
be worse in geographical areas where all aetiological agents causing a STI syndrome are 
endemic. In southern Africa, all pathogens causing major STI syndromes were highly 
prevalent during the 1980s and 1990s. For example, the bacterial agents which cause genital 
ulcerations (T. pallidum, H. ducreyi, C. trachomatis (LGV strains), and Klebsiella 
granulomatis) were highly endemic. Similarly, the aetiologic agents causing sexually 
transmitted urethritis were also highly prevalent. Due to the lack of easy availability and 
accessibility of sensitive and specific STI laboratory tests in many developing countries, WHO 
recommended the use of syndromic management of STIs35. In our study, all STI episodes 
seen at the clinic were recorded syndromically except for selected diseases such as genital 
herpes and LGV.  
 
Syndromic surveillance alone, however, was not sufficient to adequately monitor the changing 
pattern of STIs. It is possible that the incidence of an STI syndrome may remain unchanged 
while significant changes may occur in the relative proportion of specific aetiologies causing 
the syndrome. Therefore, a new surveillance approach was established and implemented in 
our STI clinic at Carletonville for a better understanding of changing profile of STI aetiologies 
(Figure 3.22).  Epidemiological data obtained from two systems were analyzed and 
interpreted in an integrated manner. This approach was implemented in the Gauteng 
Province and a national STI surveillance programme for South Africa based on the model 
described here was constituted in 2003.  
 
 - 82 - 
 Figure  3.22 Tiered syndromic STI surveillance systems 
 
Syndromic STI surveillance data indicated that there was a high incidence of genital 
ulcerations among miners during the early phase of HIV epidemic.  This sustained high 
incidence of GUDs in the early 1990s was followed by a rapid increase in HIV prevalence in 
1995. Comprehensive information on the aetiological patterns of GUD syndromes was 
obtained from the periodic cross-sectional aetiological studies conducted at 4-yearly intervals 
using the same study design.  
 
During 1992 – 1998, the relative prevalence of genital ulcer disease (GUD) was significantly 
higher than other STI syndromes with the highest proportion of GUD amongst STI syndrome 
was reported in 1994. Overall, more than 50% of STI episodes presented at the clinic were 
genital ulcerations in the early-1990s, and majority of cases were non-vesicular GUD. Their 
clinical presentation was mostly compatible with bacterial causes of GUD particularly that of 
chancroid. This observation was confirmed by the aetiological studies conducted in 1986 and 
1990 when over 60% of GUD were bacteriologically proven to be caused by H. ducreyi. 
Similarly, the highest RPR seropositivity rate was found among GUD patients during the early 
1990s. In the GUD aetiology study conducted in 1994, the relative prevalence of primary 
syphilis and chancroid was in excess of 10% and 69% respectively when more sensitive M-
PCR assays were used.  Meanwhile, the relative proportion of vesicular ulcerations (clinically 
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suggestive of genital herpes) was less than 10% of total STI burden in 1992 – a finding 
confirmed in aetiological studies that laboratory-confirmed genital herpes in 1990 was less 
than 5% of GUDs. 
 
This period (1992 – 1994) could be described as ‘the early phase of HIV epidemic’ in 
southern Africa when HIV prevalence increased steadily in both high-risk and low-risk 
population groups23,36. During this early phase, our surveillance systems indicated a high 
incidence of GUDs due to chancroid among the miners, and showed that the prevalence of 
HIV among patients with GUD was almost two-fold higher than among urethritis patients. The 
syphilis seroprevalence as identified by a positive RPR test confirmed with a treponemal test 
was also high among STI patients with a higher prevalence of positive tests being found in 
patients with GUD.  
 
Subsequently, ‘the accelerated HIV transmission phase’ was documented during the mid-
1990s, and continued until the epidemic peaked in the late-1990s. During this period, there 
was exponential growth in HIV prevalence in many countries in the region, including miners 
with STIs in Carletonville. The HIV prevalence among STI patients in the mine doubled from 
20.8% in 1994 to 42.4% in 1995. This doubling in HIV prevalence was found across all STI 
syndromes. The highest HIV prevalence was found among patients presenting with genital 
warts. Our observation does not explain the nature of the associations between genital warts 
and HIV. However, this phenomenon might have been due to an increase in persistence and 
severity of genital warts related to HIV-induced immunodeficiency as reported elsewhere37-39. 
Although there was a slight increase in patients presenting with new or recurrent episodes of 
genital warts, these lesions represented less than 5% of the total STI burden throughout the 
study period. 
 
A similar stable trend was found in the case of LGV and epididymo-orchitis. The HIV 
prevalence among patients presenting with epididymo-orchitis was significantly higher than 
those presenting with urethritis (i.e. 29.6% vs. 36.3, χ2 = 8.89, p 0.003). The relative 
prevalence of epididymo-orchitis also increased from 0.8% in 1992 to 1.7% in 2002. Although 
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no epidemiological and clinical studies elsewhere have reported a similar association, it is 
plausible that HIV positive patients may have higher risks of developing ascending infection 
due to the STI agents causing urethritis. In our study, we did not conduct the radiological or 
sonographic investigations required to exclude other causes such as tuberculous epididymo-
orchitis. However, we observed that most patients presenting with epididymo-orchitis in the 
mines have either a past history of or presented with concurrent urethritis, and a high titre of 
type-specific chlamydial antibody based on chlamydial microimmunofluorescent serology 
tests (Ye H and RC Ballard personal observation). Prospective studies are still required to 
confirm this association.  
 
The relative proportion, as well as absolute incidence of non-vesicular GUD declined while 
vesicular ulcerations (clinically suggestive of genital herpes) increased rapidly. This trend was 
supported by aetiological studies conducted during the period, where the relative prevalence 
of laboratory-confirmed chancroid declined to its lowest level in 1998, and genital herpes 
increased significantly. The relative prevalence of genital herpes among HIV-seropositive 
GUD patients increased sharply and genital herpes was highly associated with HIV-
seropositivity. Due to the nature of our cross-sectional study design, we were unable to verify 
whether the association was due to an increase in the frequency of recurrent herpes induced 
by HIV-related immunodeficiency or an increase in the acquisition of HIV in patients with 
genital herpes due to recurrent micro/macro ulcerations caused by genital herpes. Our study 
confirmed, however, that the attributable risk of HIV associated with the increase of genital 
herpes among miners with GUDs could have been over 80% in 1994. The rapid increase in 
the relative prevalence of genital herpes among HIV-seronegative patients occurred in 1998.  
This could have been due to a rapid decline in bacterial GUDs responding to effective 
intervention activities in and around the areas, and/or an increase in transmission of genital 
herpes attributable to an increasing pool of infectious individuals associated with HIV 
infection. An increase in the absolute incidence rate of clinically suspected herpes ulcerations 
among miners was also observed during the study period and it is likely that both a decline in 
bacterial STIs and an absolute increase in genital herpes contributed to the overall changes in 
aetiology of GUDs. 
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In 1994, improved STI management was implemented in mine clinics and all GUD patients 
were treated with effective antibiotic therapy covering both primary syphilis and chancroid. All 
patients presenting with new STI episodes were routinely screened for syphilis using a 
quantitative RPR and treatment for syphilis was provided if they were found positive. Since 
then, the incidence of non-vesicular GUD among miners has decreased significantly and a 
similar decline in the relative prevalence of chancroid was found in the aetiological study 
conducted in 1994.  
 
Following enhanced syphilis screening and treatment activities initiated in the mine, RPR 
seropositivity rates among GUD patients steadily declined to their lowest level in 1998-99. 
The RPR seropositivity rate was even lower in STI patients presenting with urethritis in 1999. 
Surprisingly, the RPR positive rate among patients with non-ulcerative STIs in 1999 was 
lower than that of pregnant women residing in the Carletonville mining town. This interesting 
phenomenon can possibly be attributed to the successful implementation of enhanced 
syphilis screening and treatment activities in the mine STI clinic. The high-risk miners 
frequently attending the clinic with new STI episodes had been repeatedly screened and 
treated for syphilis since 1994. Therefore, the probability of latent syphilis being detected and 
treated was much higher for a high-risk miner with repeated STI episodes than for a pregnant 
women who had the opportunity to be screened only when she became pregnant. 
 
Many studies have reported that the probability of HIV acquisition and transmission is higher 
in patients with ulcerative STIs40-44. During 1992 – 1994, STI episodes due to non-vesicular 
GUDs and urethritis have proportionately increased in miners. This trend was associated with 
accelerated spread of HIV among miners with STIs. It is also epidemiologically plausible that 
the high incidence of genital ulcerations in the mine during early 1990s may have contributed 
to the rapid and explosive increase in HIV prevalence among miners with STIs. Most GUD-
causing pathogens exhibit a higher transmission efficiency than HIV and the GUD epidemic in 
southern African countries during 1990s provided a fertile ground for the subsequent rapid 
spread of HIV. In addition, a high incidence of GUD has been documented among regular 
partners of miners at their places of origin as well as the sexually active population at various 
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major urban centres (Lesotho personal observation). Although the most effective antibiotics 
for treatment of bacterial STIs were available at the mine clinics, this was often not the case 
at public clinics outside the mines. Lack of effective treatment in these areas presumably led 
to continued transmission of major STIs within the sexual networks. 
 
Since 1995, several intervention activities have been implemented which targeted both high 
and low-risk population groups in the community residing in the areas surrounding mines. 
These activities included (1) improvement in quality of STI care (by training and 
implementation of syndromic management)45;  (2) behavioural interventions including condom 
promotion46-47; and (3) targeted interventions for high-risk women using periodic presumptive 
therapy for STIs48 . A more effective contact tracing system was also implemented through 
collaboration with a network of private and public STI services situated in areas surrounding 
mines49. Within the two most common STI syndromes in the mines (GUD and urethritis), a 
rapid and sustained decline of GUD of bacterial origin was observed among miners and their 
casual sexual partners residing in informal settlements surrounding mines. The provision of 
azithromycin monthly to high-risk casual partners of miners could have contributed to the 
rapid decline in chancroid cases seen among miners50-52. As documented in other studies, 
targeted intervention activities focusing on high-risk women were shown to have had a 
positive impact in controlling curable STIs among their partners or clients50-57. However, the 
impact of these activities on the wider community is dependent on the size of bridging 
populations between core group at high-risk and other groups. The sexual networks between 
these groups have also contributed to the impact of targeted intervention activities on STI and 
HIV transmission in the general population. In addition, in the case of some STIs, the majority 
of infected individuals are either asymptomatic or have inapparent infections despite the fact 
that they are infectious (e.g. gonococcal/chlamydial infection in women and genital herpes). 
To contain the spread of these diseases, behavioural modification activities targeting all 
vulnerable population groups are needed. Other community-based prevalence studies 
conducted in Carletonville have found that the prevalence of gonococcal and chlamydial 
infections in various population groups in this area has not changed significantly despite a 
significant decline in symptomatic STIs among miners. 
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In summary, the syndromic STI surveillance data are useful but there should be caution when 
interpreting trends suggested by cumulative data.  Dynamic changes in the relative 
prevalence of specific aetiological agents causing a syndrome in response to the effective 
prevention as well as treatment and outreach interventions, together with the phase of the 
HIV epidemic must also be taken into consideration. The high incidence of GUD in the gold 
miners and their sexual partners at the early phase of HIV epidemic fueled the rapid spread of 
HIV among high-risk miners and probably their sexual partners in the region. Improvement in 
the quality of STI management in the mines had a limited impact in controlling GUD epidemic 
in the mines, but this measure, together with the implementation of successful intervention 
activities targeted at casual or paid female sexual partners of miners, resulted in containment 
of the GUD epidemic to its lowest level in the late-1990s. Unfortunately, the relative 
prevalence of genital herpes has increased significantly, particularly among those patients 
with HIV co-infection and management of genital herpes with antiviral drugs was not 
considered in the GUD management algorithm until the mid-1990s. Based on our findings on 
the changing aetiological patterns of GUDs, an urgent review of GUD management protocols 
is required in order to improve the performance of the GUD management algorithm. In 
addition, further studies to explore the potential role of genital herpes in transmission and 
acquisition of HIV in southern Africa have either been undertaken, or are planned58-59. 
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CHAPTER 4 
 
Influence of HIV/AIDS on the clinical presentation and 
diagnosis of genital ulcer disease in southern Africa 
 
4.1 Aetiology of genital ulcer disease in southern Africa  
4.1.1 Cross-sectional observational studies 
Eight hundred and sixty-eight patients with genital ulcerations were enrolled in aetiological 
studies conducted in Maseru (Lesotho), Johannesburg, Durban and Carletonviile STD clinics 
during 1994 - 1999.  All patients were of black African ethnicities and the majority (97%) were 
male. The overall mean age was 29 years (range 14 – 65 years) and the HIV prevalence rate 
was 46.7%. 
 
Of 868 patients included in the analysis, H. ducreyi (HD) was detected by M-PCR in 436 
(50.2%), T. pallidum (TP) in 163 (18.8%), herpes simplex virus (HSV) in 268 (30.9%) and  
C. trachomatis (CT) in 29 (3.3%) patients. No organism could be demonstrated in 88 (10.1%) 
patients. A single aetiology was detected in 672 (77.4%) and multiple aetiologies in 108 
(12.4%) patients. Among those with a single aetiology, HD was detected in 346 (51%), HSV 
in 203 (30.2%), TP in 106 (15.8%) and CT in 17 (2.5%) patients. The most common mixed 
infections involved syphilis, chancroid and genital herpes (Table 4.1). Of 163 TP-positive 
patients, 57 (34.9%) were co-infected with other aetiological agents, namely: 33 (57.9%) with 
HD, 13 (22.8%) with HSV and 7 (12.3%) with both. Co-infection with HD and HSV was also 
common (Table 4.1). 
 
Overall, 211 (24.3%) of sera obtained from these patients were positive by both RPR and 
FTA-ABS tests, a further 236 (27.2%) were positive by the FTA-ABS test alone, and 421 
(48.5%) were negative for both. No false positive RPR reactions were detected. Among RPR 
sero-positive patients, 137 (64.9%) had a titre of 1:8 or higher. The overall geometric mean 
titre was 11.5 (Figure 4.1). 
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 Table 4.1 Aetiology of GUD among patients in South Africa and Lesotho  
(1994 – 1999)
 
 
Aetiology No of Patients %
Single Aetiology (N=672)
     Primary Syphilis 106 12.2
     Chancroid 346 39.9
     Genital Herpes 203 23.4
     LGV 17 2.0
Multiple Aetiology (N=108)
     Primary Syphilis & Chancroid 33 3.8
     Primary Syphilis & G.Herpes 13 1.5
     Primary Syphilis, Chancroid & G.Herpes 7 0.8
     Primary Syphilis & LGV 3 0.3
     Primary Syphilis, Chancroid & LGV 1 0.1
     Chancroid & G.Herpes 43 5.0
     Chancroid & LGV 6 0.7
     G.Herpes & LGV 2 0.2
Indeterminate 88 10.1
Total 868 100.0  
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Figure 4.1 Distribution of RPR titres in 211 GUD patients with a positive RPR test 
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4.2 Primary Syphilis 
 
4.2.1. Presentation of primary syphilis among HIV-seropositive and -seronegative 
patients 
 
Of 106 patients who were M-PCR (TP) positive alone, complete information on clinical 
presentation of their disease was available in 58 patients. These data are presented in this 
section. The median duration of ulceration at the time of presentation was 9.5 days (range 1 – 
44 days) with the majority (56.9%) seeking medical attention within 10 days of the 
appearance of a nodule/ulcer. Only two of 17 (11.8%) HIV co-infected patients presented with 
a single ulcer while 14 out of 41 (34.1%) HIV-seronegative patients with primary syphilis 
presented with a single ulcer. However, this difference was not statistically significant 
(Fisher’s Exact test, p 0.11). The majority of patients in both groups complained of pain and/or 
tenderness around the ulcers (88% of HIV-seropositive and 73% of patients HIV-seronegative 
patients, respectively). Only three of 17 patients (17.6%) in the HIV-seropositive group, 
compared to 19 of the 41 HIV-seronegative patients (46.3%) had deep ulcerations (χ2 = 4.2, p 
0.04). Inguinal lymphadenopathy was associated with primary syphilis in both HIV-
seropositive (41.2%) and seronegative patients (68.3%, χ2 = 3.69, p 0.054) and the majority 
presented with bilateral discrete lymph nodes. Three of 17 (18.8%) HIV-seropositive patients 
and 13 of 41 (31.7%) seronegative patients with primary syphilis alone were correctly 
diagnosed clinically as primary syphilis. This difference was not statistically significant (χ2 = 
0.59, p 0.4). 
 
4.2.2 Impact of HIV on diagnosis of primary syphilis 
The rates of positive syphilis and HIV serology among patients with different GUD aetiologies 
is shown in Table 4.2. The highest RPR positivity rate of 69.3% was found among patients 
with positive M-PCR (TP). Of 163 M-PCR (TP)-positive patients, the RPR positivity rate was 
higher in patients with single TP infections (79.2%) than in those with mixed aetiology 
involving TP and other agents (50.9%) (χ2 = 14.03, p 0.0001) (Table 4.2). The RPR 
seropositivity rate among patients with a negative M-PCR (TP) was significantly lower than 
that recorded among patients with positive M-PCR (TP) (13.9% vs 69.3%, χ2 = 216.9, 
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p<0.001). The difference was more obvious when the rates between patients with TP only 
(79.2%) and those with aetiologies other than TP (11.8%) were compared (χ2 = 241, 
p<0.001).  
 
Table 4.2 RPR positivity by GUD aetiology 
 
No % No %
Only M-PCR (TP) +ve 84 79.2 22 20.8 106
Mixed TP & Others 29 50.9 28 49.1 57
Other Aetiologies 73 11.8 544 88.2 617
Indeterminate 25 28.4 63 71.6 88
Total 211 24.3 657 75.7 868
Aetiology of GUD TotalPositive Negative
RPR
 
 
The geometric mean titre of RPR tests in those solely with treponemal GUD was similar to 
that of patients with mixed treponemal GUD (1:17.1 vs 1:16.8). The geometric mean titre was, 
however, significantly lower in RPR-seropositive patients with non-treponemal GUDs (1:5.9) 
(ANOVA, F statistics=2.9, p<0.05).  
 
All RPR-seropositive patients were confirmed to be truly positive by FTA-ABS testing. No 
biological false positive reactions were detected. The overall FTA-ABS seropositivity rate was 
35.9%. Of 657 RPR-seronegative patients, 236 (35.9%) were positive by the FTA-ABS test. 
As was the case with the RPR test, GUD patients who were only M-PCR (TP) positive had a 
higher FTA-ABS seropositivity rate than those with other aetiologies recorded (81.8% vs. 
33.6%, χ2 = 21.4, p <0.001) (Table 4.3). 
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 Table  4.3 FTA-ABS seropositivity by GUD aetiology  
 
No % No %
Only M-PCR (TP) +ve 18 81.8 4 18.2 22
Mixed TP & Others 15 53.6 13 46.4 28
Other Aetiologies 183 33.6 361 66.4 544
Indeterminate 20 31.7 43 68.3 63
Total 236 35.9 421 64.1 657
RPR -ve & FTA-ABS +ve
FTA-ABS +ve Both NegativeAetiology of GUD Total
 
 
 
 
 
 
 
 
The overall HIV seroprevalence among GUD patients was 46.7%. Of 163 patients who were 
M-PCR (TP)-positive, 47 (28.8%) were co-infected with HIV. Among patients with a single 
aetiology, the lowest HIV prevalence was found among the patients infected with TP (20.8%). 
A higher HIV prevalence rate (43.9%) was however found in patients with mixed TP and other 
aetiological agents (43.9% vs 20.8%, χ2 = 9.64, p 0.001).  The highest HIV prevalence 
(53.3%) was found in patients infected with non-treponemal agents of GUD (Table 4.4).  
 
Table 4.4 Prevalence of HIV by GUD aetiology  
 
No % No %
Only M-PCR (TP) +ve 22 20.8 84 79.2 106
Mixed TP & Others 25 43.9 32 56.1 57
Other Aetiologies 329 53.3 288 46.7 617
Indeterminate 29 33.0 59 67.0 88
Total 405 46.7 463 53.3 868
Aetiology TotalPositive Negative
HIV
 
 
The RPR test was, however, positive in 27 patients (57.4%) in the HIV-seropositive group and 
86 patients (74.1%) in the HIV-seronegative group (OR 0.47, 95% CI 0.23 – 0.96, p<0.05). 
Irrespective of their RPR status, no significant difference in FTA-ABS seropositivity rates was 
found among HIV-seropositive and seronegative patients with TP infection (83% vs. 92.2%, 
NS), Eight HIV-seropositive patients (17%) and 9 HIV-seronegative patients (7.8%) with TP 
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No % No %
Positive RPR 27 57.4 86 74.1 0.47 (0.23 - 0.96) <0.05
Positive FTA-ABS* 39 83.0 107 92.2 0.41 (0.15 - 1.14) NS
Both RPR & FTA-ABS Negative 8 17.0 9 7.8 2.4 (0.88 - 6.8) NS
*with or with RPR +ve
HIV +ve (N = 47) HIV -ve (N = 116) OR (95% CI) pSyphilis Serostatus of MPCR-TP Positive Cases
Of 705 patients with a negative M-PCR (TP) test, 358 (50.8%) were co-infected with HIV and 
the overall RPR seropositivity rate was 13.9%. The RPR seropositivity rate in HIV-
seropositive patients was 12.3% and in HIV-seronegative patients 15.6% (χ2 = 1.6, p 0.2). 
The RPR seropositivity rate was significantly higher in patients with indeterminate laboratory 
findings when compared with that seen in patients with known aetiologies other than TP 
(28.4% vs. 11.8%, χ2 17.7, p <0.001). This significance was independent of HIV serostatus 
(HIV-seropositives: 24.1% vs. 11.2%, χ2 = 4.1, p 0.04; HIV-seronegative group: 30.5% vs. 
12.5%, χ2 = 12.1, p 0.001). 
Among 163 M-PCR (TP) positive patients, 106 (65%) were solely infected by TP and 57 
(34.9%) had mixed infections with other aetiological agents. Of 106 patients with a single 
aetiology, 22 (20.8%) were co-infected with HIV (Table 4.6). There was no significant 
difference in RPR positivity rates between HIV-seropositive and seronegative groups with a 
single TP infection (81.8% vs. 78.6%, Fisher’s exact test NS). There was, however, a 
significant difference in the RPR seropositivity rate among HIV-positive and negative groups 
with mixed GUD aetiologies (36.0% vs 62.5%, χ2 = 3.9, p<0.05). 
 
 
Table 4.5 Syphilis serostatus of primary syphilis patients by HIV status 
 
infection were negative by both serological tests (Table 4.5).  There was no significant 
difference in the geometric mean titre of the RPR test between HIV-seropositive and 
seronegative patients with a positive RPR test (1:13.7 vs 1:18.2, respectively). 
 
Both RPR & 
FTA-ABS +ve
No % No % No % No %
Single Aetiology
     Primary Syphilis 106 84 79.2 18 17.0 4 3.8 22
     Chancroid 346 45 13.0 115 33.2 186 53.8 163
     Genital Herpes 203 14 6.9 49 24.1 140 69.0 126
     LGV 17 3 17.6 5 29.4 9 52.9 10
Multiple Aetiology
20.8
47.1
62.1
58.8
     Primary Syphilis & Chancroid 33 17 51.5 6 18.2 10 30.3 14
     Primary Syphilis & G. Herpes 13 6 46.2 6 46.2 1 7.7 7
     Primary Syphilis, Chancroid & G. Herpes 7 4 57.1 2 28.6 1 14.3 3
     Primary Syphilis & LGV 3 2 66.7 - 1 33.3 1
     Primary Syphilis, Chancroid & LGV 1 - 1 100.0 - -
     Chancroid & G. Herpes 43 9 20.9 10 23.3 24 55.8 27
     Chancroid & LGV 6 2 33.3 3 50.0 1 16.7 2
     G. Herpes & LGV 2 - 1 50.0 1 50.0 1
Indeterminate
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Table 4.6 Syphilis and HIV seroprevalence by GUD aetiology 
 
42.4
53.8
42.9
33.3
62.8
33.3
50.0
88 25 28.4 20 22.7 43 48.9 29
Total 868 211 24.3 236 27.2 421 48.5 405
HIV
PositiveNumber of 
PatientsAetiology
FTA-ABS +ve
only
Both RPR & 
FTA-ABS -ve
33.0
46.7
The association of the median duration of ulcers and HIV seroprevalence rates in three groups 
of patients with different syphilis serological status is shown in Table 4.7. No significant 
differences were found between the groups. 
 
Table 4.7 Median duration of ulcer and syphilis serostatus among GUD patients 
 
Median duration  
of ulcer 
RRP & FTA-
ABS Positive 
RPR Negative & 
FTA-ABS Positive 
Both RPR & 
FTA-ABS Negative 
    
Treponemal GUD 10 days  (2 - 90 days) 
10 days  
(1 – 120 days) 
10 days  
(2 – 35 days) 
    
Non-treponemal GUD 7 days  (1 – 132 days) 
7 days  
(1 – 90 days) 
7 days  
(1 – 150 days) 
    
 
A comparison of the performance of syphilis serology in HIV-seropositive and seronegative 
patients with single and mixed infections is shown in Table 4.8. Eighty-eight patients with 
unknown or indeterminate aetiology were excluded from this analysis. The overall sensitivity of 
RPR to detect primary syphilis in our setting was 69.3% and its specificity was 86.1%. The 
sensitivity of syphilis serology improved to 89.6%, when using the FTA-ABS test. The sensitivity 
of the RPR test was found to be significantly higher in HIV-seronegative than HIV-seropositive 
patients (74% vs 57.4%, χ2 = 4.94, p 0.026). The sensitivity of the RPR test decreased further to 
36% in HIV-seropositive patients with mixed infections. Among HIV-seropositive patients, there 
was a significant difference in the sensitivity of the RPR test in patients infected solely by TP as 
a single infection when compared to those who had mixed TP infections (81.8% vs 36%, p  
0.001). This difference was, however, not statistically significant among those patients who were 
HIV-seronegative.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 100 - 
 
Table 4.8 Performance of syphilis serology in the diagnosis of primary syphilis 
 
 
RPR FTA-ABS  
Single infection Mixed infection 
 
p 
Single infection Mixed infection
 
p 
HIV-
seropositive       
Sensitivity 18/22 (81.8%) 9/25 (36%) 0.001 21/22 (95.5%) 18/25 (72%) 0.08 
Specificity 271/299 (90.6%) 21/30 (70%) 0.002 175/299 (58.5%) 14/30 (54.5%) 0.58 
PPV 18/46 (39.1%) 9/18 (50%) 0.4 21/145 (14.5%) 18/34 (52.9%) 0.001
NPV 271/275 (98.5%) 21/37 (56.8%) 0.001 175/176 (99.4%) 14/21 (66.7%) 0.27 
       
HIV- 
seronegative       
Sensitivity 66/84 (78.6%) 20/32 (62.5%) 0.08 81/84 (96.4%) 26/32 (81.3%) 0.02 
Specificity 233/267 (87.3%) 19/21 (90.5%) 0.9 160/267 (59.9%) 12/21 (57.1%) 0.8 
PPV 66/100 (66%) 20/22 (90.9%) 0.02 81/188 (43.1%) 26/35 (74.3%) 0.001
NPV 233/251 (92.8%) 19/31 (61.3%) 0.001 160/163 (98.2%) 6/18 (66.7%) 0.02 
 
 
4.3 Genital herpes  
As described in the previous chapter (Sections 3.4.2 and 3.4.3), the true incidence as well as 
the relative prevalence of genital herpes among GUD patients increased significantly in 
southern Africa during the period 1994-2000. In this section, the clinical presentation and natural 
history of genital herpes diagnosed either by culture and/or M-PCR (HSV) among the patients 
recruited into the studies described in Chapter 3.3.1 will be presented. The impact of the 
increasing incidence and relative prevalence of atypical herpes (either as a single or mixed 
infections) among GUD patients and the relevance of these findings to treatment outcomes 
based on the WHO recommended syndromic management protocol (1995) is also outlined in 
this chapter. 
 
4.3.1 Atypical presentations of genital herpes 
During 1998 - 2000, 396 GUD patients who fulfilled the inclusion criteria (i.e. non-vesicular 
ulcers of > 2 mm in largest diameters and no history of treatment received) were enrolled in a 
clinical trial designed to explore the efficacy of different treatment options for non-vesicular 
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ulceration in men. Of those, a single HSV infection was detected by M-PCR in 49 cases (15.4%) 
and of these, 36 (73.5%) were HIV-seropositive. Among these patients, the median CD4+ count 
was 335 cells/mm3 (range – 63 –787 cells/mm3) at the enrolment visit and 60% had CD4+ 
counts of less than 350 cells/mm3. Five patients (14.3%) had CD4+ counts of less than 200 
cells/mm3 although no AIDS-defining illnesses were detected. 
 
All patients presented with large, deep and purulent ulcerations with or without inguinal and/or 
femoral lymphadenopathy and thus fulfilled the clinical criteria for a diagnosis of chancroid. The 
patients did not recall any vesicular lesions during the early stages of their disease and no 
vesicles were detected on examination. A summary of cases that presented with chronic 
atypical ulcerations due to HSV infection follows: 
 
Case 1  
An HIV-seropositive male patient presented with three extensive purulent penile ulcerations of 7 
days duration. The largest ulceration measured approximately 20 mm in diameter. The patient 
was treated syndromically using antibiotics for primary syphilis and chancroid on Day 1. His 
plasma viral load (PVL) at Day 1 was 8.7x105 copies/ml which increased to 1.1x106 copies/ml by 
Day 21. Anti-viral treatment was initiated only on Day 14 (due to unavailability of acyclovir at the 
clinic). The ulcer diminished in size after initiation of anti-viral therapy. 
 
Case 2  
An HIV-seropositive male patient presented with two deep, purulent and painful ulcerations of 3 
days’ duration. The size of the largest ulcer on Day 1 was approximately 9 mm in diameter. His 
HIV PVL on Day1 was 10,000 copies/ml and CD4+ count was 470 cells/mm3. He received 
syndromic treatment with antibacterial antibiotics on Day 1. At follow-up on Day 7, his PVL had 
increased to 180,000 copies/ml and then declined to 13,000 copies/ml by Day 21. No clinical 
improvement was noted on the Day 7 or 14. Clinical improvement was observed only after anti-
viral therapy with valaciclovir was initiated on Day 14.  
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 Case 2: Clinical presentation of Genital Ulcer on Day 1 Case 2: Clinical presentation of Genital Ulcer on Day 7  
 
Case 3 
This HIV-seropositive patient initially presented with a single, painful purulent ulceration of 4 
days duration. His HIV PVL at the initial visit was 3.5x105 copies/ml and CD4+ count was 244 
cells/mm3. He was treated syndromically with antibacterial antibiotics and his condition 
deteriorated at subsequent follow-up visits. The ulcer size increased from approximately 5 mm 
in diameter on Day 1 to 15 mm by Day 21. His HIV PVL also increased to 4.7x105 copies/ml on 
Day 14. The ulceration improved after the initiation of valaciclovir therapy on Day 21. 
 
 
 
 
 
 
 
 
 
  Case 3: Clinical presentation of Genital Ulcer on Day 1     Case 3: Clinical presentation of Genital Ulcer on Day 21  
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Case 4  
This patient was HIV-seropositive and presented with a single painful ulcer of approximately 6 
mm in diameter of 6 days duration. His HIV PVL at the initial visit was 5.6x105 copies/ml and the 
CD4+ count was 288 cells/mm3. The patient was treated syndromically using antibacterial 
antibiotics. No improvement occurred during the first two weeks and valaciclovir therapy was 
initiated on Day 14. The PVL on Day 7 increased to 1.0x106 and then declined to 4.5x105 
copies/ml by Day 14. 
 
 
 
 
 
 
    
 Case 4: Clinical presentation of Genital Ulcer on Day 1      Case 4: Clinical presentation of Genital Ulcer on Day 7   
    
 
 
 
 
 
 
 
Case 4: Clinical presentation of Genital Ulcer on Day 14 Case 4: Clinical presentation of Genital Ulcer on Day 21  
    
In southern Africa, the classical bacterial causes of GUD, namely primary syphilis, chancroid, 
granuloma inguinale and LGV have been chronically endemic for many years. The findings of 
studies conducted during the period 1998 – 2000, showed 49 of 396 patients (12%) presenting 
with deep, purulent, tender and non-vesicular ulcerations were caused by single infections with 
HSV. In addition, ulcerations in a further 19 patients (4.8%) with similar presentations were 
caused by mixed infections involving HSV together with HD and/or TP. The mean CD4+ count of 
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the 36 HIV-seropositive patients with single HSV infections was 367 cells/mm3. The majority of 
these (66%) had persistent ulcerations at Day 7 after they had completed standard syndromic 
treatment for non-vesicular GUD (i.e. treatment for primary syphilis and chancroid) at enrolment.  
At their return visit on Day 14, 40% of HIV-seropositive patients with single genital herpes had 
persistent ulcerations. The treatment outcomes of 270 HIV-seropositive patients enrolled in the 
study is shown in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Atypical clinical presentation and prolonged ulceration of genital herpes in HIV co-
infected miners in the absence of anti-herpes therapy (1998 – 2000) 
 
4.4 Chancroid 
 
The clinical presentations of 264 laboratory-confirmed chancroid cases (either by culture and/or 
M-PCR) are reviewed in this chapter. Of 264 chancroid patients, only 232 who returned for their 
two-weekly follow-up visits were included in this review. All patients fulfilled standard clinical 
criteria and were diagnosed as chancroid at enrolment. Of the 232 subjects, 151 (65.1%) were 
HIV-seropositive and 48% had CD4+ counts less than 350 cells/mm3. No atypical presentations 
were observed among HIV-seropositive patients. Although 54 patients (23.3%) did not achieve 
clinical cure at Day 14, there was no difference in cure rates between HIV-seropositive and HIV-
seronegative patients (22.5% vs. 22.2%, p 0.78).  Five of 34 HIV-seropositive patients (14.7%) 
who exhibited treatment failure at Day14 were subsequently found to be positive by M-PCR 
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(HSV) compared to 1 of 18 (5.6%) HIV-seronegative patients (p = 0.59). Similar proportions of 
HIV-seropositive and HIV-seronegative patients who experienced treatment failure at Day 14 
were initially positive for M-PCR (HD) alone (38.2% vs. 38.9%). In summary, we did not observe 
any atypical presentations or unexpected treatment failures among HIV-seropositive patients 
presenting with chancroid where HD was the only pathogen demonstrated. 
 
4.5. Other STIs (LGV, Donovanosis) 
Careful scrutiny of limited information available from the studies conducted in 1994 – 2000, 
revealed no noticeable changes in clinical presentation of LGV and donovanosis in HIV-
seropositive patients.  
 
4.6 Discussion 
 
Since HIV was discovered in 1984, many anecdotal reports have revealed that the natural 
history, clinical presentation, performance of diagnostic tests and response to conventional 
therapy of some STIs are altered in patients co-infected with HIV1-3.  
 
Most atypical presentations of syphilis reported in patients with HIV infection include unusual 
eye, bone and neurological involvement4,5. A more aggressive clinical course of syphilis has 
also been observed6. Changes in performance of routine laboratory tests, particularly RPR test 
have also been reported7,8. In these studies, more frequent biological false-positive results were 
reported among patients infected with HIV than among the HIV-seronegative population. Other 
studies have reported that HIV-seropositive patients who received adequate treatment for 
syphilis appear more likely to serorevert to negative treponemal antibody testing instead of 
remaining seropositive for their life-time9. Studies have also indicated that atypical presentations 
such as persistent chancres10, early ocular involvement11, ulcerative skin lesions12,13, 
gummatous disease14,15, are more commonly found in HIV-seropositive patients with syphilis 
than HIV-seronegative persons.  
 
The study reported here reviewed the clinical presentation of patients with syphilitic ulceration 
and their response to conventional therapy. We observed that atypical presentations of primary 
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syphilitic chancres were common among patients in southern Africa. Patients often presented 
with multiple painful ulcers, and the overall clinical accuracy of diagnosis was very low (31.7% in 
HIV-seropositive and 17.6% in HIV-seronegative patients, p=0.4). The majority of primary 
chancres mimicked the clinical features of chancroid (i.e. purulent, deep, multiple and painful). 
During our studies, we did not observe any unusual increase in an aggressive form of syphilis 
such as lues maligna or a higher incidence of secondary syphilis among HIV positive patients. 
Similarly, there was no significant difference in treatment responses of primary syphilis between 
HIV-seropositive and HIV-seronegative patients following standard therapy using a single 
intramuscular dose of benzathine penicillin. Complete healing of ulcers was usually achieved 
within two weeks after initiation of therapy in both HIV-seropositive and seronegative patients. 
Even with application of sensitive M-PCR, the clearance of TP from the ulcerations was found 
as early as Day 7 after therapy in both groups. Similarly, the quantitative RPR titres of those 
patients at 14 days after therapy were either the same or lower than baseline titres.   
 
No unusual presentations related to abnormal neurological or ophthalmic presentations were 
observed during general examination of our patients. However, a system-specific clinical 
examination and additional laboratory investigations were not conducted in the present study. 
Our study also did not make provision for long-term follow-up of the patients with primary 
syphilis nor was it designed to perform invasive investigations such as routine lumbar punctures.  
 
Concerns have been expressed over the natural history of syphilis in HIV-infected individuals, 
particularly the possibility of an accelerated course to neurosyphilis and possible 
neurorelapses16,17. The 1998 CDC STD treatment guidelines recommend conducting more 
frequent follow-up evaluations of therapeutic responses at three to six-months intervals for two 
years in HIV-seropositive patients with early or latent syphilis or syphilis of unknown duration18. 
In addition, it recommends CSF examination on failure to show a 4-fold decline in serum 
nontreponemal (reagin) test titre at specific times (ranging 6 to 24 months depending on the 
stage of syphilis). Unfortunately, these guidelines are not feasible in developing countries; 
therefore, the long-term consequences of HIV-infected patients presenting with primary syphilis 
in these countries remain unknown. More studies are required to explore the long-term impact of 
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HIV on syphilis co-infection and the effectiveness of currently recommended therapies for 
various stages of syphilis in HIV-seropositive individuals. 
 
In this chapter, we studied the effect of HIV-co-infection in patients with M-PCR-confirmed 
primary syphilis on the performance of treponemal and non-treponemal serological tests. 
Studies reported unusual serological responses in HIV infected individuals with syphilis such as 
false negative tests or delay in seroconversion19,20 and falsely positive serological 
responses21,22. In our study, no biological false positive reactions of RPR tests were detected 
among HIV-seropositive patients. Unlike studies conducted in developed countries, the 
prevalence of intravenous injecting drug usage was very rare in our patients co-infected with 
HIV and syphilis. Overall, only 69.3% of patients with M-PCR-confirmed TP infection were found 
RPR-seropositive. The rate of RPR-positivity among primary syphilis patients co-infected with 
HIV (57.4%) was significantly lower than those without HIV co-infection (74.1%).  Similarly, the 
RPR seropositivity was significantly lowered in the patients presenting with mixed TP and other 
GUD aetiologic agents (50.9%) when compared to the rate of patients with single TP infection 
(79.2%). The sensitivity of RPR test in detecting primary syphilis in HIV-seropositive patients 
was significantly reduced in those with mixed TP infection compared to patients with single TP 
infection. Therefore, the utility of RPR test in detecting primary syphilis may be reduced further 
in areas where both HIV-coinfection as well as GUD with multiple aetiologies are common.  
 
Changes in the natural history and clinical presentation of genital herpes in HIV-infected 
individuals have been reported since the early days of the HIV epidemic. When AIDS was first 
reported in 1981, HSV was one of the initial opportunistic infections described in the report. In 
1986, Schneiderman et al also reported a case of genital herpes in a man with acquired 
immunodeficiency syndrome (AIDS), who was receiving chemotherapy for Hodgkin's disease23. 
Typical primary HSV infections present with skin lesions in different stages of evolution including 
pustules, vesicles, shallow painful ulcers, and crusted lesions. HSV ulcers in people with 
advanced HIV-1 disease are often large, deep, slow to heal, and, not infrequently, appear in 
atypical areas of the body.   
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In southern Africa, the HIV epidemic reached maturity in the late-1990s with an increasing 
number of immunocompromised patients being recorded. Most patients with genital herpes who 
were included in the studies reported here presented with large non-vesicular, deep, purulent 
ulcerations that mimicked chancroid. These patients were treated according to the syndromic 
STI management alogorithm covering only primary syphilis and chancroid. As a result, the 
failure of treatment for non-vesicular genital ulcer diseases in southern Africa increased 
substantially during the mid-1990s. HIV-seropositive patients presenting with atypical genital 
herpes represented up to 13% of chancroid-like ulcerations in one series and the majority had 
persistent ulcerations for more than two weeks. Over 16% of patients with HIV and HSV co-
infection who were treated with antibacterial agents continued to shed HSV in their genital 
lesions for more than two weeks. Some patients also experienced extremely high HIV plasma 
viral loads during these protracted episodes. In these patients, rapid improvement and eventual 
cure had only been achieved after initiation of specific anti-herpes therapy.  
 
As the HIV-epidemic advanced in southern Africa, the changing GUD situation was reported in 
other countries in the region. Lack of genital herpes cover would therefore undermine the 
ultimate goal of syndromic GUD management, namely to achieve a rapid diagnosis and 
effective treatment in order to control further STI and HIV transmission. In the late-1990s, 
increasing numbers of patients with genital herpes were presenting with atypical, chronic, 
erosive lesions with no spontaneous healing. Unfortunately, antiviral drugs for treatment of 
genital herpes remained expensive and were not universally available in public health care 
facilities in most southern African countries.  
 
In our study, only limited information was available on frequency of reactivation of genital herpes 
in HIV-seropositive individuals and the level of subclinical HSV shedding. However, 
Corey et al have described that HSV-2 reactivation occurs more frequently in HIV-seropositive 
than HIV-seronegative men while a high frequency of subclinical disease can also be observed 
in the immunocompromised populations24. Both CD4+ counts and HIV PVLs influence HSV-2 
reactivation rates. A negative correlation has been documented between CD4+ count and the 
frequency of HSV reactivation. 
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Generally, it has been recommended that chancroid patients co-infected with HIV should be 
closely monitored due to potential treatment failure. Studies previously conducted in Malawi and 
Kenya reported that healing of chancroid ulcerations was slower among HIV-infected patients25-
26. Higher failure rates were reported in Kenya with single dose therapy for chancroid27-29. In 
contrast, in Rwanda, researchers found that HIV and the degree of immunosuppression as 
measured by CD4+ counts had no effect on bacteriological and clinical outcomes and that 
treatment failures were entirely attributable to resistance of H.ducreyi to trimethoprim-
sulfamethoxazole (TMP-SMX)30. The dosage and duration of the fleroxacin regimen also 
needed to be increased to treat HIV infected patients in Nairobi31. A higher treatment failure rate 
among HIV infected patients has, however, not been observed by the same Kenyan team in a 
more recent study using low dose erythromycin or single dose ciprofloxacin32.  
 
The U.S. Centers for Disease Control and Prevention recommends that "since data on 
therapeutic efficacy with the recommended ceftriaxone and azithromycin regimens among 
patients infected with HIV are limited, those regimens should be used among persons known to 
be infected with HIV only if follow-up can be assured" (CDC, 1997). Some experts suggest using 
the full dose 7-day regimen of erythromycin for treating HIV infected persons. 
 
In our study, HIV-seropositive patients with chancroid who have shown poor clinical response to 
routine chancroid therapy, were often co-infected with genital herpes. The antimicrobial 
resistance patterns of H.ducreyi were the same for the isolates obtained from HIV-seropositive 
and HIV-seronegative patients (unpublished observation). Caution should be exercised in 
interpretation of the results obtained in earlier studies where laboratory investigations for HSV 
co-infection were not performed. 
 
4.7 Concluding remarks 
In summary, atypical clinical presentations of genital ulcer disease, particularly of genital herpes, 
have become increasingly common in southern Africa, and have been strongly associated with 
HIV infection and related immunodeficiency. However, high prevalence of mixed infections 
associated with genital ulcerations has also contributed to the poor accuracy of clinical 
diagnosis of GUD in the region. The treatment failures associated with genital herpes have, 
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HSV as well as HIV. Caution should be exercised in the interpretation of syphilis serological 
testing in cases of GUD particularly in those who are co-infected with HIV because many cases 
of primary syphilis may be associated with other causes of GUD.
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CHAPTER 5 
HIV shedding from genital ulcerations 
Male patients presenting with genital ulcerations were enrolled in these studies to measure 
HIV shedding from genital lesions and the subsequent effect of treatment on HIV viral 
shedding. A clinical and microbiological evaluation was performed using standard methods as 
described in section 2. A novel specimen collection technique for the quantitative 
measurement of HIV shedding from genital ulcer lesions was devised by the investigator. 
Follow-up visits were scheduled on Day 7, Day 14 and on Day 21, during which the clinical 
and microbiological status of lesions was assessed and levels of HIV shedding determined. 
 
5.1 Collection of genital ulcer exudates for HIV viral load  
measurement  
In order to determine quantitatively the number of HIV RNA copies in fixed amounts of genital 
ulcer exudate, a standard volume of exudate was collected. After a target ulcer had been 
identified according to standard criteria (see section 2), 10 ml of sterile distilled water was 
gently expressed onto the target ulcer using a syringe and wide-bore injection needle (Figure 
5.1).  The washings were collected in a sterile disposable plastic container with a wide 
opening, taking care that no spillage occurred. The total volume of washings was transferred 
into a 10 ml plastic tube and kept on ice and placed in storage at − 70C° within 12 hours.  
 
 
 Figure  5.1 Collection of genital ulcer exudates  
  for HIV RNA measurement 
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5.2 Quantification of HIV viral load in ulcer washings  
The quantitative measurement of HIV RNA copies in ulcer washings was conducted at the 
National Institute for Virology (Johannesburg), using the Roche Amplicor (Cobas Amplicor 
HIV version 1.0 monitor, Roche Diagnostics, USA) test. Processing of washing fluid followed 
the standard procedures used for HIV viral load determinations (on plasma specimens) as 
described in Section 2.3.4.2. The results were expressed in terms of the number of HIV RNA 
copies per ml of washings fluid collected. A pilot evaluation of the method was conducted 
before initiation of the study. No significant inhibition of PCR was encountered even following 
the precautionary step of re-testing all critical washings with low or negative counts before 
they were reported. The consistency of viral load measurements between batches was also 
evaluated. 
 
In order to minimize contamination with blood as a result of bleeding which could occur 
following swabbing of the ulcerations, the washing procedure was conducted before other 
specimens were collected.  
 
5.3 Patient characteristics 
All patients were HIV-seropositive miners seeking treatment at the Carletonville mine STI 
clinic for genital ulcer disease. The mean age patients was 35 years (range 22 – 50 years). 
None had clinical symptoms or signs of AIDS at the time of their initial consultation visit.  
 
Of 78 patients enrolled, CD4+ results were available for 70 patients. The mean CD4+ count 
measured at Day 1 was 398 cells/mm3 (SD = 233, range 10 – 1500 cells/mm3). Although no 
AIDS defining illnesses had been diagnosed previously, seven patients (10%) had a CD4+ 
count of fewer than 200 cells/mm3, while 31 (44%) patients had counts of 200 – 350 
cells/mm3 and 32 (46%) counts of >350 cells/mm3 (Table 5.1). 
 
 
 
 
 - 115 - 
Table  5.1 Distribution of CD4+ counts of patients at Day 1 (N=70) 
CD4+ Counts (cells/mm3) 
Median (range) 336 (10 – 1,500) 
CD4+ Group  Number  %
<200   7 10% 
200-350 31 44% 
>350 32 46% 
 
The HIV plasma viral load (PVL) at Day 1 was determined for all patients and the median PVL 
was 115,838 copies/ml (range 400 – 871,617 copies/ml). The majority (97%) of patients had a 
detectable PVL level (i.e. more than 400 copies/ml) at Day 1 (Table 5.2). Of 74 patients who 
returned for their Day 7 follow-up visit, repeat PVL results were available for 22 (29.7%) 
patients. 
 
Table 5.2 Distribution of HIV-PVL among GUD patients at Day 1 (N = 78) 
HIV-PVL (copies/ml) 
Median (range) 115,838 (1086 – 871,617) 
PVL Group Number %
≤10,000 10 13% 
>10,000 - 30,000 11 14% 
Above 30,000 57 73% 
 
The clinical presentation of ulcers and the results of laboratory investigations are shown in 
Table 5.3.  
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Table 5.3 Clinical parameters of genital ulcers (N = 78) 
Clinical Parameters of Genital Ulcers 
Duration of Ulcers  
Median 5 days (1 - 30 days)#
Ulcer of < 7 days 80% 
Median Ulcer Size*  8 mm (3 - 30 mm) #
Mean Number of Ulcers         3 (1 - 18) #
Clinical Diagnosis  
Chancroid 63 (80.0%) 
Herpes 16 (20.0%) 
Aetiological Diagnosis  (Culture/M-PCR +ve)  
Chancroid 41 (52.6%) 
Genital Herpes 31 (39.7%) 
Mixed Chancroid & Herpes         6  (7.7%) 
*  Approximate measurement of the largest ulcer (i.e. target ulcer) diameter in mm 
#  Parentheses indicate range 
 
 
5.4. Patients positive for H. ducreyi only at enrolment (N= 41) 
A total of 41 patients were found to be positive for H. ducreyi alone at the enrolment visit (Day 
1). The Day 1 clinical and laboratory findings of 41 patients positive for HD only at enrolment 
were as follows.  
 
The median ulcer size was 9 mm (range 4 – 30 mm) and the median number of ulcers was 2 
(range 1 – 9). The median CD4+ count was 361 cells/mm3 (range 10 – 1028 cells/mm3). The 
majority of patients (95%) had a detectable HIV plasma viral load (PVL) and the median PVL 
was 98,519 copies/ml (range - 1371 – 871,617 copies/ml). Thirty-four patients (82.9%) had 
HIV PVL >10,000 copies/ml at Day 1. Thirty-four patients (82.9%) had detectable HIV RNA in 
their ulcer lavage fluid with a median lesional HIV shedding of 3,782 copies/ml (range 568 – 
62,756 copies/ml of lavage fluid). Among patients with PVL >10,000 copies/ml, HIV RNA was 
detected in the lavage of 33 patients (97.1%) compared to only 1 of 7 patients (14.3%) with a 
PVL ≤ 10,000 copies/ml.  
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All patients were treated syndromically using antibiotics known to be effective for both primary 
syphilis and chancroid. Patients were grouped into three categories based on treatment 
outcome (i.e. both clinical and microbiological) at Day 7 and Day 14. Group A included 17 
patients who had achieved both clinical and microbiological cure at Day 7; Group B included 
20 patients who had achieved clinical improvement with or without microbiological cure at Day 
7; and Group C included four patients with no clinical improvement with or without 
microbiological cure at Day 7. Thirty-seven (90.2%) of patients in Groups A and B showed 
clinical improvement at Day 7 while four patients in Group C experienced clinical failure. 
Among patients in Groups A and B, the overall reduction in ulcer size ranged from 12.5% to 
100% (i.e. completely healed) compared with initial measurements at Day 1. The mean ulcer 
size reduction at Day 7 was 72.5% of initial ulcer size measured at Day 1.  
 
Overall, 18 patients (43.9%) from Groups A, B and C continued shedding HIV in their lavage 
fluid on Day 7 with a median number of 4,649 HIV copies detected per ml (range 771 – 
53,630 copies/ml ). At Day 14, 27 patients (65.9%) achieved a clinical cure (i.e. ulcer 
completely healed) and continued shedding of HIV was reduced in seven patients (17.1%).  
 
The clinical and microbiological treatment responses seen in patients in Groups A, B and C 
are shown in Figure 5.2. The patients in Group A had a successful treatment outcome, their 
ulcerations were completely healed (clinical success) and no aetiological agents were 
detected in the ulcer exudates (microbiological success) at Day 7. In this group, 13 patients 
(76.5%) had initial PVLs of >10,000 copies/ml and 12 patients (70.6%) had detectable HIV 
RNA in their lavages at Day 1. All but two patients stopped shedding HIV RNA in their lavage 
fluids. HIV shedding rates declined from 70.6% on Day 1 to 11.8% on Day 7. Two patients 
continued to shed HIV RNA in their washings at Day 7 despite the fact that their ulcers were 
completely epithelialized; one had a high PVL (259,188 copies/ml) at Day 1, and HSV was 
still detected from the specimen taken on Day 14. The remaining patient also had a high PVL 
(227,538 copies/ml) and a very low CD4+ count (54 cells/mm3). In addition, both had 
laboratory-confirmed urethritis. All patients in Group A, including two cases that had relapsed 
clinically (one HD +ve and the other HSV +ve) stopped shedding HIV by Day 14. 
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The remaining 24 patients in Groups B and C presented with continuing ulcerations on Day 7 
although 20 patients (Group B) showed some reduction in ulcer size (i.e. mean ulcer size 
reduction of 50% of measurements recorded on Day 1).  Only two patients exhibited 
microbiological failure for HD at Day 7. However, both were found HD negative at Day 14. 
Twelve of 20 patients (60%) had shown a complete clinical and microbiological cure at Day 
14. Culture and/or M-PCR for HD were negative in 18 of 20 patients (90%) at Day 14. 
 
In Group B, 18 patients (90%) had initial PVLs of >10,000 copies/ml and all 18 patients had 
detectable HIV RNA in their lavages at Day1. Two patients with initial PVL of ≤ 10,000 
copies/ml did not shed HIV in their ulcer exudates. After treatment, 7 patients (35%) stopped 
HIV RNA shedding in their lavages by Day 7. HIV RNA was, however, detectable in the 
lavages of 12 patients, including one patient who did not shed HIV on Day 1, although the HIV 
shedding rate decreased by 60% among patients on Day 7. Of these 12 patients with 
detectable HIV RNA in their lavages on Day 7, two exhibited microbiological failure (positive 
HD by culture and/or M-PCR) and 10 had a microbiological cure.  
 
Of 18 patients who achieved microbiological cure by Day 7, three had microbiological 
relapses (two became HD and one HSV positive by M-PCR), three had microbiological cure 
and 12 had both clinical and microbiological cure by Day 14. One of the two patients 
exhibiting microbiological relapses with HD on Day 14, also resumed HIV shedding, while the 
other remained a non-shedder for HIV RNA by Day 14. 
 
One patient, who tested HSV positive on Day 14, had an initial PVL of 31,550 copies/ml. H. 
ducreyi culture and M-PCR became negative at Day 7 following anti-chancroid treatment. 
However, HIV shedding from lesions increased from 3,028 copies/ml on Day 1 to 16,217 
copies/ml on Day 7. On Day 14, as mentioned above, HSV was detected in the patient’s ulcer 
exudates while HIV shedding in lavage fluid was maintained at 11,181 copies/ml. 
Lesional HIV shedding became undetectable in three patients who achieved microbiological 
cure at Day 14, despite their ulcers not having healed completely. Of 12 patients who 
achieved both clinical and microbiological cure at Day 14, three patients continued shedding 
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HIV on Day 14. Two of these three patients had relatively high PVL, but no other reason could 
be determined for the continued shedding of HIV on Day 14 in these cases. 
 
Of four patients who experienced clinical failure at Day 7 (Group C), two had the same ulcer 
size as on Day 1, and the remaining two had an increase in ulcer size. Two patients 
continued shedding H. ducreyi at Day 7 and Day 14 and one patient had a microbiological 
relapse (positive for HD after initial clearance) at Day 14.  
 
In Group C, three of four patients (75%) had an initial PVL of >10,000 copies/ml and all four 
continued to shed HIV RNA in their lavages. No clinical improvement was detected among 
these patients and three of the four were microbiological failures on Day 14.  
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Figure 5.2 Clinical and microbiological course of genital ulcerations and impact of HIV 
shedding from ulcers among patients with only H. ducreyi detected on Day 1  
 
 
5.5 Patients with mixed herpes and chancroid at enrolment (N=6) 
Six patients were positive for HD and HSV at enrolment and their clinical and microbiological 
findings are summarised in Figure 5.3. At the enrolment visit, the mean ulcer size for these 
patients was 10.3 mm (range: 6 – 15 mm) and the mean number of ulcers was 4.1 (range: 1 -
18). The median CD4+ count was 225 cells/mm3 and the median PVL was 258,989 copies/ml 
(range: 19,030 – 753,240 copies/ml). All patients had PVL of >10,000 copies/ml at Day 1. The 
majority (93.3%) of patients shed HIV RNA in their lavages at Day 1 with a median HIV RNA 
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of 6,458 copies/ml (range: 764 – 37,661 copies/ml). The clinical and microbiological outcomes 
and patterns of HIV shedding in lavage specimens are shown in Figure 5.3. 
 
Following syndromic treatment using antibacterial agents, 3 (50%) continued to shed HIV 
RNA in their lavages at Day 7 despite having microbiological cure and clinical improvement. 
One patient was microbiologically cured for HD at Day 7, but continued to be positive for HSV 
on Day 7 and Day 14. There was no sign of clinical improvement in this patient and he 
continued to shed HIV RNA on both Day 7 and Day 14 while the remaining patients stopped 
shedding HIV by Day 14. 
 
 
 
 
Figure 5.3 Patients with mixed herpes and chancroid at enrolment (N=6) 
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5.6 Patients with atypical herpes at enrolment (N=15) 
At the enrolment visit, 15 (19.2%) HSV-positive patients were wrongly diagnosed as 
chancroid based on their atypical clinical presentations (i.e. soft, deep, purulent ulcerations 
without any history of vesicular lesions).  All patients received syndromic treatment with 
standard antibiotic therapy. The clinical, microbiological and HIV shedding pattern of these 
patients are summarised in Figure 5.4. The mean size and number of ulcers in this group 
were similar to those of patients with chancroid and mixed chancroid and herpes (mean ulcer 
size = 10.5 mm; mean ulcer number = 3.8). The median CD4+ count was 288 cells/mm3 
(range: 233 – 787 cells/mm3) and median PVL was 223,809 copies/ml (range: 2,242 – 
871,058 copies/ml) at Day 1. Fourteen patients (93.3%) had PVLs >10,000 copies/ml and 12 
patients (80%) shed HIV in their lavages with a median of 3,018 copies/ml (range: 412 – 
38,745 copies/ml) at Day 1. 
 
Following syndromic treatment with antibiotics, three patients had clinical and microbiological 
cure at Day 7. Of the remaining, four patients (26.7%) showed some clinical improvement (i.e. 
mean ulcer size reduction of 41% compared to Day 1) and eight patients (53.3%) exhibited 
clinical failure on Day 7. HIV shedding in lavages continued in the majority of patients (80%) 
with a median HIV shedding of 1,643 copies/ml (range 464 – 9,212 copies/ml) at Day 7. The 
majority of patients (92%) who shed HIV were those who did not achieve clinical and/or 
microbiological cure at Day 7. HIV shedding was reduced in five patients (33.3%) on Day 14. 
Of those, four also shed HSV at Day 14 (Figure 5.4).  
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Figure  5.4  Patients with atypical herpes at enrolment (N=15) 
 
 
5.7 Patients with typical herpes at enrolment (N=16) 
Among patients with GUD, 16 (20.5%) presented with typical genital herpes (i.e. multiple, 
shallow, non-purulent ulcerations with blisters or history of blisters). All patients received anti-
herpes therapy at Day 1 (i.e. valacyclovir 500 mg BD x 5 days). The mean ulcer size at 
enrolment was 4.6 mm (range: 3 – 10 mm). The median HIV PVL was 72,005 copies/ml 
(range 1,086 – 750,000 copies/ml) and the median CD4+ count was 376 cells/mm3 (range: 
256 – 1500 cells/mm3).  The majority of patients (87.5%) had a PVL of more than 10,000 
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copies/ml and HIV shedding was detected in 56.3% of patients at Day 1. The median HIV 
RNA detected in lavages at Day 1 was 1,890 copies/ml UL (range: 530 – 8,215 copies/ml ).  
 
Fourteen patients (87.5%) achieved clinical and microbiological cure at Day 7 and none 
continued to shed HIV at this visit. Two patients without clinical cure at Day 7, however, 
continued to shed HIV, although a slight decline in the amount of HIV shedding was observed 
in both patients. All patients achieved complete clinical and microbiological cure and none 
shed HIV at Day 14 (Figure 5.5).
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 Figure 5.5 Patients with typical herpes at enrolment 
 
 
 
5.8 Summary of viral shedding from genital ulcerations 
The clinical, microbiological and treatment responses of patients with genital herpes infections 
of any kind are summarised in Table 5.4. Overall, the mean size of ulcers in patients with 
classical genital herpes was significantly smaller than in other groups. (F=4.03, p<0.01) The 
median PVL of patients with atypical herpes was significantly higher than patients with 
chancroid (Mann-Whitney U test, p<0.05).  
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Table 5.4 Summary of clinical and microbiological outcomes 
G.Herpes Chancroid Atypical G.Herpes
Chancrod & 
G.Herpes
N=16 N=41 N=15 N=6
Baseline Clinical Characteristics
4.6* 11.5 10.5 10.3
(3 - 10) (4 - 30) (4 - 27) (6 - 15)
4 2.6 3.8 4.1
(2 - 10) (1 - 9) (1 - 7) (1 - 18)
376 361 288 225
(256 - 1500) (10 - 1028) (233 - 787) (124 - 440)
72004 98,5191 223,8092 258897
(1,086 - 750,000) (1,371 - 871,617) (2,242 - 871,058) (19,030 - 753,240)
34 14 6 14
(82.9%) (87.5%) (100%) (93.3%)
9 34 12 5
(56.3%) (82.9%) (80%) (83.3%)
1,890 3,782 3,018 6,458
(530 - 8,215) (568 - 62,756) (412 - 38,745) (764 - 37,661)
Follow-up visits
12 37 9 5
(75.0%) (90.2%) (60.0%) (83.3%)
92.5 72.5 63.7 57.4
(50 - 100) (12.5 - 100) (16.7 - 100) (50 - 66.7)
2 18 12 4
(12.5%) (43.9%) (80.0%) (66.7%)
2,688 4,649 1,643 4,134
(1307 - 4069) (771 - 53,630) (464 - 9,212) (3,338 - 29,209)
16 27 5 5
(100.0%) (65.9%) (33.3%) (83.3%)
0 7 6 1
(0%) (17.1%) (40.0%) (16.7%)
Patients with HIV shedding in ulcer 
lavage (UL) in Day14
Median HIV RNA detected in
ulcer lavage (UL) in Day7
Patients achieved clinical cure at 
Day14
Mean ulcer size reduction
at Day7 (% of ulcer size in Day1)
Patients with HIV shedding in ulcer 
lavage (UL) in Day7
Median HIV RNA detected in
ulcer lavage (UL) in Day1
Patients with clinical improvements 
at Day7
Median HIV PVL 
at enrolment (copies/ml)
HIV PVL >10,000 copies/ml
at enrolment
Patients with HIV shedding in ulcer 
lavage (UL) in Day1
Mean Ulcer Size
at enrolment (mm)
Mean Ulcer Number
at enrolment
Median CD4 + Counts
(cells/mm3)
Sig.
Mann-Whitney U test
1 vs 2 (p=0.04)
Anova F=4.03. p=0.01
 
 
The majority of patients in the various groups had PVLs greater than 10,000 copies/ml at the 
time of enrolment visit. Although the rate of HIV shedding at enrolment (56.3%) was lower in 
patients with typical herpes than in other groups (82.3%), this difference was not statistically 
significant (χ2 = 3.49, p 0.06). HIV shedding was significantly reduced in this group at Day 7 
after patients had received treatment with anti-herpes therapy (56.3% vs 12.5%, χ2 = 6.79, p 
0.009). All patients ceased shedding HIV by Day 14. 
 
Similarly, shedding of HIV decreased significantly following treatment among patients with 
chancroid alone - from 82.9% on Day 1 to 43.9% on Day 7 (χ2 = 13.46, p<0.001). A further 
significant reduction in HIV shedding was found on Day 14 (43.9% vs. 17.1%, χ2 = 6.96, 
p<0.001). There was a decrease in HIV shedding from 83.3% on Day 1 to 66.7% on Day 7 
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among patients with mixed chancroid and herpes. However, this decline was not statistically 
significant. (83.3% vs 66.7%, p NS) A similar trend was observed on Day 14. 
 
In contrast, the same rate of HIV shedding was observed between Day 1 and Day 7 in 
patients with atypical herpes who received treatment with antibiotics only on Day 1. The 
shedding of HIV was reduced on Day 14 although 40% of patients still continued to shed HIV. 
When comparing the rates of shedding on Day 7 between the different groups, the atypical 
herpes group had significantly higher shedding than the other groups who had received either 
correct or partially correct therapy (Figure 5.6). 
 
The majority of patients in all aetiology groups had HIV PVLs of more than 10,000 copies/ml.  
When comparing the rate of shedding at enrolment, there was an association between HIV 
PVL and HIV shedding (Table 5.5). The rate of HIV shedding in patients with PVL >10,000 
copies/ml was significantly higher than in patients with PVL ≤10,000 copies/ml with an odds 
ratio of 59 (95% CI – 6.7 – 552.9, p<0.0001).  
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Figure 5.6 Proportion of patients shedding HIV in genital ulceration by ulcer 
aetiology 
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Table 5.5 Association between HIV PVL and HIV shedding in lavage fluids 
 
HIV Shedding in Lavage Fluid 
PVL at Day1  ≥ 400 
copies/ml < 400 copies/ml 
Total 
PVL >10,000 copies/ml 59 (86.8%) 9 (13.2%) 68 (87.2%) 
PVL ≤ 10,000 copies/ml 1 (10.0%) 9 (90.0%) 10 (12.8%) 
All patients 60 (76.9%) 18 (23.1%) 78 (100.0%) 
Odds Ratio = 59.0 (95% CI – 6.7 – 552.9). p<0.0001  
 
 
 
5.9 Discussion 
 
 
Since the beginning of the HIV epidemic, the natural history and mode of transmission of HIV 
have been extensively studied by researchers. The major modes of transmission of HIV are 
accepted to be unprotected sexual intercourse with infected individuals, transfusion of 
infected blood and blood products, parenteral injections using contaminated needles and 
mother-to-child transmission. Globally, the predominant mode of transmission of HIV varies 
significantly between regions. UNAIDS/WHO estimated that the global total number of people 
living with HIV had reached 39.4 million in 20041. Despite the fact that that transmission 
through sexual intercourse has been reported to be lower than that of transmission through 
other routes such as sharing contaminated needles, mother to child transmission and 
transfusion of contaminated blood2, in most developed countries, this mode of transmission 
still accounts for 75 to 85 percent of the total global burden of HIV3.  
 
As described by Anderson and May, the rate of spread of HIV infection depends on the 
duration of infectiousness of infected individuals and the average rate of sex partner change4. 
Although untreated HIV-infected persons can be expected to be infectious for the rest of their 
lives, the level of infectiousness through sexual transmission varies with many biological and 
epidemiological determinants. For example, an individual’s infectiousness is known to 
increase during primary HIV infection and again during the late stage of the disease 
associated with low CD4+ counts and an AIDS defining illness2,5-9. It has been documented 
that from the time of primary HIV infection, dissemination of the virus to patients’ tissue 
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compartments results in the early establishment of viral reservoirs and shedding into oral and 
genital fluids9-10. It has also been shown that high-level shedding persists in the seminal 
plasma in some patients, despite effective anti-retroviral therapy resulting in reduction of 
PVLs2. STD-associated local immune activation together with inadequate drug penetration, 
slower clearance of HIV particles and/or slower decay rates of infected cells within the genital 
tract have been quoted as possible reasons for this phenomenom. Genital infections 
documented to be associated with increased detection of HIV in semen include seminal 
leukocytosis, urethritis, gonorrhoea, and cytomegalovirus infection11-13. Successful treatment 
of acute urethritis has been shown to reduce the rate of detection of HIV in semen11. 
 
In the studies reported in this chapter, we investigated the level of dissemination of HIV in 
another compartment, genital ulcer exudates. The HIV RNA concentration in genital ulcer 
exudates was quantitatively measured at different stages of the disease. Various biological 
and clinical determinants associated with the level of shedding were also explored.  
 
With the rapid advancement of the HIV epidemic in southern Africa, we have documented the 
co-existence of a GUD epidemic that may have assisted in driving the epidemic to its highest 
level. In this setting, successful treatment of GUD in HIV-seronegative patients should reduce 
the risk of acquisition of HIV. This is even more so when over one third of men and women 
with GUD admit to having continued their sexual activities despite the presence of 
ulcerations14 .  When the HIV prevalence among GUD patients reached extremely high levels 
in the mid-1990s (over 50% of STI clinic patients on the gold mines), HIV shed in genital ulcer 
exudates could have contributed considerably to the increase in infectiousness of these core 
HIV transmitters.   
 
During the period 1998 – 1999, we recruited HIV-seropositive GUD patients with chancroid 
alone (52.6%), genital herpes alone (39.7%) and mixed chancroid/genital herpes infections 
(7.7%) into our studies.  HIV RNA was detected in genital ulcer exudates in more than 80% of 
78 patients with large ulcerations which were clinically diagnosed as chancroid at the time of 
diagnosis. All patients were ART naïve and the majority (87.2%) had PVL >10,000 copies/ml 
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at the time of enrolment. Patients presenting with a typical clinical presentation of genital 
herpes (small, superficial, multiple vesicular ulcerations) had the lowest prevalence of HIV 
shedding (56.3%) at enrolment. The amount of HIV shedding, as measured by the number of 
HIV RNA copies detected per ml of ulcer lavage, varied considerably between patients. The 
highest amount of shedding of over 60,000 HIV RNA copies/ml of lavage fluid was detected in 
one patient with chancroid. The median shedding in the group was 3,782 copies/ml. In these 
studies, 10 ml normal saline was used to collect the exudates from ulcers in the form of ulcer 
lavage. The amount of exudates captured from the target ulcers in the 10 ml wash fluid would 
be relatively small and likely to be considerably less than 1 ml. Therefore, the amount of HIV 
RNA copies in actual ulcer exudates would be more than 10 times higher than that of the 
lavage fluid. By taking into account that most patients have multiple ulcerations, the total 
quantity of HIV copies shed from genital lesions could be several fold higher than the ‘per ml’ 
measured in the lavage specimen. Furthermore, the transmission efficiency in STI patients 
with untreated or inadequately treated genital ulcerations might have significantly increased 
and therefore contributed to the rapid spread of HIV infection in the community. 
 
Various effective interventions such as overall improvement of GUD management in the mine 
and surroundings, targeted intervention of high-risk women using peer education and periodic 
presumptive treatment using azithromycin, brought the epidemic situation of chancroid in 
southern Africa under control in the early 2000s15. Similarly, enhanced screening and 
treatment of asymptomatic syphilis patients are recognised as factors that led to a rapid 
decline in syphilis seroprevalence among high-risk populations and this reached its lowest 
level in the early 2000s. Unfortunately, a decrease in cases of bacterial GUDs was 
accompanied by a rapid increase in the relative prevalence of genital herpes, particularly 
among HIV-seropositive patients in recent years (Section 3.4.3). A large proportion of these 
patients presented with atypical ulcerations that mimicked chancroid. In the absence of anti-
herpes therapy in most public sector clinics, all patients with atypical herpes are routinely 
treated only with antibacterial agents and treatment failures are common; ulcerations often 
continue for more than two weeks, and shedding of HIV from ulcer exudates also continues. 
In our study, up to 40% of patients with atypical herpes who did not receive appropriate anti-
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herpes treatment had detectable HIV RNA copies in their ulcer exudates at the Day 14 follow-
up visit. Of those patients presenting with clinically recognisable genital herpes and who 
received appropriate antiherpes therapy, none had detectable HIV RNA in ulcer exudates at 
Day 14.   
 
Our study findings also provide evidence of high level of dissemination of HIV into genital 
ulcer exudates when co-infected with HD and/or genital herpes. The rate of HIV shedding in 
genital ulcer exudates was directly associated with patient’s PVL. Based on a proxy PVL cut-
off level of 10,000 copies/ml and the degree of HIV shedding found in the study, shedding 
was significantly higher in patients with PVLs >10,000 copies/ml than with lower PVLs with an 
odds ratio of 59.0 (95% C, 6.7 – 552.9).  
 
The important role of PVL in heterosexual transmission of HIV has been reported in various 
studies16-17. Gray et al found that higher plasma viral loads and genital ulcerations were the 
main determinants of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 
discordant couples in Rakai, Uganda. That study also concluded that the overall probability of 
transmission per coital act was 0.0011 which is within the range of transmission probabilities 
per act (0.0001 – 0.0020), found in other countries18-21. That study was conducted in Rakai 
during the period 1994 – 1998, and although their study population was different from ours, it 
is interesting to observe that the median PVL of the participants in their study was much lower 
than patients enrolled in our study (i.e. 12,476 copies/ml vs.115,838 copies/ml). The 
difference might be partially explained by a difference in the type of specimen used between 
the two studies. In our study, plasma samples were used for viral load measurement, while 
serum specimens were used in the Rakai study (up to a 21% lower counts have been 
recorded in serum when compared to plasma specimens, although this difference was not 
considered statistically significant; p=0.09)22. In the Rakai study, Quinn et al also reported that 
among HIV discordant couples in whom the initially HIV-1 negative partner seroconverted, the 
mean serum HIV-1 RNA level of the HIV-1 seropositive partner was significantly higher than 
in couples with seronegative partners who remained seronegative (mean, 90,254 copies per 
ml vs. 38,029 copies per ml, p 0.01)17 . A dose response effect was found in the study in 
 - 132 - 
which the rate of transmission increased from 2.2 per 100 person-years to 23.0 per 100 
person-years as the serum HIV-1 RNA level increased from less than 3500 copies per ml to 
50,000 or more copies per ml (adjusted rate ratio, 11.87). Our study findings also established 
a similar association between PVL and excretion of HIV RNA in genital ulcer exudates. Our 
study did not, however, include the measurement of HIV PVL in semen, but highlights the 
association between PVL and genital ulcer exudates and the role of PVL in dissemination of 
HIV into genital fluids. 
 
In summary, appropriate diagnosis and treatment of genital ulcerations resulted in a rapid 
decline of HIV shedding in ulcer exudates, while any treatment failures or inadequate 
therapies led to delay in healing of ulcerations as well as continued shedding of HIV in ulcer 
exudates. Our study also highlighted the rapid increase in the relative prevalence of genital 
herpes among HIV-seropositive patients with genital ulcerations since the late 1990s. 
Therefore, syndromic management of GUD in southern Africa utilizing antibiotics alone 
should, theoretically become less effective, leading to a situation of increased treatment 
failure and continued shedding of both HSV and HIV in the community. Some countries such 
as Botswana and South Africa have initiated pilot projects to explore the feasibility in inclusion 
of anti-herpes therapy in the syndromic GUD management protocols. However, the 
availability and cost of non-curative anti-herpes therapy remain major problems in many 
developing countries. 
 
In conclusion, effective control of the GUD epidemic in southern Africa is of paramount 
importance in preventing the continued rapid spread of HIV infection. Reduction or elimination 
of GUD cases is likely to contribute substantially to the prevention of HIV acquisition among 
high-risk HIV-seronegative patients and in addition lead to reduced infectiousness of HIV-
seropositive individuals. 
 
In 2003, WHO and partner agencies declared a commitment to improve access to anti-
retroviral therapy (ART) for all HIV-seropositive patients in developing countries23. Wider 
access to ART in the coming years could ultimately reduce the PVL in the HIV-seropositive 
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population in southern Africa, although the highest PVLs could be among those with GUD 
who have not yet seroconverted. It is also possible that the overall immune reconstitution 
which occurs in treatment naïve population after introduction of ART could provide a positive 
spin-off effect in reducing the infectiousness of HIV-seropositive individuals in southern Africa 
by reducing recurrences of genital herpes. Safeguard activities must be implemented to re-
enforce promotion of safer sex behaviour among high-risk individuals to prevent potential 
backlash of “treatment optimism” as seen among MSM population in more developed 
countries24-25. Further studies are needed to monitor these rapidly changing dynamics of HIV 
and STI epidemiology in southern Africa. 
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CHAPTER 6 
 
Interactions between HIV and STIs in women 
 
6.1 Introduction 
 
UNAIDS/WHO has estimated that 37.8 million people (range: 34.6–42.3 million) worldwide 
were living with HIV by the end of 20031. While in the early days of the HIV epidemic, a 
disproportionately high number of men were infected with HIV, this proportion has 
dramatically changed in recent years with the number of women infected by HIV worldwide 
steadily growing. By the end of 2003, almost half of all people infected (approximately 17 
million) were women. The HIV epidemic has also spread geographically; the burden of 
infection differing in different parts of the world. Although it has just over 10% of the world’s 
population, up to two-thirds of all people living with HIV— approximately 25 million (range: 
23.1–27.9 million) are resident in sub-Saharan Africa.  
 
Countries in the southern African region including South Africa, Botswana, Zimbabwe, 
Malawi, Lesotho, Swaziland, Namibia and Mozambique were hardest hit by the exponential 
spread of HIV in the mid 1990s and they accounted for 38.3% of all the infections on the 
continent by 19992. In 2003, HIV prevalence among pregnant women in most countries in 
southern Africa exceeded 20% (Figure 6.1). In South Africa, estimates of the number of 
women of reproductive age (15 – 49) who were living with HIV at the end of 2003 ranged from 
2.5 million to 3.3 million3.  
 
 
 
 
 
 
 
 
   
  Figure 6.1 Trend of HIV infection in Africa (1988 – 2003)  
   Source: UNAIDS3
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Studies of discordant couples in North America and Europe reported a higher male-to-female 
transmission efficiency than from female-to-male.4-6 Data also suggest that male-to-female 
transmission during sex is about twice as likely to occur as female-to-male transmission, if no 
other sexually transmitted infections are present. Moreover, young women are biologically 
more susceptible to infection than older women prior to menopause1. Women’s increased 
vulnerability to HIV is not only due to biological determinants. Many other social and 
economic determinants also play a significant contribution. In many societies, sexual 
decision-making remains solidly in the hands of men and therefore, male partners’ sexual 
behaviour is often the most important risk factor for HIV acquisition among women.  
 
Other important factors associated with HIV dissemination have been mentioned by Quinn in 
19947. These include population migration (both internal and cross-border), urbanization, 
social disruption, poor medical services, declining economies or inequitable distribution of 
wealth, low social status of women, and rates of infection with conventional STIs. These 
macro factors, in addition to those of behaviour, combine to shape the course of the HIV 
epidemic in southern Africa. It has been suggested that, in South Africa, various factors linked 
to social inequality have combined to shape the pattern and growth of the HIV/AIDS epidemic 
and it is therefore necessary to focus on all social dimensions in order to fully understand and 
combat the epidemic8. Biological and epidemiological interactions between STI and HIV in 
women are also very important and require the implementation of evidence-based 
interventions.  
 
Many studies have documented these interactions in different countries largely during the 
early phase of the epidemic9 – 12.  As in men, STI/HIV interactions in women are also bi-
directional in nature. Interactions between HIV and STIs caused by human papilloma viruses 
(HPVs), herpes simplex virus (HSV), bacterial vaginosis (BV), candida vaginitis, 
trichomoniasis (TV), gonorrhoea (GC) and chlamydial (CT) infections have all been noted. 
Owing to the presence of physical, physiological and hormonal complexities involved with the 
female reproductive system, there are many limitations to studies performed previously13 -15. 
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In our studies, we have undertaken to specifically explore the association between HIV and 
more conventional reproductive tract infections including HPV among South African women in 
Johannesburg, South Africa. 
 
6.2 Study sites, population and methods 
 
6.2.1 Background information: study site 
 
The epidemiological and microbiological studies on HIV and STI interactions among women 
were conducted at the Esselen street STI clinic and the HIV clinic at the Hillbrow Hospital 
both serving an inner-city area of greater Johannesburg, South Africa which has a population 
of close to three million16. During the study period, major transformation of the city 
administration took place.  Five previously-independent metropolitan areas were merged in 
2000 to form the current Johannesburg "Unicity".   
 
According to the Greater Johannesburg Metropolitan Council, the estimated size of the 
Hillbrow area, in which both the clinic and hospital are situated, is 35 hectare and the 
population density (100 or more per hectare) is 615.  The area is the most densely populated 
area in Greater Johannesburg with significant inner city decay owing to lack of essential 
services and poorly maintained buildings17. 
 
Overall, the economic growth of the city has been unable to keep pace with population 
growth. The loss of low-skilled employment opportunities as a result of the decline in the 
mining and manufacturing sectors in the area has further exacerbated the unemployment 
situation. The decentralization of economic development to the north of Johannesburg has 
impacted on the low-income households living in the southern areas of the city including 
Hillbrow (Figure 6.2). An influx of illegal immigrants has also had an influence on employment 
possibilities for residents of the area. 
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  Figure 6.2 Analysis of total poverty in Johannesburg 
   (Source: http://ceroi.net/reports/johannesburg/csoe/html/nonjava/Poverty/analysis.htm) 
 
6.2.2 Study objectives 
The study was undertaken to investigate the patterns of vaginal and cervical infections in HIV-
seropositive and HIV-seronegative women and their role in genital shedding of HIV infection 
among HIV-seropositive women. 
 
The microbiological flora of the vaginal and cervix among HIV-seropositive and HIV-
seronegative women was investigated and demographic and clinical indicators identified to 
predict cervical infection among women presenting with vaginal discharge. The magnitude of 
the problem of pelvic inflammatory disease (PID) among HIV-seropositive and HIV-
seronegative women with vaginal discharge was also investigated. With respect to viral STIs, 
we assessed the prevalence of HPV and HSV infections. In addition, the association between 
HPV, HIV and abnormal cervical cytology and determinants of shedding of HIV among HIV-
seropositive women were also studied. The study focused on the role of vaginal and cervical 
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infections on cervico-vaginal shedding of HIV and the effect of treatment of these infections 
on HIV shedding. 
 
6.2.3 Study population  
The study population comprised women attending the Esselen Street STI Clinic, Hillbrow, 
Johannesburg with symptoms of vaginal discharge. Non-menstruating women with vaginal 
discharge and no recent history of antibiotics usage were included in the study. Women who 
did not give consent for a speculum examination were excluded. However, the demographic 
and sexual history of these women was recorded for comparative analysis with those who 
were included in the study. A sub-group of HIV-seropositive women were recruited in order to 
explore the impact of vaginal and cervical infections on genital shedding of HIV. Women were 
included in this sub-group who were found to be HIV-seropositive after agreeing to voluntary 
HIV counseling and testing. 
 
The majority of women attending the STI clinic were middle or low-income residents of inner 
city areas although some residents from remote townships who were working in or around the 
inner city also attended.  Anecdotal evidence indicated considerable population movement in 
the area due to migration from other provinces within South Africa, or neighbouring countries 
(personal observation). Both an informal and formal sex trade was thriving in the area and a 
substantial number of STI patients were working as sex workers. Based on a study conducted 
by Reproductive Health Research Unit (RHRU) at the same clinic, around the same time 
period,18 the majority (93%) of clients of sex workers are South African, with a mean age of 31 
years (range 19-53). Most clients (53%) are single men who had never married. Sex workers 
indicated that they were having a mean of 2 sexual partners per day at the time of interview 
(range 1-8). Fifteen percent of clients said openly that they would offer more money to sex 
workers for sex without a condom. 
 
The HIV Clinic at Hillbrow Hospital serves as a tertiary referral clinic for HIV-seropositive 
patients from Johannesburg and surrounding townships. The clinic population is largely 
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composed of mixed socioeconomic groups but came mostly from low or middle-income 
families. 
 
6.2.4 STI services in study areas 
Following the restructuring of health services in the city, the Esselen Street Clinic was 
administered under Region 8 and covered areas including Hillbrow, Berea, Yeoville, 
Jeppestown, Berea and downtown Johannesburg. The estimated number of people reached 
by the Region 8 health services was approximately 169,00019. 
 
The routine clinic protocol for management of female STI patients includes the collection of 
demographic and personal details, clinical history taking, genital examination including 
speculum and bi-manual examination, serological screening for syphilis and the offer of VCT 
for HIV, syndromic diagnosis and management, using a standard treatment algorithm catering 
for counselling, provision of contact slips and condom promotion. When indicated clinically, 
additional laboratory investigations (e.g. cervical smears for cytological examination and 
laboratory tests for vaginal/cervical infections) and referrals are provided routinely.  
 
6.2.5 Methodology (specific to STI and HIV interactions in women) 
6.2.5.1 The cross-sectional prevalence study 
A pre-coded questionnaire was developed based on experience gained from earlier studies. 
The questionnaire was pre-tested using interviewers at the clinic where the studies were 
being conducted. Dedicated interviewers conducted the interviews in a private room. 
Following the interview and completion of the questionnaire, the investigator examined the 
patient and recorded the clinical findings. The sample questionnaire is shown in Annexure 
6.1. 
 
During the speculum examination, a high vaginal swab was taken for pH testing, an amine 
test, wet mount microscopy and examination of Gram-stained smear. A further two high 
vaginal swabs were taken and immediately inoculated into culture media for the culture of 
Trichomonas vaginalis, Ureaplasma urealyticum, Mycoplasma hominis and Candida species. 
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Any abnormalities of the cervix and vaginal canal observed during the examination were 
recorded.  Ten ml of sterile normal saline was used to flush out the cervix with a 20 ml 
syringe. The cervicovaginal lavage (CVL) fluid was allowed to pool in the posterior fornix for 2 
– 3 minutes. The CVL was then aspirated using a sterile 10 ml disposable pipette. 
 
After wiping the cervix with sterile gauze, cervical specimens were collected for gonococcal, 
chlamydial culture and PCR testing for HPV and HSV. A Cytobrush® (Histobrush, Hardwood 
Products Company, USA) was used to collect specimens from the endocervix and the 
transformation zone and fixed immediately on a slide for cytological examination. Two 
ectocervical specimens (one cotton swab for HSV PCR and one Digene Hybrid Capture 
specimen collection kit for HPV testing) were also collected. PCR for HSV and HPV (MY 9/11) 
were conducted using the methods outlined in Sections 2.3.3.7 and 2.3.3.8.   
 
After removal of the speculum, potential cervical excitation was elicited on bimanual 
examination and recorded by using a subjective scoring system. Blood was then taken from 
patients for syphilis, chlamydial and type-specific herpes serology. A small amount of serum 
was separated, coded and kept for future unlinked anonymous HIV testing. To maintain 
anonymity, sera were kept in the –70° C freezer until completion of the study. Thereafter, the 
record of identity of the patient was destroyed and the sera tested for HIV antibody. A first 
catch urine specimen was also collected for ligase chain reaction (LCR) for chlamydial and 
gonococcal infections. The aetiology of vaginal and cervical infections was assessed through 
the application of standard laboratory methods as described in Section 2.3.3.   
 
After collection of specimens, patients were treated according to the standard syndromic 
management algorithm for vaginal discharge (Annexure 6.4). Other presenting syndromes, if 
present, were treated concurrently, using appropriate algorithms. Patients were requested to 
return for a follow-up visit after 14 days. The contact address of the patient was recorded for 
active follow-up if, necessary.  
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During the follow-up visit, available laboratory and cytology results were considered and 
additional treatment provided where necessary. A recommended protocol was followed for 
women with abnormal cervical cytological reports. Attempts were made to contact patients 
who defaulted by mail or telephone. If they were not available at a given address, evidence of 
their identity was removed and destroyed from case report forms and their sera were 
subsequently tested anonymously for HIV antibodies.  
 
6.2.5.2 HIV shedding and impact of STI treatment 
At the Esselen Street clinic, a further sub-group of women who requested voluntary HIV 
testing for various reasons was included for HIV shedding studies. In collaboration with the 
Outreach Program of the Greater Johannesburg Metropolitan Council and the Reproductive 
Health Research Unit, female sex workers voluntarily requesting HIV testing were also 
included in the studies. All participants were given an explanation of the study and written 
informed consent was obtained. Thereafter, pre-test and post-test counselling for HIV was 
conducted by trained counsellers.  
 
Interviews were conducted to obtain information on demography, sexual practices and STD 
symptoms. A thorough clinical and gynaecological examination was conducted, including 
speculum examination. Vaginal and cervical specimens, including cervico-vaginal lavage 
specimens, were collected as previously described. Through the vaginal speculum, 10 ml of 
sterile normal saline was slowly and gently applied to the cervix using a syringe. After 
approximately 2 to 3 minutes, all fluid pooled in the posterior fornix was collected using a 10 
ml sterile disposable pipette and placed in a sterile plastic tube. All specimens were stored at 
-70ºC until processed to measure HIV RNA copies using a standard protocol as described in 
Section 2. All participants with STD signs and symptoms were treated immediately using the 
appropriate syndromic STD management protocols. 
 
Two endocervical specimens (using sterile cotton-tipped swabs) and a first-catch urine 
specimen were collected to detect C. trachomatis and N. gonorrhoeae by culture and LCR 
testing (See Section 2.3.3). Finally, a specimen was collected from the squamo-columnar 
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junction of the cervix and a Papanicolaou smear prepared. Plasma specimens were also 
collected but tested for HIV viral load measurement only if the patient was found to be HIV-
seropositive. 
 
Blood was collected and tested for syphilis serology (RPR and FTA-ABS), HIV antibody status 
and chlamydial and herpes serology.  The rapid HIV test was used to screen patients and all 
positive specimens were confirmed by two different ELISA tests. The SAIMR and South 
African National HIV testing protocol was followed for all specimens. CD4 counts and HIV 
plasma viral loads were determined for all HIV-seropositive women. 
 
Appointments were made for a follow-up visit after 7 days. All participants were given their 
HIV results and post-test counselling at the follow-up visit. The significance of CD4 results 
was explained to all HIV-seropositive women and they were referred to the Hillbrow Hospital 
HIV clinic for further management. A further general and gynaecological examination was 
conducted at the follow-up visit. At this visit, the vaginal, cervical and blood specimens were 
repeated from HIV-seropositive women as were all other laboratory investigations, except for 
syphilis serology, HPV and Papanicoloau smear testing. 
 
6.2.6. Data entry and analysis 
Each subject was given a unique study number which was recorded on all interview and 
examination sheets and on all specimens. The name, address and clinic number of each 
participant was recorded next to the study number in a separate register that was used for the 
follow-up of subjects. This register also included laboratory results. The register was kept in a 
confidential file at the Reference Centre for STI (RCSTI). 
 
All demographic, sexual behavioural and clinical information together with laboratory results 
were entered in the customized SPPS® (SPSS Inc., Chicago, IL.) database and stored at the 
RCSTI. Patient identifiers were removed permanently after results were provided to the 
patients at their follow-up visit. Descriptive statistics of pre-coded demographic and clinical 
variables were analysed and presented. The prevalence of vaginal and cervical infections and 
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positive syphilis serology was calculated and the associations between HIV and other 
reproductive tract infections explored.  
 
6.2.7. Ethical considerations 
The protocol was reviewed and approved by the Ethics Committee of the University of 
Witwatersrand, and by a joint RCSTI-Gauteng Transitional Metropolitan Council panel.  
 
Informed written consent was obtained from all subjects (Annexure 6.2 and 6.3). Subjects 
who refused to participate were assured that they would not be penalized in any way and 
would have a right to be examined and treated in the same way as study participants. Any 
abnormalities detected during examination were addressed or referred to the appropriate 
service. All participants were invited to return for the results of their tests on a certain date 
where results were explained and acted upon if necessary. While waiting to be examined, a 
health education session, including demonstration of condom use, was conducted for all STI 
patients. 
 
6.2.8 Data Collection Instruments  
6.2.8.1 Study questionnaires  (Annexure 6.1) 
6.2.8.2 Patient information sheet (Annexure 6.2) 
6.2.8.3 Informed consent (Annexure 6.3) 
6.2.8.4 Treatment algorithm for vaginal discharge  (Annexure 6.4) 
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Annexure 6.1 Study questionnaires 
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 Annexure 6.2 Patients information sheet 
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 Annexure 6.3 Informed consent  
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 Annexure 6.4 Treatment algorithm for vaginal discharge 
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6.3 Results  
6.3.1 Interactions between HIV and STIs in women 
6.3.1.1 Demographic and socioeconomic status of patients 
A total of 274 women presenting with vaginal discharge during the period May 1996 – 
December 1996 were enrolled in the study. The overall HIV seroprevalence among those 
enrolled was 48.2% (95% CI – 42.3% - 54.1%). Of these, 257 patients agreed to provide 
details on demographic and sexual behaviour-related issues relevant to the study. The 
associations between these parameters and HIV infection are presented here. 
 
The mean age of 257 patients from whom information was available, was 24 years (range – 
15 – 59 years). More than 80% of patients were under 30 years of age and 39 of 257 (15.2%) 
were in the 15 – 19-year age group (Figure 6.3). 
 
 
Figure 6.3 Age distribution of women presenting with STI symptoms, 
Johannesburg (May 1996 - December 1996) (N= 257) 
 
The majority (70%) of patients resided in Hillbrow and surrounding areas while the remaining 
patients came from different residential areas (townships) outside Johannesburg.  Two 
hundred and twenty-eight patients (89.1%) were never married but 96.1% had current sexual 
partner(s).  The median duration of a sexual relationship with a current partner was 24 
months (range: 1 – 180 months). Of 254 patients with current sexual partners, 42.9% were 
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living with their partners for a median duration of 21 months (range: 1 – 468 months).  
Although only 3% of patients were educated to a post-matriculation level (completed high 
school), the majority had at least a primary or secondary school education with a median 
years-of-schooling duration of 8 years schooling. Of 159 patients who acknowledged that they 
required external financial support, 93 (58.5%) received support from family members (i.e. 
parents, husband, sisters etc.) and 41.5% from boyfriends.  
 
The association between socioeconomic and demographic determinants and HIV serostatus 
is shown in Table 6.1. HIV seropositivity was significantly associated with a short duration of 
partnership with the current sexual partner – less than 12 months (Odds ratio 2.2; 95% CI 1.3 
– 3.7, p 0.005); being an unemployed or a school leaver at secondary school level (Odds ratio 
2.7, 95% CI 1.2 – 6.1, p 0.02) and economically dependent on a boyfriend (Odds ratio 2.8, 
95% CI 1.4 – 5.3, p 0.002) (Table 6.1). 
 
6.3.1.2 Sexual behaviour and reproductive health 
Overall, the median age at first sexual intercourse was 17 years (range: 13 – 24 years), and 
the median number of life-time sexual partners was 3 (range: 1 – 35).  Women who reportedly 
had only one sexual partner during their life-time had a significantly lower prevalence of HIV 
than those with more than one partner (33.3% vs. 52.1%, Odds ratio 2.2, 95% CI 1.0 – 4.6, p 
0.04). The HIV seroprevalence was significantly higher among women who had their sexual 
debut at less than 15 years of age compared with those whose sexual debut occurred when 
they were older (81% vs. 45.7%, Odds ratio 5.1; 95% CI 1.6 – 15.5, p 0.005). Twenty percent 
of patients had more than five life-time sexual partners. However, the mean number of sexual 
partners during the past six months was 1.4 (range – 0 - 17) with 23% of patients having more 
than one sexual partner during the past six months. Contraceptive usage was also low with 
only 47.5% of patients ever having used any form of contraception. Pills (14.4%) and 
injectables (25.7%) were the most frequently used methods of contraception among patients. 
Condom use was very low with only 40.9% ever having used a condom in the past six 
months. A high proportion, (45.1%) of women noticed that their current sexual partner had 
STI-associated signs such as “drop”, sores or genital swellings during their current 
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relationship (Table 6.1). Multivariate analysis indicated that only recent sexual partnerships 
(i.e. those <12 months duration) and economic dependency on a boyfriend were 
independently associated with a high risk of HIV-seropositivity (Adjusted Odds ratio for recent 
sexual partnership 3.7; 95% CI 1.7 – 7.9, p 0.001, and for economic dependency on 
boyfriends – 2.6; 95% CI 1.2 – 5.7, p 0.013). 
 
Table 6.1 Association between demographic, sexual and reproductive determinants  
and HIV infection in women with STIs 
 
Variable    n (%) HIV (%) OR 95% CI P
Demographic characterisitcs
Age n = 257
15 - 19 39 (15.2) 53.8 1
20 - 24 104 (40.1) 52.4 0.9 0.5 - 2.0
25 - 29 79 (30.7) 45.6 0.7 0.3 - 1.5
30 & Above 36 (14.0) 38.9 0.5 0.2 - 1.4
Martial status n = 256
Married 28 (10.9) 32.1 1
Never married 228 (89.1) 50.4 2.1 0.9 - 4.9
Current sexual partner present n = 256
No 10 (3.9) 40.0 1
Yes 246 (96.1) 48.8 1.4 0.4 - 5.2
Duration of sexual partnership n = 246
?12 months 161 (65.4) 42.2 1
<12 months 85 (34.6) 61.2 2.2 1.3 - 3.7 0.005
Highest education level n = 254
Secondary & above 176 (69.3) 48.3 1
Primary 78 (30.7) 48.7 1.0 0.6 - 1.7
Occupation n = 256
Student 42 (16.4) 33.3 1
Unemployed/School leavers 53 (21.9) 57.1 2.7 1.2 - 6.1 0.02
Domestic or similar jobs 65 (25.4) 49.2 1.9 0.9 - 4.3
Other employment 93 (36.3) 49.5 2.0 0.9 - 4.2
Main economic support n = 159
Family (Parents/Husband etc.) 93 (58.5) 34.4 1
Boyfriend 66 (41.5) 59.1 2.8 1.4 - 5.3 0.002
Sexual & Reproductive History
Age at first sex n = 256
15 & Above 232 (91.7) 45.7
Under 15 21 (8.3) 81.0 5.1 1.6 - 15.5 0.005
Current contraceptive use n = 257
None 135 (52.5) 46.7 1
Non-hormonal devices 19 (7.4) 31.6 0.5 0.2 - 1.5
Hormonal (pills/injectable) 103 (40.1) 48.2 1.3 0.8 - 2.2
Number of life-time sexual partners n = 251
One 36 (14.3) 33.3 1
More than one 215 (85.7) 52.1 2.2 1.0 - 4.6 0.04
Number of sexual partners in past 6 months n=255
One 196 (76.9) 46.4 1
More than one 59 (23.1) 55.9 1.5 0.8 - 2.6
Condom use in past six-months n = 254
No 150 (59.1) 45.3
Yes 104 (40.9) 52.9 1.4 0.8 - 2.2
STI symptoms in current sexual partner n = 255
No 140 (54.9) 43.6
Yes 115 (45.1) 54.8 1.6 1.0 - 2.6
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6.3.1.3 Clinical presentation and HIV infection 
The majority of patients (68.6%) reported a past history of STI symptoms. Over one third of 
patients with STI symptoms had more than one episode of vaginal discharge during the past 
six months while 18.9% had genital sores, 2.9% genital warts, 29.1% burning on urination, 
and 33.3% lower abdominal pain. No significant association between the presence of past 
history of STI symptoms and HIV infection was found (Table 6.2). 
 
A summary of presenting STI signs and symptoms is shown in Figure 6.4.  
On examination, genital ulcerations were found in 27 cases (10.5%). The HIV seroprevalence 
rate among these women were significantly higher than those without genital ulcerations 
(74.1% vs. 45.0%, Odds ratio 3.5; 95% CI 1.4 – 8.6, p 0.006). Majority (98.9%) of patients 
examined in this series were found to have an abnormal vaginal discharge. 
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Figure 6.4 Presenting STI signs and symptoms  
 
 
A significant association between HIV seropositivity and “profuse” vaginal discharge was 
found (55.0% vs. 42.1%, Odds ratio 1.7; 95% CI 1.03 – 2.8, p 0.04). Abnormal cervical 
lesions were frequently observed and cervical mucopus was detected in 43.5%, and cervical 
ectopy or erosion in 51.8%. Cervical excitation tenderness was elicited in 17% of patients, 
indicating a mild to moderate degree of PID. Although no significant association between HIV 
seropositivity and the presence of the aforementioned clinical signs was found, HIV 
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seroprevalence among those with any type of cervical lesions (i.e. erosions/warts/ulcerations) 
was significantly higher than those without cervical lesions (60.4% vs. 40.3%, Odds ratio 2.3; 
95% CI 1.36 – 3.8, p 0.002) (Table 6.2). 
 
Multivariate analysis showed that there was a significant association between HIV-
seropositive status and the presence of genital sores on examination (Adjusted odds ratio 3.3; 
95% CI 1.2 – 3.5, p 0.017) and any abnormal cervical lesions (Adjusted odds ratio 2.0; 95% 
CI 1.2 – 3.5, p 0.008). 
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Table 6.2 Association between STI symptoms and signs and HIV infection  
 
Variable    n (%) HIV (%) OR 95% CI P
STI Symptoms
Past history of STI symptoms n = 255
No 80 (31.4) 46.3
Yes 175 (68.6) 49.7 1.1 0.7 - 2.0
Past history of vaginal discharge n = 175
Never 32 (18.3) 56.3
Once 74 (42.3) 47.3 0.7 0.3 - 1.6
More than once 69 (39.4) 49.7 0.8 0.3 - 1.8
Past history of genital sores n = 175
Never 97 (55.4) 46.4
Once 45 (25.7) 55.6 1.4 0.7 - 2.9
More than once 33 (18.9) 51.5 1.2 0.6 - 2.7
Past history of genital warts n = 175
Never 163 (93.1) 48.5
Once 7 (4.0) 57.1 1.4 0.3 - 6.5
More than once 5 (2.9) 80.0 4.3 0.5 - 38.9
Past history of burning micturation n = 175
Never 74 (42.3) 48.6
Once 50 (28.6) 50.0 1.1 0.5 - 2.2
More than once 51 (29.1) 51.0 1.1 0.5 - 2.2
Past history of lower abdominal pain n = 174
Never 58 (33.3) 55.2
Once 58 (33.3) 50.0 0.8 0.4 - 1.7
More than once 58 (33.3) 43.1 0.6 0.3 - 1.3
Clinical Signs (on examination)
Genital ulcerations n = 258
No 231 (89.5) 45.0
Yes 27 (10.5) 74.1 3.5 1.4 - 8.6 0.006
Profuse vaginal discharge n = 255
No 126 (49.4) 42.1
Yes 129 (50.6) 55.0 1.7 1.03 - 2.8 0.039
"Curd-like" vaginal discharge n = 255
No 199 (78.0) 51.3
Yes 56 (22.0) 39.3 0.6 0.34 - 1.1
Cervical mucopus n = 255
No 144 (56.5) 47.2
Yes 111 (43.5) 50.5 1.1 0.69 - 1.9
Cervical ectopy/erosion n = 255
No 123 (48.2) 46.3
Yes 132 (51.8) 50.8 1.2 0.73 - 2.0
Cervical excitation tenderness n = 247
No 205 (83.0) 48.3
Yes 42 (17.0) 52.4 1.2 0.61 - 2.3
Any cervical lesions (Erosion/Warts/Ulcers) n = 255
No 149 (58.4) 40.3
Yes 106 (41.6) 60.4 2.3 1.36 - 3.8 0.002  
 
 
 
6.3.1.4 Interactions between vaginal infections and HIV 
Of 274 patients complaining of vaginal discharge and other related symptoms, 223 (81.4%) 
had at least one identifiable cause of their discharge (i.e. bacterial vaginosis, candidiasis or 
trichomoniasis). The majority of patients (50.5%) had a single aetiology of their discharge 
while 25.8% had two and 5.3% had three identifiable aetiologies that could have accounted 
for the vaginal discharge. Among patients with a single vaginal infection, 58 had bacterial 
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vaginosis (42.6%), 50 had candidiasis (36.8%) and 28 had trichomoniasis (20.6%).  Mixed 
infections of all three main aetiological conditions were common. The rate of HIV infection 
was also significantly higher in patients suffering from multiple vaginal infections (any two 
aetiologies) compared with those without vaginal infections (26.3% vs. 18.6%, Odds ratio 2.4; 
95% CI 1.2 – 5.1, p 0.02). 
 
More detailed descriptions of each cause of vaginal discharge and its association with HIV 
are also discussed in the specific section on each disease.  
 
 
6.3.1.4.1 Bacterial vaginosis and HIV 
Clue cells with typical morphology indicative of bacterial vaginosis were present in 133 of 274 
(48.5%) patients. All except one patient had vaginal pH readings of >4.5, and 75.2% of clue 
cell-positive patients were also amine test positive. No significant association between the 
presence of BV and any of the following: age, age at sexual debut, numbers sexual partners 
in past six months and condom use was detected. A significantly lower risk of BV was, 
however, found to be associated with a history of hormonal contraceptive use (i.e. either oral 
or injectable contraceptives) (40.8% vs. 54.8%, Odds ratio – 0.57, 95% CI 0.34 – 0.95, p 
0.03). All patients with BV were confirmed as having an abnormal vaginal discharge on 
examination but no significant association was found between BV and early signs of pelvic 
inflammatory disease (PID) as diagnosed by the presence of cervical excitation tenderness. 
Although patients with BV had a higher HIV prevalence rate than HIV-seronegative patients, 
this was not statistically significant (52.6% vs 44.0%, χ2 = 2.1, p 0.15).  
 
6.3.1.4.2 Vaginal candidiasis and HIV 
One hundred and thirteen patients (41.2%) were found to be positive by culture for Candida 
species. Unlike BV, there was no association between hormonal contraceptive use and the 
detection of yeasts using the culture (46.6% in users vs. 39.3% among non-users, p 0.2). A 
significant proportion of patients with vaginal candidiasis presented with vaginal itchiness 
(49.6% vs. 31.9%, χ2 = 8.2, p 0.004). A significantly higher proportion of patients with a 
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typical clinical presentation of vaginal candidiasis (i.e. curd-like vaginal discharge) were 
positive for yeasts on culture (66.1% vs. 34.7%, χ2 = 17.7, p<0.0001).  
 
There was an association between HIV and vaginal candidiasis. Of 113 patients with a 
positive culture for yeasts, 66 (58.4%) were HIV-seropositive compared to 66 (41%) of 
patients without candidiasis The HIV prevalence among patients with vaginal candidiasis was 
significantly higher than those without candidiasis (58.4% vs. 41.0%, Odds ratio 2.0; 95% CI 
1.2 – 3.3., p 0.005) (Table 6.3). Alternatively, a significantly higher proportion of HIV-
seropositive patients presented with vaginal candidiasis compared to HIV-seronegative 
patients (50% vs. 33%, Odds Ratio 2.02, 95% CI – 1.24 – 3.29, p 0.005).  
 
6.3.1.4.3 Trichomoniasis and HIV 
A total of 78 patients (28.6%) were confirmed positive for T. vaginalis (TV) on direct 
microscopic examination and/or culture. No association between demographic data, 
contraceptive use and sexual behavioural determinants and trichomoniasis was found. An 
abnormal vaginal discharge was observed in all patients with TV and a significantly higher 
proportion had a profuse vaginal discharge (42.2% in TV-positive vs. 14.3% in TV-negative, 
Odds ratio 4.4, 95% CI 2.4 – 8.1, p<0.0001).  
 
A similar HIV prevalence rate was detected among TV-positive and TV-negative patients 
(46.2% vs. 49.2, χ2 = 0.2, p 0.6). 
 
6.3.1.5 Cervical Infections and HIV 
Of those interviewed, 156 (61.4%) complained of lower abdominal pain; however, only 42 
(17%) were confirmed by the clinician to have cervical excitation tenderness on bi-manual 
gynaecological examination. During speculum examination, the following abnormalities were 
found: 111 patients (43.5%) exhibited cervical discharge; 132 (51.8%) cervical erosions and 
16 (5.5%) had cervical warts. Up to 41.6% of patients had at least one or more abnormal 
cervical lesions such as cervical erosions, ulcerations, or warts, and these lesions were 
significantly associated with HIV infection. HIV prevalence was 60.4% in those with positive 
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cervical abnormalities compared to 40.3% among those without abnormalities (Odds ratio 2.3; 
95% CI 1.36 – 3.8, p 0.002). 
 
Overall, gonococcal and/or chlamydial cervical infections were detected in 119 (43.4%) of 
patients. Sixty-one patients (22.3%) were positive for N. gonorrhoeae alone, 33 for C. 
trachomatis alone (12.0%), and 25 for both (9.1%).  
 
6.3.1.5.1 Gonococcal infection in women 
The prevalence of gonococcal cervicitis (GC) among STI patients was 31.4%. There was no 
difference in mean age between GC-positive and GC-negative patients (Mean age 24 ± SD 6 
years in GC-positive group vs. 24.7 ± SD 5.4 years in GC-negative group, t-test, p 0.56). 
Although the difference was not statistically significant, the age-specific prevalence rates were 
higher among younger women with the highest rate of 36.9% found in among those in the 20-
24 year age group. The prevalence was also high in the 15 – 19 year age group with 33.3% 
being GC-positive. No significant association between positive GC status and other 
socioeconomic and demographic determinants was detected. 
 
During clinical history taking, 115 patients (45.1%) reported that their current sexual partner 
was suffering from STI symptoms such as discharge, sores, warts or genital swelling. There 
was no association between the presence of any STI symptoms among sexual partners and 
GC-positive status (36.5% in patients positive history vs. 30.0% in patients with no history, χ2 
= 1.2, p 0.27). However, the GC-positivity rate was significantly higher among those who 
reported that their partner was suffering from genital discharge (i.e. ‘drop’) compared to those 
without such a history (45.6% vs. 23.9%, Odds Ratio 2.7, 95% CI – 1.2 – 6.1, p 0.02). 
 
During clinical examination, the physical appearance of the cervix was recorded in 255 cases. 
It was found that 111 (43.5%) patients had a cervical discharge and 132 (51.8%) had cervical 
erosion. The presence of abnormal cervical discharge was significantly associated with 
gonococcal infection (46.8% vs. 22.2%, Odds Ratio 3.1, 95% CI – 1.8 – 5.3, p<0.0001). 
Similarly, 38.6% patients with cervical erosions were GC-positive compared to 26.8% among 
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patients with no cervical erosions (Odds Ratio 1.7, 95% CI – 1.0 – 2.9, p 0.045).  
 
During bi-manual examination, the cervical excitation test (CET) was conducted in 247 
patients. Of these, 42 patients (17.0%) had a positive CET which was significantly associated 
with gonococcal infection (50.0% vs. 30.2%, Odds Ratio – 2.3, 95% CI – 1.8 – 4.5, p 0.014).  
 
Multivariate analysis showed that the presence of cervical mucopus was the only symptom 
independently associated with gonococcal cervicitis (Table 6.3).  
 
 
Table 6.3 Multivariate analysis on potential predictors of cervical GC infection 
 
Criteria Adjusted OR 95% CI P
Sexual partner with urethritis ('drop') 2.3 1.0 5.6 0.06
Cervical mucopus 3.7 1.5 9.3 0.006
Cervical ectopy/erosion 1.0 0.4 2.5 0.99
CET-positive 1.5 0.5 4.6 0.48
 
 
There was no association between the presence of specific vaginal infections or the number 
of mixed infections and the gonorrhoea status of the patients (Table 6.4). 
 
Table 6.4 Association between vaginal and gonococcal cervicitis 
Gonococcal Infection Number of Vaginal Infections 
Detected Positive Negative 
Total 
13 38  51 
No Vaginal Infection 
25.5% 74.5%  
44 92 136 
One Vaginal Infection 
32.4% 67.6%  
26 46 73 
Two Vaginal Infections 
36.1% 63.9%  
3 12 15 
Three Vaginal Infections 
20.0% 80.0%  
86 188 274 
Total 
31.4% 68.6%  
χ2 = 2.5, p 0.47  
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The HIV seroprevalence among patients with gonococcal infections was higher (52.3%) than 
those without gonococcal infection (46.3%). However, this difference was not found to be 
statistically significant. (χ2 = 0.87, p 0.35) 
 
6.3.1.5.2. Chlamydial infection in women   
Of 274 patients, 58 (21.2%) were positive for C.trachomatis (CT), and 33 (12.0%) had a 
single infection with CT. The mean age of CT-positive patients was 23.4 years (SD ± 3.8 
years) and there was no significant difference when compared to that of CT-negative patients. 
(23.4 years vs. 24.9 years, p 0.08) The highest prevalence rate was found in the 20-24 age 
group (30.1%) and the prevalence among teenagers (i.e. 15-19 age group) was 17.9%. 
No significant association was found between CT-positive status and other socioeconomic 
and demographic characteristics. Unlike gonococcal infection, there was no significant 
difference in CT prevalence between women who reportedly observed STI symptom(s) in 
their partners and those did not. The rate of chlamydial infection was similar among women 
who reported that their partner had a urethral discharge and those did not notice urethral 
discharge among their partners. (27.9% vs. 21.7%, χ2 = 0.55, p 0.46)  
 
Although the rate of CT infection was higher among patients with cervical discharge 
compared to those without cervical discharge, this difference was not statistically significant 
(27.9% vs.18.8%, χ2 = 3.0, p 0.08). Similarly, neither cervical erosion (25.8% vs 19.5%, χ2 = 
1.4, p 0.24) nor a positive CET test (21.4% vs. 23.4%, χ2 = 0.77, p 0.78) showed a significant 
association with chlamydial infection. HIV prevalence was virtually identical among those with 
and without CT infection (48.3% vs, 48.1%, p NS) (Table 6.5). 
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Table 6.5 Association between vaginal infection and chlamydial cervicitis 
 
Chlamydial Cervical Infection Number of Vaginal Infections 
Detected Positive Negative 
Total 
No Vaginal Infection 11 40 52 
 21.6% 78.4%  
One Vaginal Infection 27 109 136 
 19.9% 80.1%  
Two Vaginal Infections 17 55 72 
 23.6% 76.4%  
Three Vaginal Infections 3 12 15 
 20.0% 80.0%  
Total 58 216 274 
χ2 = 0.41, p 0.94 (NS) 
 
6.3.1.6 HPV and HIV in women 
6.3.1.6.1 Results of HPV PCR (MY 9/11) 
Of 274 patients enrolled in the study, the overall prevalence of HPV detected by HPV PCR 
using a consensus primers (MY9/11) was 73%. No significant difference in the mean age of 
HPV PCR-positive when compared to PCR-negative women was found (24.4 years vs. 24.8 
years, t-test p=0.68). No significant differences in socioeconomic, demographic and selected 
sexual behavioural determinants between HPV PCR-positive and negative patients were 
found (Table 6.6). However, patients who reported that their partners had current symptoms 
of STIs had significantly higher rate of HPV infection diagnosed by PCR (MY 9/11) (80% vs. 
65%, Odds Ratio 2.2; 95% CI = 1.2 – 3.8, p 0.008).  
 
A lower HPV prevalence was observed among HIV-seronegative patients in all age groups 
compared with their HIV-seropositive counterparts. The HPV prevalence rates were 
significantly higher among the HIV-seropositive women in the 20 – 24 and 25 – 29 groups 
than their HIV-seronegative counterparts (85.2% vs. 65.3%, Odds ratio 3.1; 95% CI 1.2 – 7.9 
and 77.8% vs. 55.8%; 95% CI 2.8; 95% CI 1.03 – 7.5) respectively. However, no significant 
differences were found in the 15 – 19 and 30 years and above age groups (Figure 6.5). 
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Table 6.6 Association between demographic and behavioural risk factors and HPV (MY 
9/11) 
 
Variable    n (%) HPV (%) OR 95% CI P
Demographic characterisitcs
Age n = 257
15 - 19 39 (15.2) 71.8 1
20 - 24 103 (40.1) 75.7 1.2 0.5 - 2.8
25 - 29 79 (30.7) 65.8 0.8 0.3 - 1.7
30 & Above 36 (14.0) 75.0 1.2 0.4 - 3.3
Martial status n = 256
Married 28 (10.9) 67.9 1
Never married 228 (89.1) 72.4 1.2 0.5 - 2.9
Current sexual partner present n = 256
Yes 246 (96.1) 71.5 1
No 10 (3.9) 80.0 1.6 0.3 - 7.7
Duration of sexual partnership n = 246
?12 months 161 (65.4) 66.5 1
<12 months 85 (34.6) 81.2 2.2 1.2 - 4.1 0.015
Highest education level n = 254
Secondary & above 176 (69.3) 72.2 1
Primary 78 (30.7) 71.8 1.0 0.5 - 1.8
Occupation n = 256
Student 42 (16.4) 71.4 1
Unemployed/School leavers 53 (21.9) 75.0 1.2 0.5 - 3.0
Domestic or similar jobs 65 (25.4) 76.9 1.3 0.6 - 3.2
Other employments 93 (36.3) 66.7 0.8 0.4 - 1.8
Main economic support n = 159
Family (Parents/Husband etc.) 93 (58.5) 73.1 1
Boyfriend 66 (41.5) 74.2 1.1 0.5 - 2.2
Sexual & Reproductive History
Age at sex n = 253
15 & Above 232 (91.7) 71.6 1
Under 15 21 (8.3) 71.4 1.0 0.4 - 2.7
Current contraceptive use n = 257
None 135 (52.5) 73.3 1
Non-hormonal devices 19 (7.4) 57.9 0.5 0.2 - 1.3
Hormonal (pills/injectable) 103 (40.1) 72.8 1.0 0.5 - 1.7
Number of life-time sexual partners n = 251
One 36 (14.3) 63.9 1
More than one 215 (85.7) 73.0 1.5 0.7 - 3.2
Number of sexual partners in past 6 months n=255
One 196 (76.9) 70.9 1
More than one 59 (23.1) 74,6 1.2 0.6 - 2.3
Condom use in past six-months n = 254
No 150 (59.1) 67.3 1
Yes 104 (40.9) 77.9 1.7 0.96 - 3.0
STI symptoms in current sexual partner n = 255
No 140 (54.9) 65.0 1
Yes 115 (45.1) 80.0 2.2 1.21 - 3.8 0.01  
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Figure 6.5 Age-specific prevalence of HPV by HIV status using PCR  
(MY9/11) 
 
 
6.3.1.6.2 High & low-risk types detected by Hybrid Capture Tube (HCT) method 
 
When using the hybrid capture technique to detect and type HPV infection, a total of 84 
patients (30.7%) were positive for low- and/or high-risk HPV types.  Of these, 17 patients 
(6.2%) were positive for both low- and high-risk HPV types. The overall prevalence of low-risk 
HPV types was 8.8% (95% CI; 5.6 – 12.8%) and that of high-risk HPV was 28.1% (95% CI; 
22.9 – 33.8%) The highest prevalence of HPV (low- and high-risk types) was found in the 15 
– 19 years age group (43.6%), followed by the 20-24 years age group (32.0%), the 25-29 
years age group (24.1%) and the 30 years and above group (25.0%). The difference in age-
specific prevalence was however not statistically significant (Figure 6.6). 
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Figure 6.6 Age-specific prevalence rate of HPV (Low- &/or High-risk types) 
 
Overall, the prevalence of low- and/or high-risk HPV was significantly higher among HIV- 
seropositive women than among HIV-seronegative women (40.2% vs 21.8%, Odds Ratio 2.4, 
95% CI -1.4 – 4.1, p 0.001). In HIV-seropositive women, the highest prevalence of HPV 
infection was also found in the 15-19 age group (52.4%). The prevalence rates among older 
age groups were slightly lower, except for the 30 and above age group. In contrast, the age-
specific HPV prevalence rate among HIV-seronegative women steeply declined in the older 
age groups. In these women, the highest prevalence (33.3%) was found in the 15-19 age 
group while the lowest prevalence (9.1%) was found in the 30 & above age group. However, 
these differences were not found to be statistically significant (Table 6.7 & Figure 6.7). 
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Table 6.7 Trend in Age-specific prevalence of low- and/or high-risk HPV infections in  
HIV-seropositive and HIV-seronegative patients 
 
HIV Status n Prevalence of HPV (%) (High- & Low-risk types) Odds Ratio 95% CI P
HIV-negative 132
15 - 19 18 33.3 1
20 - 24 49 24.5 0.6 0.2 2.1
25 - 29 43 16.3 0.4 0.1 1.4 NS
30 & Above 22 9.1 0.2 0.03 1.2
HIV-positive
15 - 19 21 52.4 1
20 - 24 54 38.9 0.6 0.2 1.6
25 - 29 36 33.3 0.5 0.2 1.4 NS
30 & Above 14 50.0 0.9 0.2 3.5  
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Figure 6.7 Trend in age-specific prevalence of low- and/or high-risk HPV  
infections in HIV-seropositive and HIV-seronegative patients 
 
 
The demographic and socioeconomic risk factors for the low-risk HPV types are shown in 
Table 6. 8. 
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Table 6.8 Association between demographic and behavioural risk factors  
and HPV (low-risk types) infection 
 
Variable    n (%) HPV (%) OR 95% CI P
Demographic characterisitcs
Age n = 257
15 - 19 39 (15.2) 17.9 1
20 - 24 103 (40.1) 7.8 0.4 0.1 - 1.1
25 - 29 79 (30.7) 7.6 0.4 0.1 - 1.2
30 & Above 36 (14.0) 5.6 0.3 0.1 - 1.4
Martial status n = 256
Married 28 (10.9) 14.3 1
Never married 228 (89.1) 8.3 0.5 0.2 - 1.7
Current sexual partner present n = 256
Yes 246 (96.1) 8.5 1
No 10 (3.9) 20.0 2.7 0.5 - 13.4
Duration of sexual partnership n = 246
?12 months 161 (65.4) 5.6 1
<12 months 85 (34.6) 14.1 2.8 1.1 - 6.9 0.28
Highest education level n = 254
Secondary & above 176 (69.3) 10.8 1
Primary 78 (30.7) 5.1 0.4 0.1 - 1.4
Occupation n = 256
Student 42 (16.4) 11.9 1
Unemployed/School leavers 53 (21.9) 12.5 1.1 0.3 - 3.6
Domestic or similar jobs 65 (25.4) 6.2 0.5 0.1 - 1.9
Other employments 93 (36.3) 7.5 0.6 0.2 - 2.0
Main economic support n = 159
Family (Parents/Husband etc.) 93 (58.5) 10.8 1
Boyfriend 66 (41.5) 9.1 0.8 0.3 - 2.4
Sexual & Reproductive History
Age at sex n = 253
15 & Above 232 (91.7) 8.6 1
Under 15 21 (8.3) 9.5 1.1 0.2 - 5.1
Current contraceptive use n = 257
None 135 (52.5) 9.6 1
Non-hormonal devices 19 (7.4) 15.8 1.8 0.5 - 6.9
Hormonal (pills/injectable) 103 (40.1) 6.8 0.7 0.3 - 1.8
Number of life-time sexual partners n = 251
One 36 (14.3) 11.1 1
More than one 215 (85.7) 8.8 0.8 0.2 - 2.4
Number of sexual partners in past 6 months n=255
One 196 (76.9) 9.7 1
More than one 59 (23.1) 6.8 0.7 0.2 - 2.1
Condom use in past six-months n = 254
No 150 (59.1) 10.0 1
Yes 104 (40.9) 7.7 0.8 0.3 - 1.8
STI symptoms in current sexual partner n = 255
No 140 (54.9) 6.4 1
Yes 115 (45.1) 12.2 2.0 0.8 - 4.8  
 
Although the prevalence of low-risk HPV infection was significantly lower than that of high-risk 
HPV infection, there was a stronger association between the low-risk HPV and HIV infection 
compared to the high-risk HPV-HIV association. The prevalence of low-risk HPV infection in 
HIV-seropositive patients was 15.2% compared to only 2.8% in HIV-seronegative patients 
(Odds Ratio 6.2; 95% CI – 2.1 – 18.5, p 0.001). The highest prevalence was found in the 
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younger age groups in both HIV-seropositive and HIV-seronegative groups (Table 6.9 and 
Figure 6.8). 
 
Table 6.9 Trends in age-specific prevalence of low-risk HPV infections in HIV-
seropositive and HIV-seronegative patients 
 
HIV Status n Prevalence of HPV (%) (Low-risk types) Odds Ratio 95% CI P
HIV-negative 132
15 - 19 18 5.6 1
20 - 24 49 2.0 0.4 0.02 6.0
25 - 29 43 2.3 0.4 0.02 6.8 NS
30 & Above 22 0.0 -
HIV-positive 125
15 - 19 21 28.6 1
20 - 24 54 13.0 0.4 0.11 1.3
25 - 29 36 13.9 0.4 0.11 1.5 NS
30 & Above 14 14.3 0.4 0.07 2.4  
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Figure  6.8 Age-specific prevalence rates of HPV (low-risk types) by  
HIV sero-status 
 
For high-risk HPV infections, the prevalence in HIV-seropositive patients was 36.4% 
compared to 20.4% in HIV-seronegative patients (Odds Ratio 2.2, 95% CI – 1.3 - 3.8, p 
0.003). Similar age-specific prevalence trends were found among patients with high-risk HPV 
types and low-risk HPV types (Table 6.10 and Figure 6.9).  
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 Table 6.10 Trends in age-specific prevalence of high-risk HPV infections in HIV-
seropositive and HIV-seronegative patients 
 
HIV Status n Prevalence of HPV (%) (High-risk types) Odds Ratio 95% CI P
HIV-negative 132
15 - 19 18 27.8 1
20 - 24 49 22.4 0.8 0.22 2.6
25 - 29 43 16.3 0.5 0.14 1.9 NS
30 & Above 22 9.1 0.3 0.04 1.5
HIV-positive 125
15 - 19 21 42.9 1
20 - 24 54 35.2 0.7 0.26 2.0
25 - 29 36 30.6 0.6 0.19 1.8 NS
30 & Above 14 50.0 1.3 0.34 5.2  
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Figure 6.9 Age-specific prevalence rate of HPV (high-risk types) by HIV sero-status 
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The demographic and socioeconomic risk factors for high-risk HPV types are shown in Table 
6.11.  
 
Table 6.11 Association between demographic and behavioural risk factors  
and HPV (high-risk types) 
 
Variable    n (%) HPV (%) OR 95% CI P
Demographic characterisitcs
Age n = 257
15 - 19 39 (15.2) 35.9 1
20 - 24 103 (40.1) 29.1 0.7 0.3 - 1.6
25 - 29 79 (30.7) 22.8 0.5 0.2 - 1.2
30 & Above 36 (14.0) 25.0 0.6 0.2 - 1.6
Martial status n = 256
Married 28 (10.9) 25.0 1
Never married 228 (89.1) 28.1 1.2 0.5 - 2.9
Current sexual partner present n = 256
Yes 246 (96.1) 27.2 1
No 10 (3.9) 40.0 1.8 0.5 - 6.5
Duration of sexual partnership n = 246
?12 months 161 (65.4) 24.8 1
<12 months 85 (34.6) 31.8 1.4 0.8 - 2.5
Highest education level n = 254
Secondary & above 176 (69.3) 27.8 1
Primary 78 (30.7) 26.9 1.0 0.5 - 1.7
Occupation n = 256
Student 42 (16.4) 33.3 1
Unemployed/School leavers 53 (21.9) 25.0 0.7 0.3 - 1.6
Domestic or similar jobs 65 (25.4) 35.4 1.1 0.5 - 2.5
Other employments 93 (36.3) 21.5 0.5 0.2 - 1.2
Main economic support n = 159
Family (Parents/Husband etc.) 93 (58.5) 31.2 1
Boyfriend 66 (41.5) 21.2 0.6 0.3 - 1.2
Sexual & Reproductive History
Age at sex n = 253
15 & Above 232 (91.7) 26.3 1
Under 15 21 (8.3) 33.3 0.7 0.3 - 1.9
Current contraceptive use n = 257
None 135 (52.5) 28.9 1
Non-hormonal devices 19 (7.4) 26.3 0.9 0.3 - 2.6
Hormonal (pills/injectable) 103 (40.1) 26.2 0.9 0.5 - 1.6
Number of life-time sexual partners n = 251
One 36 (14.3) 16.7 1
More than one 215 (85.7) 28.8 2.0 0.8 - 5.1
Number of sexual partners in past 6 months n=255
One 196 (76.9) 27.6 1
More than one 59 (23.1) 27.1 1.0 0.5 - 1.9
Condom use in past six-months n = 254
No 150 (59.1) 28.7 1
Yes 104 (40.9) 26.0 1.1 0.7 - 2.0
STI symptoms in current sexual partner n = 255
No 140 (54.9) 25.0 1
Yes 115 (45.1) 30.4 1.3 0.8 - 2.3  
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6.3.1.6.3 Semi-quantitative measurements of low- & high-risk HPV by HCT assay 
 
Semi-quantitative measurements of HPV viral burden in cervical specimens were assessed 
using the Relative Light Unit (RLU)/Positive Controls (PCs) ratio (i.e. amount of light emission 
expressed as relative light units equalling or exceeding the mean of positive controls 
consisting of 10 pg/ml HPV DNA). 
 
In 26 patients with positive HC-probe A (low-risk types), the median RLU/PCs ratio was 5.13 
(range 1.1 – 154.3).  The median RLU/PCs ratio was lower in HIV-seronegative patients 
compared to HIV-seropositive patients (5.13 vs. 1.68, p NS). The viral burden (RLU/PC ratio) 
decreased with age with a more precipitous decline observed among HIV-seronegative 
patients (Figure 6.10). 
 
 
Figure 6.10 Scatter diagram of age and log RLU/PCs ratio for HPV low-risk types in HIV-
seronegative and HIV-seropositive patients 
 
In 80 patients who were positive for HC-probe B (high-risk types), the median RLU/PCs ratio 
was 5.63 (range 1.02 – 166.1). Forty-eight patients (60%) were co-infected with HIV. The 
median RLU/PCs ratio was significantly higher in HIV-seropositive patients than that of HIV-
seronegative patients (8.96 vs. 3.03, Mann-Whitney U, p 0.018). The viral burden as 
measured by the log RLU/PCs ratio tended to remain high in older HIV-seropositive women 
while a steady decline with age was observed among HIV-seronegative patients (Figure 
6.11). 
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Figure 6.11  Scatter diagram of age and log RLU/PCs ratio for HPV high-risk types in HIV-
seronegative and HIV-seropositive patients 
 
6.3.1.6.4 Pap smear results 
Of 185 patients on whom Pap smear findings were available, 168 (90.8%) were found to have 
normal results. Low grade squamous intraepithelial lesions (LSILs) were found in 13 patients 
(7.0%) and high grade SIL (HSIL) in 4 (2.1%). The prevalence of abnormal Pap smears (i.e. 
LSIL or HSIL) was significantly higher among HIV-seropositive patients than HIV-
seronegative patients (16.7% vs. 3.0%, Odds Ratio 6.5, 95% CI – 1.8 – 23.6, p 0.001). All 
patients with LSIL were under the age of 30 years while all patients with HSIL were in the 30 
and above age group.  
 
A significantly higher proportion of women with low- and/or high-risk HPV infections compared 
with uninfected patients had an abnormal Pap smear (19.0% vs. 4.7%, Odds Ratio 4.7, 95% 
CI 1.7 – 13.5, p 0.002). This association was found to be highest in patients with mixed low- 
and high-risk HPV infection (Odds Ratio 10.1, p 0.002) (Table 6.12). A normal Pap smear was 
however detected in 44 of 56 (78.6%) women with high-risk HPV.  
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Table 6.12 Association between HPV infection and abnormal Pap smears 
HPV Infection
(Low- &/or High-risk) n
Normal
Pap Smear (%)
Abnormal
Pap Smear (%) Odds Ratio 95% CI P
None 127 121 (95.3) 6 (  4.7) 1
Single (Low or High-risk types) 46 39 (84.8) 7 (15.2) 3.6 1.1 11.4 0.03
Mixed (Low & High-risk types) 12 8 (66.7) 4 (33.3) 10.1 2.4 43.1 0.002
 
 
Overall, the presence of abnormal Pap smear was associated with HPV infection and HIV-
seropositivity. In multivariate analysis, a significant association was found between abnormal 
PAP smear status and positive status for high-risk HPV and HIV infection (Table 6.13). 
 
Table 6.13 Multivariate analysis of risk-determinants in patients with abnormal PAP 
smears 
 
Risk Determinants Adjusted 95% CI Sig.
for Abnormal Pap Smears Odds ratio Lower Upper
Low-risk HPV (Pos) 1.3 0.32 5.25 0.71
High-risk HPV (Pos) 3.8 1.23 11.94 0.02
HIV Positive 4.7 1.24 18.01 0.02
Age (30 & Above) 1.4 0.33 5.67 0.66
 
 
6.3.1.7 Genital herpes in women with vaginal discharge 
Of 274 women presenting with vaginal discharge, 27 (10.5%) were found to have concomitant 
genital ulcerations on clinical examination. Nine patients (33.3%) were clinically diagnosed as 
chancroid, 16 patients (59.3%) with genital herpes and two patients (7.4%) with primary 
syphilis. Of 27 patients with clinical ulcerations, clinical specimens for H. ducreyi (HD) culture 
and HSV-PCR were collected from 19 patients. Seven patients (36.8%) were positive for HD 
culture while 8 (42.1%) were positive on HSV PCR testing. No aetiological agent was found in 
four cases (21%). No mixed infection involving HD and HSV was encountered. 
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Swabs for HSV-PCR were collected from the ectocervix in 274 cases. Of these, 18 (6.6%) 
were positive on HSV-PCR and five patients had HSV-positive external genital ulcerations. 
Ten of these patients (55.6%) were also positive for HSV-2 type specific antibody, suggesting 
recurrent herpes infection. A significantly higher proportion of patients with cervical HSV 
infection was associated with cervical erosion compared to those without cervical HSV 
infection (77.8% vs. 49.6%, Odds Ratio 3.6, 95% CI 1.1 – 11.1, p 0.02). The rate of HIV 
infection detected among patients with cervical HSV infection was significantly higher than 
that detected among those without HSV (72.2% vs. 46.0%, Odds Ratio 3.1; 95% CI 1.1 – 8.8, 
p 0.03).  
 
A subset of patients was tested to detect HSV-2 type specific antibody. Of 198 patients with 
available results, 105 (53%) were HSV-2 antibody positive. No difference in rates of HSV-2 
sero-positivity was detected among HIV-seropositive when compared to HIV-seronegative 
patients (53.5% vs. 52.5%, p 0.9). 
 
6.3.1.8 Syphilis serology 
Of 283 patients, 40 (14.1%) were found to be RPR-positive confirmed by a positive FTA-ABS 
test. Of these, 19 patients had RPR titres ≥ 1:8. In addition, a further 53 patients (18.7%) were 
found to be RPR-negative but positive by the FTA-ABS.  No significant difference in rates of 
HIV infection between RPR-seropositive and RPR-seronegative patients was detected (45% 
vs. 48.7%, p 0.6). 
 
6.4  Discussion 
In southern Africa, reproductive tract infections (RTIs) and their complications contribute 
significantly towards morbidity and mortality among women.  As documented extensively in 
the literature, the sexual behaviour of women explains only partially the high burden of 
RTIs/STIs in southern Africa. More complex gender-specific issues are involved such as 
gender-based socio-economic inequality in the society and gender differences in HIV 
transmission efficiency including increased susceptibility of common infection as a result of 
physiological/hormonal influences, effectiveness of early detection of STIs, health care-
seeking behaviours and outcome of partner management20. 
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In South Africa, the availability of epidemiological data and reliable information on RTI/STI 
disease burden among women during the early phase of the HIV epidemic was limited. Some 
investigators however, had previously discussed the complexity of the diagnosis and 
management of RTI/STIs in women in southern Africa and explored the application of 
syndromic management as well as the role of rapid methods for diagnosis to increase the 
specificity of management of STIs in the 1980s21. With the development of the HIV epidemic 
in southern Africa, more STI aetiological studies were conducted to improve the diagnosis 
and management of STI syndromes as recommended by WHO22. Schneider et al. reported a 
high prevalence of RTIs/STIs among women attending a family planning clinic in a rural area 
of South Africa in 1994.  She and her co-workers found prevalence of C. trachomatis of 12%, 
of N. gonorrhoeae 3% and of T. vaginalis and bacterial vaginosis 18% and 29% 
respectively23. In contrast, the present studies were conducted in a major urban area among 
symptomatic women and therefore higher prevalence rates of RTI/STI were observed with 
CT (20.1%), GC (31.8%), TV (28.6%) and BV (47.3%). Similarly high prevalence rates were 
found among symptomatic women attending the STI clinics in other major urban areas such 
as Cape Town and Durban (Figure 6.12) 24.  
0
10
20
30
40
50
60
70
N. gonorrhoeae C. t rachomat is T. vaginalis Bact . vaginosis RPR/ FTA-ABS+ Candidiasis HIV
pe
rc
en
t p
os
iti
ve
Durban (1996) Cape Tow n (1995)
source -  NRCSTI/ SAIMR (Report )
 
Figure 6.12 Prevalence of vaginal and cervical infections in major cities of South Africa 
 
Unfortunately, no comprehensive aetiological data were available for women attending STI 
clinics in Johannesburg during the early 1990s. Anecdotal evidence however, indicated that 
the prevalence of STIs in the study population was high during that time and could have 
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served as an early indication of imminent spread of HIV in mid-1990s. An aetiological study 
conducted in Cape Town in 1995 showed that there was a high prevalence of GC, CT and 
BV prevalence among women presenting with vaginal discharge, despite having a lower HIV 
prevalence rate compared to other major urban centres in South Africa (e.g. 10% in Cape 
Town vs. 48.2% in Johannesburg).  Sentinel surveillance data however, showed that HIV 
prevalence among pregnant women in Cape Town has been increasing steadily in recent 
years, from 1.66% in 1995 to 12.4% in 200225. 
 
Despite the very high prevalence of HIV (48.2%) in our study population in Johannesburg, 
the HIV prevalence in a lower risk population group such as pregnant women in Gauteng 
Province was 18.7% in 1996. Meanwhile, epidemiological evidence indicated that an 
accelerated spread of HIV among high-risk population groups in Johannesburg in the early-
1990s was imminent. Such early indications were provided by the findings of the HIV/RPR 
sentinel surveillance system implemented at the Esselen Street STI clinic and the Urban 
Health Centre located at inner-city of Johannesburg (Figure 6.13).  Unfortunately, HIV 
infection spread rapidly into the general population and reached 31.6% in the sentinel 
pregnant women population by 2002.It is clear therefore, that epidemiological trends of HIV 
and STIs provide early warning indications of potential accelerated spread of HIV in both 
high-risk and low-risk populations in South Africa. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 HIV/RPR sentinel surveillance among STI patients in Johannesburg  
(Esselen Street and Urban Health Centre Clinics) 
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Our study has shown that over 80% of women in Johannesburg presenting with STI 
symptoms had at least one or more laboratory-confirmed vaginal infection, namely, bacterial 
vaginosis, candidiasis and/or trichomoniasis. In addition, almost half (43.4%) of the patients 
were infected with sexually-acquired gonococcal and/or chlamydial infections and up to 17% 
were confirmed to have some degree of ascending infection or pelvic inflammatory disease 
(PID), as diagnosed by the CET test. Of great concern are the high levels of infection due to 
viral agents such as HPV, particularly those sub-types associated with cancer of cervix, 
especially among women who are co-infected with HIV. Based on HSV-2 type-specific 
serology, more than half of patients (53%) were found to have been infected with HSV-2, and 
6.6% of all patients were shedding HSV-2 from their cervical lesions at the time of 
consultation. Based on these findings, the STI burden in women of reproductive age in 
Johannesburg in 1996 was very high.  
 
Many STI/HIV experts have elaborated on the ongoing changes in human ecology and 
behaviour and their major impact on infectious diseases, including STIs26. Holmes has 
emphasized that any changes in the burden STIs are likely to be linked to a continuum of 
several determinants. These could be identified as (1) the most remote and least modifiable 
historical stages of economic development; (2) more proximate factors such as the changing 
patterns of the environment, demographic transition, migration, or war etc. and (3) the most 
recent or modifiable events such as new technology (e.g. contraceptives), condom 
availability, illicit drug use and effective STI treatment services.  
 
In our study areas in Johannesburg, a mixed pattern of recent and historical determinants 
conducive to rapid spread of STIs, as outlined above, was present. These determinants 
include chronic poverty, political instability, the existence of large socially/economically 
marginalised population groups, high- levels of internal and cross-border migration, crime, 
prostitution, alcohol/drug abuse, gender inequality and lack of early and effective behavioural 
change interventions. A demographic and health survey conducted by the South African 
Department of Health (1998) revealed that most urban women (91%) who participated in the 
survey responded that they could avoid AIDS by using condoms and 89.9% that they could 
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be protected by staying faithful to their respective partners27. In stark contrast, only 12.2% of 
3,718 African urban women respondents indicated that they used a condom when they last 
had sex with a casual acquaintance. Among Gauteng residents attending STI clinics in 
Johannesburg, 9.6% of 2311 women who ever had sex, responded that they had ever been 
forced or persuaded to have sex against their will. Our study also found that 48% of patients 
had never used condoms before. Unfortunately, our study findings on their own could not 
quantify the social and behavioural risk factors associated with the high STI prevalence 
present in the study population.  Triangulation of information obtained from various studies 
and our findings however, reveal that complex socio-economic and behavioural factors exist, 
which led to the rapid spread of STIs and HIV in the area. 
 
Co-factor effects of individual STIs on the transmission efficiency of HIV (i.e. increase in 
infectiousness of or susceptibility to HIV infection) are complex, particularly when multiple 
potential co-factors are present in an individual. In our study population, multiple vaginal and 
cervical STI agents were frequently detected in the same patient. Moreover, there were many 
other potential physiological (e.g. menstrual cycle, hormonal etc.)28-29 immunological (e.g. viral 
load, immune deficiency, partial immunity etc.)30-31 and cultural determinants (e.g. use of 
vaginal drying agents, circumcision etc.) which may have influenced the infectiousness of, or 
susceptibility to, HIV32-35. 
 
Owing to the cross-sectional nature of our studies, we could only detect associations between 
various STI agents and HIV but it was not possible to determine increases in susceptibility to 
or the frequency of transmission of HIV associated with individual infections.  Of the three 
common vaginal infections, vaginal candidiasis had the highest prevalence among HIV-
seropositive women. Bacterial vaginosis was overall the most common vaginal infection with a 
prevalence of 48.5%. Although bacterial vaginosis and candidiasis are not traditionally 
considered STDs36, both have been associated with increased acquisition of HIV. Studies 
suggest that a vaginal milieu with a high pH and a lack of H2O2-producing lactobacilli found in 
bacterial vaginosis, enhances susceptibility to HIV by a factor of 1.4 – 2 37-39. It has also been 
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found that the presence of bacterial vaginosis is associated with an increased prevalence of 
other STDs40. 
 
In our studies, a significant association between vaginal candidiasis and HIV infection was 
detected. A significantly higher proportion of HIV-seropositive patients than sero-negative 
patients had vaginal candidiasis with an odds ratio of 2.0 (95% CI – 1.24 – 3.29). No 
significant association was found between HIV and bacterial vaginosis or HIV infection and 
trichomoniais respectively. The presence of one or more vaginal infections in women was a 
good predictor of HIV-positivity in our study population. As the majority of women had either 
one or more vaginal infections, we could not find a significant association with HIV for specific 
vaginal infections in the study.  
 
In addition to the high prevalence of vaginal infections, almost half of our patients with a 
vaginal discharge had cervical lesions such as cervical ectopy or erosion/s of the cervix. Over 
15% of women had clinical signs indicative of early PID. These cervix-related clinical signs 
were significantly associated with gonococcal infection in our study population. We did not 
however, find a significant association between gonococcal infection and HIV infection. The 
prevalence of chlamydial infection was slightly lower than infection caused by gonococci while 
a similar HIV prevalence was found between CT-positive and CT-negative patients. Despite 
the lack of an association between gonococcal infection and/or chlamydial cervicitis and HIV, 
the extremely high prevalence of GC &/or CT cervical infections (43.4%) in women is a major 
concern. Studies have reported that women co-infected with HIV and cervical infections have 
a higher risk in developing PID and, when it develops, it is more severe in HIV-seropositive 
women41 – 45. 
 
Although longitudinal studies provide conflicting findings on the effect of STI co-infection on 
HIV infectiousness46-47, it is biologically plausible that the infectiousness of HIV could be 
higher as a result of STI-coinfection. For example, GC, CT and BV infections have been 
shown to be associated with the presence of cervical interleukin-10 which reportedly 
enhances HIV replication in macrophages48. Studies also have reported that the presence of 
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cervical GC and/or CT significantly increased the number of CD4+ cells in endocervical 
specimens49 and the detection of HIV in cervical secretion has been associated with the 
presence of cervical mucopus or inflammation50-51. 
 
In South Africa, an extremely high proportion of women with RTIs/STIs were co-infected with 
HIV. Unfortunately, in our study population, the interaction between specific RTIs/STIs and 
HIV has been compromised by the high rate of mixed infections detected. In addition, the 
cross-sectional design of the study negated differentiation between “cause and effect” of the 
interaction. For example, the association between vaginal candidiasis and HIV infection could 
be due to either increased susceptibility to HIV among women with candida vaginitis or an 
increase in the incidence of candida infection known to be associated with HIV induced 
immunodeficiency.  
 
The high prevalence of STIs in both HIV-seropositive and negative women in the mid-1990s 
could serve as a surrogate indicator of the existence of accelerated HIV transmission among 
women. This phase of the dual epidemic was soon followed by a rapid increase in HIV 
prevalence among pregnant women in South Africa (Figure 6.14). UNAIDS estimated that 
some 2.9 million (range 2.5 – 3.3 million) sexually- active women aged 15 – 49 years were 
living with HIV/AIDS in South Africa by the end of 200352. 
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Figure 6.14 HIV prevalence among pregnant women in major urban areas of 
Gauteng Province (1990 – 2002) – source: UNAIDS   
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In the early 2000s, the HIV epidemic in South Africa reached the stage where it was 
estimated to become the leading cause of premature death in women, contributing 46.3% to 
the total burden of premature death53 (Figure 6.15).  
 
 
 
 
 
 
 
 
 
 
Figure 6.15 Estimates of premature mortality in women. South Africa 
  (Source: Bradshaw et al., Initial burden of disease estimates in South Africa, 2000)53
 
In the present studies, no significant association between HIV and bacterial causes of vaginal 
and cervical infections could be detected.  However, a significant association was found 
between viral infections of the cervix, namely cervical HPV and HSV infections, and HIV. 
Overall, HPV infection was extremely common in our study population with over 70% of 
patients found to be positive by HPV PCR (MY 9/11). Human papillomaviruses are members 
of the papovaviridae family of DNA viruses and cause benign and malignant epithelial 
proliferations54. More than 100 different types of HPV have been described, including more 
than 30 anogenital types, of which approximately 15 are oncogenic55-56. The most serious 
complication of genital HPV is invasive cervical cancer which is the second most common 
cancer among women worldwide57. In South Africa it is the most common cause of cancer 
among females of African and mixed race origin58 (Figure 6.16). 
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Figure 6.16 Proportion of causes of female cancers in South Africa  
(Source: National Cancer Registry, South Africa, 1995) 
 
In 1992, the National Cancer Registry of South Africa reported 25,413 female cancer cases 
and cervical cancer was cited as the most common cancer among women with 4467 new 
cases. Of these, 3,390 (75.8%) affected black women and the incidence ranked highest in 
the world59. During 1993 – 1995, the age-standardized incidence rates for cancer of cervix 
among females of African origin was 26.47 per 100,000 population. Cervical cancer was 
among the top 20 specific causes of the premature mortality burden (years of life lost, 
abbreviated as YLL) among women in South Africa in 2000 when it contributed 
approximately 15% to premature mortality53. In response, the Department of Health 
developed national guidelines for the screening of cervical cancer, offering three free PAP 
smears every ten years to women over 30 years of age60.  
 
The evidence for a causative relationship between HPV and cancer of cervix is compelling61. 
Multi-centre studies coordinated by the International Agency for Research on Cancer (IARC) 
and conducted in 22 countries reported that HPV DNA was identified in almost all (99.7%) 
cancer cases.62 The HPV types which are generally characterized as “high-risk” types (16, 
18, 18, 31, 33, 35, 45, 51, 52 and 56) are associated with low- and high-grade squamous 
intraepithelial lesions (LSIL and HSIL) and invasive cancer, while “low-risk” types (6, 11, 42, 
43 and 44) are associated with genital warts, LSIL, and recurrent respiratory papillomatosis63-
66. In our study, the probes A and probe B of the Hybrid Capture Tube (HCT) assay system 
were used to detect low-risk HPV types and high-risk HPV types respectively. The 
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prevalence of high-risk HPV types was higher than that of low-risk HPV types in our 
population (28.3% vs. 9.2%).  Mixed infections of low- and high-risk types were also common 
with 6.4% of 283 patients being positive for both risk types. During the mid-1990s and late-
1990s, the prevalence of high-risk HPV types was high in South Africa. Wright et al reported 
that the high-risk HPV types was detected in 21.1% of 1415 women who were participating in 
routine a cervical cancer screening programme in Cape Town67. However, a more sensitive 
(i.e. detection threshold of 1 pg/ml HPV DNA or 5000 HPV genome copies per test) second 
generation hybrid capture assay (HC-II) was used in their study. The assay we used was an 
older HCT assay with a detection threshold of 10 pg/ml which did not include RNA probes for 
HPVs 39, 58, 59, and 68 in the probe-B cocktail. The prevalence rates found in the two 
studies are not comparable owing to differences in the populations studied and the location.  
 
Similar to HPV-PCR (MY9/11) results, a significant association between the prevalence of 
low- and high-risk HPV types and HIV infection was detected in our study population. Among 
HIV-seropositive patients, the prevalence of high-risk HPV types was as high as 36.4%. 
Overall, the prevalence of low- and/or high-risk HPV types was significantly higher in HIV- 
seropositive women. A stronger association was however seen in patients with low-risk HPV 
types (OR 6.2, 95% CI – 2.1 – 18.5) than in those with high-risk HPV types (OR 2.2., 95% CI 
– 1.3 – 3.8).  Generally, the HPV prevalence was lower in older women with a peak rate 
detected in women under 25 years of age and this trend could be due to the natural 
clearance of virus over time, mediated by an effective immunological response as described 
previously68-72. 
 
In our study, prospective serial measurements of HPV positivity could not be performed as 
the study population was highly mobile and adhered extremely poorly to their post-treatment 
follow-up visits. We observed that HIV prevalence was significantly lower in the older women 
compared to those in the 15- 19 age group. However, no significant decline in the prevalence 
of both low- and high-risk HPV types was detected in older women with HIV co-infection, 
while a significant decrease was found in those who were HIV-seronegative. A similar trend 
was seen when semi-quantitative measurement of HPV viral burden was compared between 
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different age groups, using log RLU/PC ratios as proxy markers of viral burden. We also 
found that the median RLU/PCs ratio for high-risk HPV types was significantly higher in HIV- 
seropositive compared to HIV-seronegative patients.  
 
Unlike other prospective studies, our study design did not allow for the assessment of the 
effect of possible persistent HPV infection in HIV-seropositive women enrolled in the study.  
However, Branca et al. reported that HIV-seropositive patients have a higher rate of  new 
HPV infections during follow-up periods (Odds Ratio 8.8, 95% CI – 1.19 – 64.61) while the 
clearance of existing HPV infection was markedly poorer than in HIV-seropositive women 
when compared with their HIV-seronegative counterparts (Odds Ratio 0.33; 95% CI 0.16 – 
0.67)73. The rate of progression of HPV infection was also higher in HIV-seropositive 
women73-75. 
 
A body of evidence suggests that infection with high-risk types of HPV appears to be 
“necessary” for the development of cancer of cervix (i.e. not “sufficient)”. A significant 
proportion of HPV-infected women do not progress to cancer and other risk-determinants 
such as prolonged hormonal use, smoking, other genital tract infections, and, more 
importantly, immunodeficiency due to HIV infection may play a role76-77. Epidemiological 
information obtained from many developed countries suggests that the incidence of cervical 
cancer is much higher among HIV-seropositive women and it is included as one of AIDS-
defining illnesses in the CDC 1993 AIDS case definition78. Studies also reported that women 
with persistent high-risk type HPV infection are at greater risk of developing cervical intra-
epithelial neoplasia (CIN) which also tends to persist79-81. Based on this evidence, it is 
biologically plausible that HIV-infected women are more likely to have persistent high-risk 
types HPV infection and, as a result, a greater chance of progression to invasive cancer than 
their HIV-seronegative counterparts who have a better capacity for clearance of HPV.  In the 
population studied here, the high prevalence and persistence of high-risk types of HPV 
among women with HIV co-infection may result in a massive increase in the burden of 
cervical cancer in South Africa.  
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In the majority of countries of southern Africa, anti-retroviral therapy is neither widely 
available nor affordable.  International efforts to improve the availability of antiretroviral 
therapy (ART) in resource poor settings should result in significantly prolonging the life-
expectancy of HIV-seropositive individuals. WHO/UNAIDS have set the target to provide 
universal access to antiretroviral therapy for all persons living with HIV/AIDS and it has 
declared a 3 by 5 target which aims to provide treatment for 3 million people by 2005. 
Historically, little attention has been paid to the interaction between HPV and HIV infection as 
well as the role of HIV-infection in increasing the risk of cervical cancer.  A possible reason 
for this lack of attention may be that the majority of HIV-infected women with high-risk types 
of HPV infection and SIL are more likely to die of other AIDS-related conditions long before 
they develop invasive cancer82-83. 
 
However, if Highly Active Anti-retroviral Therapy (HAART) becomes the standard of care for 
HIV infections in women in the region, it is possible that the magnitude of the problem of 
cervical cancer in southern Africa may be a major concern requiring a reassessment of 
current screening programmes. Clearly, prevention strategies should take into consideration 
the rapidly changing knowledge of and insights into the natural history, diagnostic methods, 
and primary/secondary prevention of these viral infections. Screening algorithms should be 
reviewed regularly to improve the cost-effectiveness, sensitivity, specificity and predictive 
values of strategies and methods. Recent achievements in vaccine development should be 
closely monitored and applied appropriately to contain the rapid spread of HPV infection and 
its sequaelae84-86. 
 
In contrast to HPV, herpes simplex virus, type 2 (HSV-2) appears to have a significant bi-
directional interaction with HIV. Many researchers have reported the presence of biological 
and epidemiological associations between genital herpes and HIV87-89. In a meta-analysis of 
relevant published information, it was reported that infection with HSV-2 doubled the risk of 
HIV acquisition through sexual transmission90. Furthermore, several studies included in the 
analysis found that when HSV-2 infection occurred before HIV acquisition, the risk of such 
acquisition was estimated to be 2.1 (95% CI, 1.4-3.2)90. The percentage of HIV transmission 
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attributable to HSV-2–positive individuals has been estimated to be 52%, with a population 
attributable risk of 19% in populations with a 22% HSV-2 prevalence increasing to 47% in a 
population with a 80% HSV-2 sero-prevalence.90 The likely mechanisms of interaction include 
(1) the role of HSV as a cause of ulcerations or inapparent micro-ulcerations which provide a 
portal of entry for HIV, (2) increased lesional and/or mucosal shedding of HIV during  
episodes of reactivation of HSV-288. In our study reported here, 18 of 274 patients (6.6%) 
were shedding HSV from their cervix and 55.6% of these were type-specific HSV-2 antibody 
positive. Moderate to severe cervical erosions were observed in the majority (77.8%) of 
cervical HSV-2 PCR-positive patients and the HIV prevalence was 72% in HSV-2 positive 
patients. The level of shedding of HIV from HSV-2 positive patients and response to anti-
herpes treatment is discussed elsewhere in this thesis (Section 7.4). 
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CHAPTER 7 
 
HIV shedding in women with vaginal discharge and impact of 
therapy  
 
7.1 Introduction 
 
Epidemiological studies have shown that the efficiency of HIV transmission is higher from 
male-to-female than from female-to-male (See Section 6.1). In their study involving HIV sero-
discordant couples in Rakai, Uganda, Gray et al. reported a higher transmission probability 
per coital act from men to women than from women to men, although this was not statistically 
significant (0.0013 vs. 0.0009, p 0.34)1. The microbiological correlates of HIV shedding in the 
female genital tract were studied extensively during the period 1996 – 20022 – 10. Among these 
investigations, the effect of coinfection with genital infections and their treatment on female 
genital HIV shedding was investigated in studies conducted in both CÔte d’lvoire and  
Kenya8-10. A better understanding of the role of microbiological and other correlates of HIV 
shedding in the female genital tract among South African women could enhance the 
prospects of implementing evidence-based intervention programmes in the region. 
 
7.2 Objectives 
 
The studies described here are focused on the role of sexually transmitted vaginal and 
cervical infections in cervico-vaginal shedding of HIV and the effect of the treatment of these 
infections on cervico-vaginal shedding of HIV. The association between other potential 
determinants including host immunity on genital shedding of HIV has also been explored in 
this chapter.  
 
7.3 Study population and methods 
7.3.1 Study population 
These studies were conducted at the Esselen Street STI clinic in Johannesburg, South Africa 
during the period July 1997 to August 1998. A detailed profile of the clinic and study 
population was described in Section 6.2. For these studies, a sub-group of patients attending 
the clinic who requested voluntary HIV testing for various reasons were approached and, 
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pending informed consent, enrolled into the study. In collaboration with the Outreach 
Programme of the Greater Johannesburg Metropolitan Council and the Reproductive Health 
Research Unit, female sex workers who voluntarily requested for HIV testing were also 
included. Following a one-on-one explanation of the study objectives and procedures and 
explanation of the risks and benefits of participation, pre-test HIV counselling was conducted 
by the trained counsellors.  
 
7.3.2 Clinical and laboratory method 
In each case, an interview was conducted to obtain information related to demographic and 
socioeconomic characteristics of patients including sexual practices as well as STD 
symptoms. Following the interview, clinical and gynaecological examinations including a 
speculum examination were performed. Vaginal and cervical specimens were collected for 
microbiological and virological investigations as described in sections 6.2.5.1 and 2.3.3. A first 
catch urine specimen was collected to detect C. trachomatis and N. gonorrhoeae by LCR 
testing. Finally, a specimen was collected from the squamo-columnar junction of the cervix 
and Pap smears were prepared.  
 
In addition to the procedures described in section 6.2.5.1, cervico-vaginal lavage specimens 
were collected to assess shedding of HIV in genital fluid. After insertion of a vaginal 
speculum, 10 ml of sterile normal saline was slowly and gently applied onto the cervix using a 
syringe. After approximately 2 – 3 minutes, all fluid that had pooled in the posterior fornix was 
collected using a 10 ml sterile disposable pipette and transferred to a sterile plastic tube. All 
specimens were subsequently stored at -70ºC until processed to measure HIV RNA copies 
using a standard protocol as described in section 2.3.4.2. 
 
Blood was collected and tested for the syphilis serology (on-site RPR) and subsequent  
FTA-ABS tests, HIV antibody testing and chlamydial and herpes serology.  A rapid HIV 
serological test was performed to screen patients and all positive tests confirmed with two 
different ELISA tests. The SAIMR and National HIV testing protocols were followed for all 
patients. CD4+ counts and HIV plasma viral loads were determined on all participants of the 
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study. Participants with signs and/or symptoms of STIs were treated immediately using the 
syndromic STD management approach. 
 
All patients were requested to return for follow-up visits on Day 7 when a general and 
gynaecological examination was conducted. On their return, vaginal, cervical and blood 
specimens including a cervicovaginal lavage specimen were collected for repeat laboratory 
investigations which were identical to those performed at the initial visit except for syphilis 
serology, HPV testing, Pap smear and CD4 counts which were not repeated. Participants 
were provided with their HIV results and given post-test counselling. The CD4 results were 
also provided, and patients were referred to the Hillbrow Hospital HIV clinic for further 
management.  
 
7.3.3 Data entry and analysis and ethical considerations 
 
Procedures outlined in sections 6.2.6 and 6.2.7 were followed. Modifications of the survey 
instruments used for the cross-sectional prevalence studies were also used in this study (See 
section 6.2.8 and Annexures 6.1 to 6.3). 
 
7.4 Results 
A total of 68 HIV-seropositive women were enrolled in the study during the period July 1997 – 
August 1998. The ages of participants ranged from 17 to 34 years of age, with the majority of 
participants (62.1%) under 25 years of age with a median age of 23 years (±SE 0.5). Most 
patients were complaining of vaginal discharge (69.1%), vulval itching (44.1%), burning on 
micturation (BOM) (32.3%) and lower abdominal pain (43.3%). Some presented with genital 
ulcerations (26.5%) or genital warts (9.0%) (Table 7.1).  A history of post-coital bleeding was 
a prominent feature involving 32.4% of the participants.  
 
 
 
 
 
 
 - 200 - 
Table 7.1 Demographic characteristics and presenting symptoms of 68 HIV-infected 
women 
 
Age
Median 23 years
Range 17 - 34 years
Symptoms
Burning on micturation (BOM) 22 (32.3%)
Abnormal vaginal discharge 47 (69.1%)
Vulvovaginal itchiness 30 (44.1%)
Genital sores 18 (26.5%)
Lower abdominal pain 29 (42.6%)
Abnormal lumps or warts 6 ( 8.8%) 
History of post-coital bleeding 22 (32.4%)
Current contraceptive use 36 (52.9%)
Injectable contraceptive (e.g. Depo) 31 (45.6%)
Oral contraceptive pills 3 (  4.4%)
Other methods (e.g. IUD) 2 (  2.9%)
Median duration of usage (range) 24 months (1 - 144 months)  
 
Thirty-six patients (52.9%) were using contraceptives at the time of enrolment and the 
majority employed injectable contraceptives (86.1%); oral contraceptives were used by 8.3%, 
while other contraceptive methods were used by 5.6%. Fifty-four patients recalled the first day 
of their last menstrual period (LMP). On average, enrolment occurred approximately two 
weeks after the first day of their LMP (Median 15 days, range – 1 – 71 days). On examination, 
genital ulcerations were detected in 9 patients (13.4%) and an abnormal vaginal discharge 
was observed in 61 (91.2%) patients. The majority (41.9%) of patients had a profuse 
discharge while 17.7% had a curd-like discharge. Twenty patients (29.4%) had a 
mucopurulent discharge from the cervix and 24 (35.3%) had cervical erosions. Four patients 
had clinically visible cervical warts. During bimanual gynaecological examination, 21 patients 
(30.9%) had cervical excitation tenderness (CET). A repeat examination was conducted on 
Day 7. The findings obtained at the two visits are presented in Table 7.2. 
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 Table 7.2 Clinical signs detected at enrolment and follow-up visits 
Enrolment visit Follow-up visit
Abnormal findings in external genitalia 10 (14.7%) 11 (16.2%)
Vaginal rash   4  (5.9%)   9 (13.2%)
Genital warts   5  (7.4%)   3  (4.4%)
Genital ulcer(s)   9 (13.2%)   3  (4.4%)
Abnormal vaginal discharge 62 (91.2%) 40 (58.8%)
Profuse discharge 26 (41.9%)   4  (5.9%)
Curd-like discharge 11 (17.7%) 16 (23.5%)
Cervical discharge 20 (29.4%) 13 (19.1%)
Cervical erosion 24 (35.3%) 18 (26.5%)
Cervical excitation tenderness 21 (30.9%)   7 (10.3%)  
 
CD4+ cell counts at enrolment were obtained in 64 cases and the mean CD4+ count was 531 
cells/mm3 (± SE 39.5, range: 12 – 1513). The majority (68.8%) of patients had CD4+ counts of 
350 cells/mm3 or more. Seven patients (10.9%) had CD4+ counts fewer than 200 cells/mm3 
(Figure 7.1). 
 
≥ 
 
 
Figure 7.1  Distribution of CD4+ counts at the enrolment visit 
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The HIV plasma viral load (PVL) was measured at the time of enrolment for all patients and 
the median PVL was 19,024 copies/ml (range: 450 – 590,203 copies/ml). The median log 
PVL at the initial visit was 4.27 (±SE 0.1, range: 2.65 – 5.77). The PVL at enrolment was less 
than 20,000 copies/ml in 34 patients (50%). No patient had received anti-retroviral therapy 
and the PVL was generally higher in those with low CD4+ counts (Figure 7.2).   
 
 
Figure  7.2 Association between CD4+ counts and log PVL measured at  
enrolment 
 
Forty-six patients (67.6%) were positive for bacterial vaginosis diagnosed by the presence of 
typical clue cells on Gram stained vaginal smears. All patients had pH>4.5 and 72.7% had a 
positive amine test. Yeasts were detected in specimens from 44 patients (64.7%) and  
T. vaginalis (TV) in 20 (30.9%). Gonococcal infection was diagnosed in 29 patients (42.6%) 
and chlamydial infection in 17 patients (25.0%). Overall, 35 patients (52.2%) were positive for 
gonococcal and/or chlamydial cervical infections. In addition, five patients (7.4%) had a 
positive HSV-PCR from cervical specimens, and one patient was HSV-PCR positive from 
genital ulcers. Low-risk HPV infection was detected at enrolment in 23 cases (33.8%) and 
high-risk HPV in 50 patients (73.5%) (Figure 7.3). The median log Relative Light Unit/Positive 
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Control ratio (RLU/PC) for low-risk HPV was 1.1 (±SE 0.21, range 0.04 – 3.1) and for high-
risk HPV 1.7 (±SE 0.14, range 0.1 – 3.3). Syphilis serology was positive (i.e. RPR confirmed 
by an FTA-ABS test) in 11 patients (16.2%).  
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Figure 7.3 Aetiogical distribution of vaginal and cervical infections detected at 
the enrolment in 68 HIV-seropositive women 
 
The manufacturer’s information on the sensitivity of viral load estimations for the equipment 
used (cut-off - 400 copies/ml) was applied to define “detectable HIV” in cervicovaginal lavage 
(CVL) specimens as well as in plasma (PVL). At enrolment, HIV RNA was detected in CVL 
collected from 26 patients (38.2%). The median HIV RNA detected in the CVL of 26 HIV 
‘shedders’ was 3068 copies/ml of CVL (± SE 2582, range 576 – 67640 copies/ml). The 
median log copies detected was 3.49 (± SE 0.1, range 2.8 – 4.8). The results of univariate 
analyses are shown in Table 7.3.  Although higher rates of HIV shedding were detected 
among several groups of patients including those using injectable contraceptives (48.4% vs 
34.4%, p 0.25); having a history of post-coital bleeding (45.5% vs. 29.3%, p 0.19); genital 
ulcerations (55.6% vs. 35.1%, p 0.23); vaginal discharge (38.7% vs. 25.0%, p 0.58) and 
cervical erosion (50.0% vs. 33.3%, p 0.18), these associations were not statistically 
significant. HIV shedding rates were not significantly different between patients with and 
without concomitant vaginal infections, namely, bacterial vaginosis, trichomoniasis or 
candidiasis (Table 7.3). Similar findings were observed in patients with gonococcal and/or 
chlamydial cervical infections as well as high-risk and low-risk HPV infections. Higher HIV 
shedding rates were observed in patients with HSV infection involving the cervix although the 
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difference did not reach statistical significance. (80.0% vs. 33.9%, Odds Ratio 7.8, 95% CI 0.8 
– 74.5, Fisher’s Exact Test, p 0.06)  
 
Table 7.3 Assessment of potential risk determinants associated with HIV  
CVL shedding 
 
Potential determinants No/Total (%) with HIVshedding
Odds Ratio
(95% CI) p
Demographic & reproductive health 
Age
15 - 19   4/11 (36.4%) 1
20 - 29 20/49 (40.8%) 1.2 (0.3 - 4.7)
30 & above   2/8  (25.0%) 0.58 (0.08 - 4.4)
Current injectable contraceptive use
No 11/32 (34.4%) 1.0
Yes 15/21 (41.7%) 1.4 (0.5 - 3.7)
History of post-coital bleeding
No 16/46 (34.8%) 1
Yes 10/22 (45.5%) 1.6 (0.6 - 4.4)
STIs related signs and symptoms
Presence of STI signs on external genitalia
No 17/56 (30.4%) 1
Yes   8/10 (80.0%) 9.2 (1.8 - 47.8) 0.008
Sores on external genitalia
No 20/57 (35.1%) 1
Yes    5/9 (55.6%) 2.3 (0.6 - 9.6)
Vaginal discharge
No 1/3 (25.0%) 1
Yes 24/62 (38.7%) 1.9 (0.2 - 19.3)
Cervical mucopus
No 17/42 (40.5%) 1
Yes 8/20 (40.0%) 1.0 (0.3 - 2.9)
Cervical erosion
No 14/42 (33.3%) 1
Yes 12/24 (50.0%) 2.0 (0.7 - 5.6)
STI pathogens
Bacterial vaginosis
No 10/22 (45.5%) 1
Yes 16/46 (34.8%) 0.6 (0.2 - 1.8)
Yeast infection
No 7/24 (29.2%) 1
Yes 19/44 (43.2%) 1.8 (0.6 - 5.3)
Trichomonas vaginalis
No 16/47 (34.0%) 1
Yes 10/21 (47.6%) 1.8 (0.6 - 5.0)
Neisseria gonorrhoeae
No 15/39 (38.5%) 1
Yes 11/29 (37.9%) 1.0 (0.4 - 2.6)
Chlamydia trachomatis
No 20/51 (39.2%) 1
Yes 6/17 (35.3%) 0.9 (0.3 - 2.7)
Any GC &/or CT infections
No 15/32 (46.9%) 1
Yes 11/36 (30.6%) 0.5 (0.2 - 1.3)
Cervical Herpes simplex virus
No 20/59 (33.9%) 1
Yes 4/5 (80.0%) 7.8 (0.8 - 74.5)
Cervical HPV (High-risk types)
No 7/16 (43.8%) 1
Yes 19/50 (38.0%) 0.8 (0.3 - 2.5)
Cervical HPV (Low-risk types)
No 14/43 (32.6%) 1
Yes 12/23 (52.2%) 2.3 (0.8 - 6.4)
Immunologic derterminants
CD4 counts (/mm3)
≥350 12/44 (27.3%) 1 0.009
200 - 350 9/13 (69.2%) 6.0 (1.6 - 2..2 )
<200 4/7 (57.1%) 3.6 (0.69 - 18.3 )
Plasma viral load
≤20,000 copies 4/34 (11.8%) 1 <0.001
>20,000 copies 22/34 (64.7%) 13.8 (3.9 - 48.4)
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There was however, a significant direct association between HIV PVL and the level of HIV 
shedding in CVL (Pearson Correlation Coefficient = 0.542, p<0.001). A significantly higher 
proportion of patients whose PVL was higher than 20,000 copies/ml at enrolment shed HIV in 
their CVL than those with PVL ≤20,000 copies/ml (64.7% vs. 11.8%, Odds Ratio 13.8, 95% CI 
3.9 – 48.4, p<0.001) (Table 7.4). 
 
Table  7.4 Association between HIV PVL and shedding of HIV in CVL (initial visit) 
 
HIV Plasma Viral Load (PVL)
n
Median HIV RNA 
Shedding (copies/ml) in 
Cervicovaginal Lavage 
Fluid (Range)
Number of
Women Who 
Shed HIV in 
CVL (%)
Odds Ratio
(95% CI) p
High PVL 
(>20,000 copies/ml) 34 3,5421 (576 - 67,640) 22 (64.7)
13.8 
(3.9 - 48.4) <0.001
Low PVL 
(≤20,000 copies/ml) 34 7,992 (602 - 10237) 4 (11.8)
Total 68 3,068 (576 - 67,640) 26 (38.2)
1 vs 2, Mann-Whitney U, p<001
 
There was an increasing trend in the amount of HIV RNA detected in CVL in patients with 
higher PVL (R2 Quadratic 0.264) (Figure 7.4). 
 
 
Figure 7.4 Association between HIV Plasma Viral Load (PVL) & HIV shedding in 
Cervicovaginal Lavage Fluid (CVL) (Horizontal reference line approximates 
the PVL amount of 20,000 copies/ml and vertical reference line indicates 
approximates of undetectable limit of HIV copies in CVL. Quadratic curve fitting 
provides – R2 Quadratic of 0.264)  
 - 206 - 
A stronger association between PVL and HIV shedding in CVL was found in the group of 
patients with CD4+ counts 350 and above compared to those with CD4+ counts lower than 
350 cells/mm3 (Table 7.5). Of 44 patients with CD4+ counts 350 and above, 20 patients 
(45.5%) had high PVL (>20,000 copies/ml). Among these, 12 (60%) patients shed HIV RNA 
in their CVL. In contrast, none of 24 patients with low PVL (20,000 copies/ml & below) shed 
HIV (χ2 19.8, p<0.001). The association between PVL and HIV shedding in CVL was not 
significantly associated in 20 patients with CD4+ counts fewer than 350 cells/mm3 (75% shed 
HIV in high PVL group vs. 50% in low PVL group, Fisher’s Exact Test p 0.35). 
 
Table  7.5 Association between CD4, HIV PVL and shedding of HIV in CVL 
HIV Shedding in CVL
HIV RNA
Detected
No HIV RNA
Detected
≥350 12 8 20
60.0% 40.0%
0 24 24
0% 100.0%
12 32 44
27.3% 72.7%
<350 9 3 12
75.0% 25.0%
4 4   8
50.0% 50.0%
13 7 20
65.0% 35.0%
High PVL (>20,000)
Low PVL (≤20,000)
Total
Total
TotalCD4 + Counts
High PVL (>20,000)
Low PVL (≤20,000)
 
 
All patients were treated syndromically to cover all vaginal and cervical infections (i.e. 
ciprofloxacin 500 mg p.o. stat plus azithromycin 1 g p.o. stat plus metronidazole 400 mg p.o. 
bd for 7 days plus fluconazole 150 mg p.o. stat). Treatment for genital herpes (i.e. valaciclovir 
500 mg p.o. bd for 5 days) was provided presumptively for those with suspected genital 
ulcerations or with significant cervical erosion and/or ulcerations.  
 
The microbiological outcomes of patients at Day 7 are shown in Table 7.6. Most treatment 
failures or persistent infections were encountered in patients with bacterial vaginosis and/or 
yeast infections. Of 45 patients who were positive for bacterial vaginosis at enrolment, 16 
(35.6%) were still positive at the follow-up visit at Day 7. Similarly, 21 out of 44 patients 
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(47.7%) with yeast infections continued to be positive at the follow-up visit. In the case of 
vaginal trichomoniasis and gonococcal cervicitis, all patients were cured by Day 7 while 4 
patients (25%) with chlamydial cervicitis were still positive at Day 7. 
 
Table 7.6 Treatment outcomes of patients with bacterial and fungal infections at Day-7  
 
Outcome at 
Follow-up Visit
Bact.
Vaginosis
Trichomo-
niasis
Yeast
Infection
Gonococcal
Infection
Chlamydial
Infection
 n % n % n % n % n %
Negative at Both Visit 18 26.5 45 66.2 14 20.6 36 52.9 49 72.1
Treatment Success 29 42.6 20 29.4 23 33.8 27 39.7 12 17.6
Treatment Failure** 16 23.5 - - 21 30.9 - - 4 5.9
Reinfection* 3 4.4 2 2.9 9 13.2 3 4.4 1 1.5
Unknown 2 2.9 1 1.5 1 1.5 2 2.9 2 2.9
Total 68 100 68 100 68 100 68 100 68 100
*remain +ve at follow-up visit; **continued +ve at follow-up visit  
All five women who were PCR positive for HSV from their cervical specimens were 
successfully treated with anti-herpes therapy. The majority of low- and high-risk HPV-positive 
patients were persistently positive on follow-up (68.2% for low-risk and 91.5% for high-risk 
HPV-positive patients) (Table 7.7). 
 
Table 7.7 Treatment outcomes of patients with viral STIs at Day 7 
Outcome at 
Follow-up Visit
Herpes
Cervicitis
HPV 
(Low-risk)
HPV 
(High-risk)
 n % n % n %
Negative at both visits 53 77.9 35 51.5 10 14.7
Treatment success* 5 7.4 7 10.3 4 5.9
Treatment failure** - - 15 22.1 43 63.2
Reinfection*** - - 4 5.9 4 5.9
Unknown 10 14.7 7 10.3 7 10.3
Total 68 100 68 100 68 100
*viral clearance  in HPV patients; ** viral persistence in HPV patients; 
*** viral appearance in HPV patients  
 
PVL was measured at follow-up in all cases, and two patients had undetectable PVL at  
Day 7. The median PVL at Day 7 was 16,970 copies/ml (range 505 – 1,060,813 copies/ml) 
and the median log PVL was 4.2 (±SE 0.12, range, 2.7 – 6.03).  When compared to their PVL 
status at enrolment, 31 out of 34 patients with high initial PVL (i.e. >20,000 copies/ml) 
continued to be in the high PVL group at follow-up. Similarly 33 out of 34 patients with low 
PVL (i.e. ≤20,000 copies/ml) continued to be in the low PVL group on follow-up. Of 26 
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patients who shed HIV in their CVL at the enrolment visit, 10 (38.5%) stopped shedding HIV 
at follow-up, while seven of 42 patients who did not shed HIV at enrolment shed HIV in their 
CVL at follow-up. 
 
 
Figure 7.5 Scattergram of Log HIV RNA in CVL at enrolment and return visits  
(Green – patients stopped shedding; Blue – patients declined in amount of shedding; 
Red – patients started shedding or increased amount of shedding; Horizontal & vertical 
reference lines represent detection cut-offs for HIV viral load in CVL, i.e. 400 
copies/ml) 
 
Of 16 patients who continued to shed HIV in their CVL, eight (50%) showed some decline in 
the amount of shedding with a median log reduction of 0.305 (range – 0.04 – 0.76) (Figure 
7.5). The other eight cases showed increases in the amount of shedding with a median log 
increase of 0.58 (range – 0.07 – 1.71). In seven patients who started shedding at follow-up, 
the median HIV RNA shed in the CVL was 1,287 copies/ml (range 412 – 52,378 copies/ml). 
The median log HIV copies in the CVL was 3.1 (range 2.61 – 4.72). 
 
Similar to the findings at the enrolment visit, there was a significant association between the 
high PVL and HIV shedding in CVL (Table 7.8). 
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Table 7.8 Association between HIV PVL and shedding of HIV in CVL (return visit) 
HIV Plasma Viral Load (PVL)
n
Median HIV RNA 
Shedding (copies/ml) in 
Cervicovaginal Lavage 
Fluid (Range)
Number of
Women Who 
Shed HIV in 
CVL (%)
Odds Ratio
(95% CI) p
High PVL 
(>20,000 copies/ml) 32 35,111 (412- 78,604) 19 (59.4)
11.7 
(3.3 - 41.1) <0.001
Low PVL 
(≤20,000 copies/ml) 36 8,192 (493 - 1,582) 4 (11.1)
Total 68 2,154 (412 - 78,604) 23 (33.8)
1 vs 2, Mann-Whitney U, p<001
 
A similar association was observed between PVL level and amount of HIV viral shedding in 
CVL at the follow-up visit (Figure 7.6). 
 
 
Figure 7.6 Association between HIV Plasma Viral Load (PVL) & HIV shedding in 
Cervicovaginal Lavage Fluid (CVL) at the follow-up visit 
(Horizontal reference line approximates the PVL amount of 20000 copies/ml and vertical 
reference line indicates approximates of undetectable limit of HIV copies in CVL. Quadratic curve 
fitting provides – R2 Quadratic of 0.326)  
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The characteristics of 10 patients who ceased shedding HIV at follow-up are shown in Table 
7.9. HIV shedding ceased in four patients who were cervical HSV PCR positive and had 
received presumptive anti-herpes treatment at enrolment.  Among them, three had high PVLs 
ranging from 81,110 to 573,791 copies/ml. Of six HSV-negative patients, three had a low PVL 
(i.e.≤ 20,000) and the remaining had high PVLs (i.e. >20,000 copies/ml) at Day 7.  
 
age CD4* PVL at
Day 1#
HIV in
CVL at Day 1#
PVL at
Day 7#
HSV at
Day 1
Reproductive Tract
Infections at Enrolment
Positive Rx 
Outcomes
Negative Rx 
Outcomes
1 27 668 377,979 9,029 318,459 Neg
Yeast, TV, HPV 
(both types)
Clearance of Yeast,
TV & HPV (both types) -
2 29 12 240,388 4,734 573,791 Pos
HSV, HPV (both types) Clearance of HSV, 
HPV (Low-risk)
Positive for BY 
& Yeast
3 29 49 178,798 858 356,916 Pos
HSV, Yeast, TV, HPV 
(both types)
Clearance of HSV, TV Persistent Yeast, 
HPV (Both types)
4 22 294 97,065 1,062 81,110 Pos
HSV, BV, Yeast, TV, GC 
& HPV (both types)
Clearance of all pathogens 
except HPV (both types)
Persistent HPV 
(both types)
5 18 412 26,005 3,277 17,175 Pos
HSV, Yeast, TV, GC, 
CT & HPV (high-risk)
Clearance of all pathogens 
except HPV (high-risk types)
Persistent HPV 
(high-risk types)
6 26 294 97,366 1,845 90,136 Neg
TV and RPR +ve Clerance of TV Positive for HPV 
(high-risk)
7 32 - 49,737 3,807 44,734 Neg
Only Yeast Clearance Yeast
-
8 26 435 20,855 4,202 4,367 Neg
BV, TV, GC, HPV (high
risk types) & RPR +ve
Clearance BV, TV 
& GC
Persistent HPV 
(high-risk types)
9 18 262 9,918 10,237 15,732 Neg
BV only Clearance of BV Positive Yeast
10 21 326 7,211 602 10,924 Neg
BV & Yeast Clearance of BV & 
Yeast -
* cells/mm 3;   #copies/ml  
Table 7.9 Characteristics of 10 patients who ceased vaginal shedding of HIV at follow-up visit 
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Among seven patients who started shedding HIV in CVL at follow-up, five (71.4%) had PVLs 
of >20,000 copies/ml at both visits. The median PVL for all patients was 69,758 copies/ml 
(range: 1,062 – 377,967 copies/ml) at enrolment and 46,636 copies/ml (range: 1649 – 
687,718 copies/ml) at follow-up. Treatment failure for BV was observed in three patients and 
one became BV-positive at follow-up. Treatment failure occurred in three patients with yeast 
infection. None of these patients was positive for HSV. 
 
Of 16 patients who continued to shed HIV in CVL at the follow-up visit, eight (66.7%) were 
successfully treated for BV, six for infection caused by yeast (46.2%), four for TV (80%), eight 
for GC (100%) and five for CT infection (100%).  The median PVL of patients on their return 
visit was 116,672 copies/ml (range: 5,472 – 1,060,813 copies/ml) and 87.5% of patients had 
high PVLs (>20,000 copies/ml). 
 
Of 35 patients who did not shed HIV in CVL at all visits, nine (36%) were persistently positive 
for BV, ten (45.5%) for yeast infection, three (33.3%) for CT infection and none for GC.  Two 
patients with HSV (one from a cervical swab and one from an ulcer) were successfully 
treated. The majority (80%) of patients had low PVL (<20,000) and the median PVL at 
enrolment and follow-up were 6,267 copies/ml (range 450 – 590,203 copies/ml) and 6,587 
copies/ml (range 505 – 192,204 copies/ml) respectively. Seven patients had high PVLs at 
enrolment with a median PVL of 156,764 copies/ml (range 23,671 – 590,203 copies/ml). Six 
of the seven patients continued to have high PVLs at follow-up visit with a median PVL of 
104,355 copies/ml (range 29,905 – 192,204 copies/ml). 
 
7.5 Discussion 
 
In sub-Saharan Africa, the majority of HIV transmission that has occurred during the past 
decade was through heterosexual transmission with the number of women infected with HIV 
infection outnumbering the men in 200311. African women appear to be infected at an earlier 
age than African men, and the difference in HIV prevalence between the sexes continues to 
grow. UNAIDS has reported that, in sub-Saharan Africa, 57% of adults infected are women, 
while 75% of young people infected are women and girls. Also, the findings of the 
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Demographic and Health Survey (1998) and other behavioral studies conducted in South 
Africa indicate that young African women in the region tend to have male partners who are 
older than themselves and this has resulted young women engaging in sexual relationships 
with those that were more likely to have a higher STI rate and more likely to be HIV-positive 
than younger men12. It is inevitable that the gender inequalities prevailing in the region make it 
much more difficult for African women to negotiate condom use. Sexual violence targeting 
women is reportedly very common and a higher risk of HIV transmission is anticipated in the 
presence of tissue trauma which occurs more frequently in women subjected to violent sexual 
abuse.  In South Africa, a survey of 1366 women attending antenatal clinics in Soweto found 
significantly higher rates of HIV infection in women who were physically abused, sexually 
assaulted or dominated by their male partners as measured by the South African adaptation 
of the Sexual Relationship Power Scale (SRPS). The study also produced evidence that 
abusive men are more likely than non-abusers to be HIV-seropositive13. The HIV sentinel 
surveillance data collected from the Esselen Street STI Clinic in Johannesburg have shown 
that more than half of women attending the clinic with STI symptoms were infected with HIV in 
199814.   It is possible that, with an increasing number of sexually active women becoming  
HIV-seropositive, any changes in patterns of sexual networking or sexual practices (e.g. 
appearance of sexual networks between young boys and women older than themselves or 
young girls who had previous sexual relationships with older men etc.), may rapidly propagate 
HIV transmission into other population groups.  
 
Studies have also reported that HIV is commonly detected in the genital fluids of women and 
STI co-infection could potentially increase the infectiousness of HIV15. However, the findings 
on the role of RTI/STIs in increased infectiousness of HIV are sketchy and inconsistent. In a 
randomised controlled study conducted in Rakai, Uganda, no association was found between 
the increase in transmission probability per coital act involving discordant couples and the 
presence of concurrent gonorrhoea, chlamydial infection, bacterial vaginosis, or 
trichomoniasis15. Unlike findings in Europe and the USA, the RCTs conducted in Africa 
indicate a higher transmission probability per act from women to men than from men to 
women16-19 . Therefore, the presence of a large number of sexually active HIV-infected 
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women may also lead to an accelerated HIV epidemic in the coming years, unless 
intervention activities targeting HIV-seropositive women are employed to lower the 
transmission efficiency including reduction of infectiousness of HIV (Figure 7.7). 
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Figure 7.7 Simplified hypothetical framework on possible transmission dynamics & 
impact of HIV infection in southern Africa. 
 
In the studies reported here, we explored the level of HIV shedding in cervicovaginal lavage 
of HIV-seropositive women with or without co-infection with RTI/STI. The study population 
was relatively young with over 60% of subjects recruited being under 25 years of ages with a 
mean age of 24 years. The majority had no clinical and laboratory evidence of 
immunodeficiency and 68.8% had CD4+ counts of 350 cells/mm3 and above. There was no 
significant association between individual RTIs/STIs and HIV shedding in our study. Four of 
five patients with positive cervical HSV infection however, shed HIV in their CVL at enrolment 
and stopped shedding at the follow-up visit after receiving anti-herpes therapy with 
valacyclovir. Our study found that HIV plasma viral load was the main determinant for vaginal 
shedding of HIV in terms of frequency as well as quantity of shedding. When we used a proxy 
cut-off of 20,000 copies/ml of PVL, the frequency and quantity of shedding were significantly 
higher in patients with PVL >20,000 copies/ml (Odds ratio 13.8; 95% CI 3.9 – 48.4). In 
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addition, a positive association between log PVL and log HIV copies in CVL was also 
observed (R2 = 0.264). This association was stronger in those with CD4 counts ≥350 as none 
of the 44 patients with PVL <20,000 had detectable HIV RNA in their CVL, despite having 
other potential risk determinants such as RTI/STIs, cervical ectopy and lack of contraceptive 
use. This finding has an important implication as sexual activity may be much higher among 
those without AIDS-related signs or symptoms than in AIDS cases. Therefore, interventions to 
reduce HIV infectiousness should target immunocompetent women. Our results also support 
the findings of larger community-based RCT studies conducted elsewhere. Quinn et al 
reported in their study on heterosexual transmission of HIV-1 among serodiscordant couples 
in Rakai, Uganda that the mean serum HIV-1 RNA level was significantly higher among HIV-
1-seropositive participants whose partners seroconverted, than among those whose partners 
did not seroconvert (90,254 copies/ml vs. 38,029 copies/ml, P=0.001) 20. Apart from a 
younger age and circumcision status of male partners, they found no other potential 
determinants such as STIs were associated with HIV transmission. Many other studies have 
also reported the association between high PVLs (e.g. primary or early HIV infection) and 
infectiousness of HIV 5, 21-25. 
 
Theoretically, if co-infection with RTI/STI is making a significant contribution to HIV 
infectiousness through increased shedding of HIV in genital secretions, any successful 
treatment of RTI/STI should reduce or stop genital shedding of HIV. Ghys et al reported that 
successful treatment of STIs reduced shedding of HIV in genital secretions of female sex 
workers in Cote d’lvoire. In their study, the association between viral load and HIV shedding 
was not significant within the same CD4 levels and therefore it was not included in their 
multivariate analysis. The conclusion was made that increased infectiousness of HIV is 
associated with immunosupression and STIs8. In our studies, the prevalence of multiple 
vaginal and cervical infections was extremely high and treatment failure at follow-up was high 
for BV and yeast infection. All gonococcal and trichomonas infections were successfully 
treated although some women had new infections detected at follow-up. We did not find a 
significant association between successful treatment of RTI/STI and reduction in HIV 
shedding among our patients. Similar to the finding during the enrolment visit, high PVLs at 
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the return visit were significantly associated with a higher frequency of HIV shedding and the 
amount of HIV shed in the CVL at the return visit (Odds ratio 11.7, 95% CI 3.3 – 41.1). 
 
Of the 10 patients who stopped shedding HIV at follow-up, four had cervical HSV infection at 
enrolment which was treated successfully using anti-herpes treatment presumptively. 
Shedding was reduced to undetectable levels in four of these HSV-positive patients, despite 
three of them having high PVLs ranging from 81,110 to 573,791 copies/ml at the return visit. 
This association between HSV and HIV infection in women needs to be explored further with 
large scale studies. In contrast, successful treatment of RTI/STI such as BV (6 patients), 
yeast infection (6 patients), trichomoniasis (4 patients), gonorrhoea (8 patients) and 
chlamydial infection (5 patients), did not stop HIV shedding. The median PVL in these 
patients was high (116,672 copies/ml) and 87.5% had PVL of more than 20,000 copies/ml at 
follow-up. 
 
Major limitations of our study include: small sample size (67 women), a high prevalence of 
multiple RTIs/STIs in the same subject and no long-term follow-up after the Day-7 visit. Our 
findings however, support the current concept that phase-specific interventions are needed to 
maximise the impact of STI control on HIV transmission at the community level26-27. Several 
debates and critical analyses followed after conflicting outcomes were apparently obtained 
following two major community-based RCTs conducted in Mwanza, Tanzania and Rakai, 
Uganda28-29. In Mwanza, the improved clinical management of symptomatic STD treatment, 
was associated with a reduction in HIV incidence by 38% [95% confidence interval 15 - 55%] 
over a period of 2 years30. Periodic mass treatment of bacterial STI in Rakai, Uganda 
however, did not reduce HIV incidence over the same period, despite achieving similar 
reductions in STIs31. 
 
Some authors conclude that the impact of STI treatment programmes on HIV transmission 
may depend more on behavioural risk reduction than on the stage of the epidemic32-33. Others 
argue that STIs may play a less important role in HIV spread in mature HIV epidemics as was 
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the case in Uganda. Non-bacterial STIs, notably genital herpes, were more common in Rakai; 
and rounds of mass treatment in Rakai may have been followed by rapid reinfection34 . 
 
Based on our findings, one of the important and generally recognised interactions between 
STIs and HIV, namely that STIs increase the infectiousness of HIV may not be universal and 
should probably be more realistically interpreted as conditional. It is possible that other high-
risk factors in the study population may have obscured the importance of HIV transmission 
and acquisition in the present study, e.g. high transmissibility in recently acquired HIV 
infection when PVLs are high may have been such a confounding factor. 
 
 The high rates of STIs that were detected in our study population at an early stage of the HIV 
epidemic provide an early warning for the potential for rapid spread of HIV. This early warning 
sign is based on the role of acute STIs as a proxy marker for the presence of high-risk sexual 
behaviours (i.e. unprotected sex with high-risk partners) as well as increased susceptibility to 
HIV if he/she is exposed. The lack of effective intervention, targeting core transmitters or high-
risk sub-population groups during the early phase of the HIV epidemic has lead to dire 
consequences for southern Africa which will become apparent in the years ahead. Any 
intervention should include enhanced STI treatment and control, risk-reduction counselling of 
high-risk individuals, education for behavioural change and partner notification and treatment. 
This should theoretically reduce two components involved in the reproductive equation, 
namely, the probability of transmission and the frequency of sexual partner change. 
 
In the mid-1990s, an accelerated spread of HIV occurred in southern Africa with almost one 
third of the sexually active population in South Africa were infected by the early 2000s. During 
this accelerated phase of spread leading to the high incidence era, the probability of 
transmission might have been largely dependent of the prevalence of STIs in HIV-
seronegative individuals, and the high-level HIV viraemia associated with primary infection 
during the early phase of HIV acquisition35-36. As the HIV epidemic became more mature, the 
number of individuals in the infectious pool steadily increased with time. Some proportion of 
people living with HIV will have reached a stable but low plateau or set point in their HIV viral 
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load, while others will have higher viral load as HIV infection progresses to AIDS. Those 
patients with high PVLs will exhibit with high-level genital HIV shedding and an increased 
probability of per-coital transmission, with or without the co-factor effect of concurrent STIs. 
Therefore, the role of concurrent STIs may be negligible in increasing the HIV transmission 
probability from HIV-seropositive people, particularly in those who already have high PVLs. 
Meanwhile, concurrent STIs may contribute to an increased transmission probability of 
asymptomatic HIV patients with a low viral set-point (therefore low PVL) who may not shed 
HIV in their genital fluid during the STI-free period.  
 
In conclusion, it is clear that STI treatment is not a “magic bullet” in controlling the spread of 
HIV. However, the role of treatment in reducing the transmission probability of HIV 
transmission in a population is dynamic and varies according to different phases of the HIV 
epidemic. In addition, the role of some viral STIs such as genital herpes should not be under-
estimated as their hyper-endemic status in a community could weaken the potential effect of 
STI prevention and treatment activities which are traditionally focused on curable bacterial 
STIs. Many RCTs are being conducted or planned to estimate the effect of episodic and 
suppressive treatment of HSV on HIV acquisition and shedding. In addition, the availability of 
HAART in many developing countries may influence the transmission probability of HIV 
through lowering the viral load in previously treated naïve patients and thereby, reduce the 
infectiousness of HIV. Current ART treatment guidelines recommend initiating therapy when 
HIV-seropositive individuals become symptomatic and qualify as AIDS patients. Therefore, 
present programmes may not have any significant impact on the sexual transmission of HIV 
which is probably driven largely by asymptomatic individual with high PVL.  
 
Finally, the findings of our studies and those of other researchers have reached a common 
conclusion – there is a strong and dynamic bidirectional interaction between STIs and HIV. 
This important knowledge must be optimally utilised and adapted in order to control HIV at 
various phases of the epidemic globally. However, scientific knowledge should be applied 
with caution in places with diverse social, cultural and epidemiological backgrounds, and the 
“one size fits all” principle is not appropriate for our attempts at controlling STI and HIV. 
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CHAPTER 8 
General discussion and conclusions 
8.1 Strengthening STI surveillance in resource-poor countries 
As described in previous chapters, the effects of STIs on HIV transmission have been 
documented in many studies, including those conducted in South Africa. It is obvious that the 
population-attributable fraction (PAF) of STI co-factor effects on new HIV infections in a 
population is highly dependent on the phase of HIV epidemic. It is estimated that PAF of STI 
co-factor effects could be significantly greater in populations during the growth phase of the 
HIV epidemic than in those populations experiencing a mature HIV epidemic1.  
 
In all the study populations, we observed that high level STI epidemics preceded the 
explosive spread of HIV infection among high-risk individuals. Following this early phase of 
the epidemic, HIV infection spread into family units or ill-defined sexual networks, finally 
resulting in wide-spread transmission within the general population2-3. 
 
Several groups have explored the potential use of the incidence and prevalence of 
conventional STIs as important measures of risk behaviour for HIV4-7. Based on these 
experiences, it has been proposed to use the incidence of selective STIs as biological 
markers for the potential risk of spread of HIV infection in a population8. In 2002, WHO 
conducted an expert consultation meeting in Treviso, Italy to devise methods for the 
estimation of the global incidence of STIs and their association with HIV infection. The 
meeting recommended the selection of proxy STI indicators to monitor the potential risk of 
HIV infection in a population9. The complexity of natural history and clinical presentation of 
STIs, however, imposed a major barrier to the implementation of comprehensive STI 
surveillance systems to generate interpretable data on what the WHO recommendations are 
based, particularly in resource-poor countries. As such, the quality of STI surveillance data 
may vary between countries and the interpretation of STI data could often be difficult.  
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WHO and UNAIDS have recommended strengthening STI surveillance as an essential 
component of second-generation surveillance of HIV infection. In order to improve STI 
surveillance activities, WHO and UNAIDS issued guidelines for sexually transmitted infection 
surveillance in 199910. The studies reported here demonstrate the importance of triangulating 
data collected from different recommended STI surveillance components, using a tiered 
surveillance approach. This approach provides useful information on both temporal changes 
in incidence of STI syndromes as well as changes in aetiological patterns of specific STI 
syndromes due to emerging or re-emerging STIs, for example, the increasing role of genital 
herpes in the aetiology of GUD in recent years11-16. 
 
8.2 Strength of interactions between HIV and different STIs 
We observed that conventional STIs vary in the magnitudes of interaction with HIV infection, 
as has been documented in several studies17-18. We found particularly strong interactions 
between genital herpes and HIV. At the individual level, HIV-seropositive patients with genital 
herpes were more frequently found to have atypical clinical presentations, delays in 
spontaneous healing, a longer duration of HSV shedding and increased association with HIV 
shedding from ulcer and genital exudates. These findings were similar to those found in 
studies conducted elsewhere19-21. 
 
As was the case with HSV infection, there was a strong association between HIV and HPV 
infection in both men and women. A higher prevalence of HPV infection was found among 
HIV-seropositive patients in our study population and this may reflect the higher frequency of 
recurrences and/or longer duration of infection (i.e. persistency). The interaction between HIV 
and HPV types associated with a higher risk for cervical cancer could influence future trends 
of cervical cancer in southern Africa. Cervical cancer causes high morbidity and mortality in 
women in southern Africa and demands innovative strategies for its containment. The role of 
targeted and enhanced cervical cancer screening in women who are positive for high-risk 
HPV types should be further explored to reduce premature mortality due to cervical cancer in 
the region. 
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Some interactions between syphilis and HIV infection were difficult to assess in our outpatient 
setting, as specialised investigations such as CSF and ophthalmological examinations are not 
performed routinely. However, we found that the biological false positive reactions in syphilis 
serology (i.e. RPR) are not a common occurrence in our HIV-seropositive study population. 
On the other hand, syphilis serology could be falsely negative in patients with PCR-confirmed 
primary syphilis who are co-infected with HIV and other aetiological agents causing GUD. We 
confirmed that the recommended treatment of syphilis provided effective clinical and 
microbiological cure in HIV-seropositive patients with primary syphilis.  
 
The clinical presentation and treatment responses of cases of chancroid were similar in HIV-
seropositive and HIV-seronegative patients. Also, mixed infections involving chancroid and 
genital herpes were found to be common, particularly in HIV-seropositive patients (Section 3). 
The effectiveness of syndromic treatment targeting only bacterial causes of genital ulceration 
was significantly reduced due to the persistent ulcerations as a result of co-infection with 
genital herpes. The need for corrective action to include genital herpes therapy in the 
syndromic management protocol has been discussed at WHO22. Further research studies to 
explore the effect of episodic and suppressive herpes therapy on HIV transmission are 
currently underway23. 
 
8.3 Impact of co-existing HIV epidemic on control of STIs  
Efforts for the control and elimination of STIs in southern Africa have been affected positively 
as well as negatively by the co-existing HIV epidemic. After a decade of neglect in controlling 
the hyper-endemic STI situation in the region, measures to prevent and control of STI have 
been incorporated into a core intervention program to contain the HIV epidemic in many 
affected southern African countries. More resources were made available for STI control 
programmes during the 1990s and many outreach and innovative STI intervention activities 
were implemented. Among these activities, the introduction of syndromic management of 
STIs played a crucial role in controlling curable STIs and in the process achieved a significant 
reduction in the duration of the infectiousness of bacterial STIs24-25. The implementation of 
region-wide surveillance programmes including detection of anti-microbial resistance among 
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bacterial STIs provided valuable information for selecting the best treatment algorithms, 
particularly for gonorrhoea and chancroid26-27. Population-based cross-sectional prevalence 
studies were conducted among low- and high-risk populations and the results of these studies 
provided a better understanding of the burden of infection due to asymptomatic or inapparent 
infectious individuals28. As a result, the focus of intervention activities has been extended to 
involve asymptomatic infectious individuals in the community through various outreach 
intervention activities. Important intervention activities include periodic presumptive therapy 
for high-risk women in mining areas (e.g. Lesedi and Mothusimpilo Projects) and enhanced 
partner notification and treatment at municipal clinics. Our studies have clearly shown the 
impact of these intervention activities on the incidence of curable STIs among the mine 
workers who were their main clients. Enhanced screening and treatment of syphilis in high-
risk population groups (e.g. all patients with new STI episodes) has led to a rapid decline in 
syphilis seropositivity in these groups. In some areas, the prevalence of RPR positivity among 
STI patients has reached a lower level than that of pregnant women. Overall, the 
improvement in community awareness on safer sex practices and STI services has led to a 
rapid decline in incidence and prevalence of STIs in the region. 
 
Meanwhile, co-infections involving conventional STIs and HIV were highly prevalent among 
high-risk population groups in the region during the study period. This situation has 
contributed to more frequent occurrences of atypical presentations, altered natural history of 
STIs, and reduction in effectiveness of some syndromic STI treatment algorithms – especially 
as a result of herpes co-infections.  
 
In our studies, the relative prevalence as well as absolute number of cases of genital herpes 
have increased significantly and a stronger association was found between herpes and HIV-
seropositivity than other STIs. The atypical presentations, lack of spontaneous healing and 
long duration of HIV shedding from herpetic ulcerations are issues of major concern for the 
containment of spread of HSV and HIV in the region. In our cross-sectional study on GUD 
aetiology, we reported that an increasing proportion of HIV-seronegative patients also 
presented with genital herpes. In addition, a high seroprevalence of HSV-2 was found in HIV-
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seronegative individuals. The impact of increasing prevalence of a viral ulcerative STI with 
known potential of causing recurrent clinical or sub-clinical ulcerations among sexually active 
population could be an additional facilitating factor for continued spread of HIV in the region. 
Based on our study findings, a firm recommendation should be made to include anti-herpes 
therapy in the syndromic management algorithms for GUD in areas where high proportion of 
GUDs is attributed to genital herpes. Some countries such as Botswana have already 
established a national plan to provide episodic treatment of genital herpes at public clinics29-
30. 
 
We also found high levels of association between HPV and HIV infection in our study 
population. We found that the most widely known determinants of spread of HPV infection 
such as the number of life-time sexual partners, age at sexual debut and a high prevalence of 
hormonal contraceptive use are very common in high-risk women. Together with high a 
prevalence of HIV, there is potential for continued increase in the number of HPV infections 
among women in southern African. Although it was not statistically significant, our study 
reported a high prevalence of HPV types associated with higher cervical cancer risk (high-risk 
HPV) among older women and the prevalence was higher in HIV-seropositive older women. 
Estimating the potential impact of such a high prevalence of HIV and HPV co-infection on the 
incidence of cervical cancer is complex. The causal relationship between high-risk HPV 
infections and cervical cancer has been well documented and the probability of progression 
could be higher in patient with persistent or chronic infections31-33. Cervical cancer has been 
included as a AIDS-defining illness in developed countries as the incidence of this condition is 
higher among HIV-seropositive women34. The excess morbidity and mortality of cervical 
cancer as a result of the co-existing HIV epidemic in developing countries has, however, not 
been documented in the literature. It is possible that the HIV epidemic may increase the 
burden of HPV infection and cervical cancer in developing countries and this effect may 
become more visible with longer life-expectancy in HIV-seropositive women due to the 
anticipated increase in accessibility to HAART. 
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8.4 Role of HIV viral load in transmission of HIV  
Our studies demonstrated unique patterns of HIV shedding from genital fluid in patients co-
infected with STI and HIV. The majority of patients with genital ulcerations shed HIV in their 
ulcer exudates; therefore, their infectiousness could be increased in settings where continued, 
unprotected sexual activity in the presence of active ulceration is common. HIV shedding in 
ulcer exudates also continued when there were treatment failures as a result of failed 
chancroid therapy or untreated genital herpes. The successful treatment of herpes in men 
and women was found to be associated with a decline or cessation in HIV shedding into ulcer 
exudates or genital fluid. Some HIV-seropositive patients with large ulcerations did not shed 
HIV in the ulcer exudates. We found that HIV-shedding in genital ulcer exudates was strongly 
associated with HIV PVL. A similar finding was also demonstrated in women presenting with 
vaginal discharge. Our studies have shown that HIV viral load is the main determinant for HIV 
shedding in both men and women presenting with STIs. This finding has been supported by 
other studies conducted elsewhere35-36. It is possible that the role of the STI co-factor effect in 
HIV shedding might be much reduced or negligible in patients with a high HIV plasma viral 
load (e.g. primary HIV infection, immunocompromised patients etc.). It is also important that 
the potential effect of increased accessibility of highly active anti-retroviral therapy (HAART) 
on HIV shedding in patients with conventional STIs should be investigated37. 
 
8.5 STI co-factor effect on HIV transmission 
The determinants of sexual transmission of HIV in developing countries are many and 
complex and their dynamics should be assessed in a wider social, economic and behavioural 
context. It would appear that the interrelationships between behavioural, biological and 
immunological determinants vary depending on different phases of HIV epidemic. It is 
however, difficult but not impossible to quantify the STI co-factor effect on HIV transmission. 
Several attempts have been made to measure STI co-factor effects through community-
based randomised controlled intervention trials, as well as by utilizing various mathematical 
modelling methods38.   
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An improved understanding of co-factor effects would contribute to the better preparedness 
and implementation of more effective interventions, and quality monitoring and evaluation 
activities for the containment of both the STI and HIV epidemics. In fact, morbidity and 
mortality due to conventional STIs are still very high in many developing countries and 
effective STI intervention activities are required to reduce the burden of these diseases. Such 
activities could have a considerable impact on the course of HIV infection in specific 
population groups or countries. Caution should however be exercised as the overall 
magnitude of the impact may vary according to prevailing local determinants including 
broader issues such as social structure, behavioural patterns, STI prevalence and the stage 
of the HIV epidemic at a specific location or country. 
 
8.6 Limitations of studies reported in this thesis 
Major limitations of our studies include those associated with the cross-sectional study design 
of some of our studies, and the inherent poor follow-up rate associated with highly mobile 
population groups in selective short-term follow-up studies.  
 
Our studies measured the associations rather that causal relationships since most information 
was collected from cross-sectional facility-based studies. A community-based randomised 
control study design could not be implemented due to the constraints in resources. We 
provided however strong support to monitoring and evaluation studies of community-based 
and outreach intervention activities implemented in the study areas. The findings of these 
studies have been published elsewhere39-41. 
 
Although the size of the mine workforce in Goldfields of South Africa mines is relatively stable, 
the total mine population served by our research clinic declined slightly during the study 
period owing to the restructuring of smaller mines. No significant differences in demographic 
characteristics and STI incidence were however observed between miners employed in the 
restructured smaller mines and those in the remaining mines.  
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The changing trends of STI syndromes and their aetiological patterns among goldminers 
might have been affected by other confounding factors such as temporal changes in health 
seeking behaviour for specific STIs, changes in clinical diagnosis criteria, and changes in 
laboratory methods. Although we did not conduct health-seeking behavioural studies in the 
mines during the study period, the utilization of STI services was relatively stable throughout 
the years. Provision of STI services in the mines are incorporated in the primary health care 
services of the Goldfield Mines and therefore all STI patients receive services free-of-charge. 
We are confident that the majority of STI episodes occurring in the serving mines were 
treated at our reference clinic although some patients may have been treated at a mine 
hospital outpatient facilities. The trends in prevalence of individual STI syndromes and their 
aetiologies were monitored solely by our study team during late 1980s till 2001, using 
standard clinical surveillance and laboratory criteria. It therefore provided good surrogate 
information relating to the STI situation among migrant miners during the study period.  
 
The changing performance of laboratory tests also influenced temporal changes in 
aetiological patterns of STI syndromes. In our study, the majority of laboratory tests were 
conducted in the Reference Centre for STIs (RCSTI) at the South African Institute for Medical 
Research (SAIMR) and other collaborating laboratories such as National Institute for Virology 
(NIV), South Africa and the Centers for Disease Control and Prevention (CDC), USA. 
Comparable laboratory methods were included in all studies although newly developed and 
more sensitive tests were employed where available. Although the prevalence of STIs was 
assessed using the most sensitive and specific laboratory techniques available, temporal 
trends were compared by using both original and new laboratory methods.  
 
HIV shedding in genital fluid was studied as a surrogate measure for increased infectiousness 
of HIV-seropositive patients with STIs. Our study has shown some important findings about 
the determinants of HIV shedding in genital ulcerations and cervico-vaginal lavages. We 
could not however measure the level of HIV shedding in seminal fluid as all male patients 
enrolled in the study had active ulcerations and collection of semen was considered 
problematic in our study population. During informal discussion with the investigator, the 
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majority of patients consulted expressed reservation on donating semen even after their STIs 
had resolved.  
 
Caution should be exercised in the interpretation of HIV shedding which we used as a 
surrogate marker for infectiousness of HIV-seropositive patients. Follow-up studies using 
discordant couples are the best way to measure determinants of HIV transmission42-44. These 
types of studies are not feasible in study populations comprising migrant miners or highly 
mobile groups (such as inner city populations). Lack of commitment of female patients to 
return for repeated follow-up visits was the most important limitation for the studies conducted 
at the Esselen Street STI clinic. To improve the quality of Pap smears, we made an attempt to 
collect Pap smear specimens after completion of antibiotic therapy. The majority of patients 
however could not commit themselves to return for follow-up appointments. For this reason, 
Pap smear specimens were collected at enrollment only. This problem also negated our plans 
to conduct a long-term follow-up programme for HPV-positive patients. 
 
We found that multiple vaginal and cervical infections were very common in our study 
population, and that syndromic treatment of vaginal discharge often failed to achieve 
microbiological cure on completion of treatment, particularly for bacterial vaginosis and 
vaginal candidiasis. Limitations of the study on vaginal shedding of HIV included the small 
sample size and multiple potential determinants associated with HIV shedding in genital fluid. 
Although we collected information on all possible determinants, the small sample size limited 
the analysis of our finding. HIV PVL was however consistently associated with HIV shedding 
in our study. Further studies should be conducted using larger sample sizes in easy-to-follow 
up population groups such as women attending family planning clinics. 
 
Overall, our studies explored the interactions between HIV and STIs in southern Africa 
through research studies integrated with the routine patient care and the surveillance 
activities of RCSTI. The results of these studies provided valuable inputs to improve STI 
surveillance, prevention and management in the region. Despite the aforementioned inherent 
limitations associated with facility-based studies, several research questions have been 
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addressed and answers provided based on our findings. Randomised controlled trials are 
underway in South Africa to explore further the relative importance of HSV-2 infection in 
acquisition of HIV infection.  
 - 232 - 
References 
1. Dallabetta G, Steen R, Saidel T, Meheus A. Operational Approaches for Evaluating 
Intervention Strategies. In: Rehle T, Saidel T, Mills S, Magnani R, editors. Evaluating 
Programs for HIV/AIDS Prevention and Care in Developing Countries. Family Health 
International, 2001. 
 
2. World Health Organization. HIV surveillance report for Africa: 2000. WHO Regional 
Office for Africa (AFRO). Harare. December 2001. 
 
3. World Health Organization. HIV/AIDS Epidemiological Surveillance Update for the 
WHO African Region. World Health Organization. Regional Office for Africa. Harare, 
Zimbabwe. September 2003. 
 
4. Renton AM, Whitaker L. Using the classical STDs to monitor HIV prevention 
programmes. In: Paccaud F et al., eds. Assessing AIDS prevention. Basle, 
Birkhauser Verlag, 1992 : 32–51.  
 
5. Renton AM, Whitaker L. Using STD occurrence to monitor AIDS prevention. Social 
science and medicine, 1994, 38 : 1153–1165.  
 
6. Wolitski RJ, Valdiserri RO, Denning PH et al. Are we headed for a resurgence of the 
HIV epidemic among men who have sex with men? Am J Public Health, 2001, 91: 
883–888.  
 
7. Stolte IG, Dukers NH, de Wit JB et al. Increase in sexually transmitted infections 
among homosexual men in Amsterdam in relation to HAART. Sexually transmitted 
infections, 2001, 77 :184–186. 
 
8. World Health Organization (WHO). Guidelines for second generation HIV 
surveillance. Geneva: World Health Organization and Joint United Nations 
Programme on HIVAIDS; 2000. WHO/CDS/CSR/EDC/2000.5. 
 
9. World Health Organization (WHO). Estimation of the incidence and prevalence of 
sexually transmitted infections, Report of a WHO consultation. Treviso, Italy, 27 
February-1 March 2002. WHO/HIV/2002.14. 
 
10. World Health Organization and Joint United Nations Programme on HIV/AIDS. 
Guidelines for sexually transmitted infection surveillance. Geneva, World Health 
Organization, 1999. WHO/CHS/HSI/99.2. 
 
11. Corey L. Herpes simplex type 2 infection in the developing world: is it time to address 
this disease? Sex Transm Dis 2000; 27:30-31. 
 
12. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M et al. 
Interactions between herpes simplex virus type 2 and human immunodeficiency virus 
type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 
182:1090-1096. 
 
13. Corey L, Handsfield HH. Genital herpes and public health: addressing a global 
problem. JAMA 2000; 283:791-794. 
 
14. Mar Pujades RM, Obasi A, Mosha F, Todd J, Brown D, Changalucha J et al. Herpes 
simplex virus type 2 infection increases HIV incidence: a prospective study in rural 
Tanzania. AIDS 2002; 16:451-462. 
 
15. Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency 
virus: double trouble. Bull World Health Organ 2004; 82:447-453. 
 
 - 233 - 
16. Blower S, Wald A, Gershengorn H, Wang F, Corey L. Targeting virological core 
groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J 
Infect Dis 2004; 190:1610-1617. 
 
17. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic 
interactions between classic sexually transmitted diseases and HIV: how much really 
is known? Sex Transm Dis 2001; 28:579-597 
 
18. Royce RA, Sena A, Cates W, Jr., Cohen MS. Sexual transmission of HIV. N Engl J 
Med 1997; 336:1072-1078. 
 
19. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R et al. Reactivation of genital 
herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J 
Med 2000; 342:844-850. 
 
20. Celum CL. The interaction between herpes simplex virus and human 
immunodeficiency virus. Herpes 2004; 11 Suppl 1:36A-45A. 
 
21. Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 
2001; 8:46-49. 
 
22. World Health Organization (WHO). Report of an expert consultation on improving the 
management of sexually transmitted infections. WHO, Geneva. 28 - 30 November, 
2001. 
 
23. Joint United Nations Programme on HIV/AIDS (UNAIDS). Herpes simplex type 2: 
Programmatic and research priorities in developing countries. Report of a 
WHO/UNAIDS/LSHTM workshop. London, 14-16 February 2001. 
 
24. World Health Organisation Programme for Sexually Transmitted Deseases, Global 
Programme on AIDS (1994) Recommendations for the management of sexually 
transmitted diseases WHO/GPA/TEM/94 World Health Organisation, Geneva. 
 
25. Vuylsteke B. Current status of syndromic management of sexually transmitted 
infections in developing countries. Sex Transm Infect 2004; 80:333-334. 
 
26. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. World Health 
Organization 2001; WHO/CDS/CSR/DRS/2001.3: 16 
 
27. Ison CA, Roope NS, Dangor Y, Radebe F, Ballard R. Antimicrobial susceptibilities 
and serotyping of Neisseria gonorrhoeae in southern Africa: influence of geographical 
source of infection. Epidemiol Infect. 1993 Apr;110:297-305.  
 
28. Fehler H., Ye H., Ballard RC. Laboratory Surveillance in South Africa: Report of 
National Reference Centre for STI, Johannesburg. South Africa. 2000. 
 
29. Rahman M, Gabriela P, Mosarwa R, Kenyon T, Cheng C, Ballard R et al. Changing 
patterns of STD in Botswana, 1993-2002. International Society of Sexually 
Transmitted Diseases Research 15th Biennial Congress. July 27 – 30, Ottawa, 
Canada. 2003. 
 
30. Ndowa F. The syndromic management of genital discharge and genital ulcer 
diseases. International Society of Sexually Transmitted Diseases Research 15th 
Biennial Congress. July 27 – 30, Ottawa, Canada. 2003. 
 
31. Koutsky L, Holmes K, Critchlow M, et al. A cohort study of the risk of cervical 
intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J 
Med. 1992;327:1272-1278. 
 
 - 234 - 
32. Ho G, Burk R, Klein S, et al. Persistent genital human papillomavirus infection as a 
risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365-1371. 
 
33. Kotloff K, Wasserman S, Russ K, et al. Detection of genital human papillomavirus and 
associated cytological abnormalities among college women. Sex Transm Dis. 
1998;25:243-250. 
 
34. Center for Disease Control (CDC). 1993 Revised Classification System for HIV 
Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents 
and Adults. December 18, 1992 / 41(RR-17)  
  
35. Uvin SC, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and 
plasma viral load in human immunodeficiency virus-seropositive women. Obstet 
Gynecol 1997; 90:739-743. 
 
36. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: 
infectiousness and prevention. AIDS 1999; 13:155-166. 
 
37. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and 
herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV 
type 1 infection. J Infect Dis 2005; 191 Suppl 1:S107-S114. 
 
38. Korenromp EL, de Vlass SJ, Nagelkerke NJ, Habbema JD. Estimating the magnitude 
of STD cofactor effects on HIV transmission: how well can it be done? Sex Transm 
Dis 2001; 28:613-621. 
 
39. Williams BG, Taljaard D, Campbell CM, Gouws E, Ndhlovu L, Van Dam J et al. 
Changing patterns of knowledge, reported behaviour and sexually transmitted 
infections in a South African gold mining community. AIDS 2003; 17:2099-2107. 
 
40. MacPhail C, Williams BG, Campbell C. Relative risk of HIV infection among young 
men and women in a South African township. Int J STD AIDS 2002; 13:331-342. 
 
41. Steen R, Vuylsteke B, DeCoito T, Ralepeli S, Fehler G, Conley J et al. Evidence of 
declining STD prevalence in a South African mining community following a core-
group intervention. Sex Transm Dis 2000; 27:1-8. 
 
42. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F et al. Molecular 
epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual 
cohort of discordant couples in Zambia. J Virol 2002; 76:397-405. 
 
43. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F et al. 
Viral load and heterosexual transmission of human immunodeficiency virus type 1. 
Rakai Project Study Group. N Engl J Med 2000; 342:921-929. 
 
44. Royce RA, Sena A, Cates W, Jr., Cohen MS. Sexual transmission of HIV. N Engl J 
Med 1997; 336:1072-1078. 
 
 
 
 
 - 235 - 
